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Summary 
Mutations in OPA1 are the leading cause of autosomal dominant optic atrophy, a disease 
in which a progressive loss of retinal ganglion cells (RGCs) leads to blindness. In the 
B6;C3-Opa1Q285STOP (het) mouse, an Opa1 mutation causes a decrease in ATP production 
and a progressive loss in visual acuity, which coincides with pruning of the predominantly 
ON-centre RGC dendrites. As 670 nm light can increase ATP production and provide 
neuroprotective effects, we hypothesise that protection from dendritic pruning will be 
observed in the ON-centre RGCs of the het mouse with 670 nm light. 
By Sholl analysis, and other measures of dendritic complexity, we found that ex vivo 
delivery of 670 nm light to retinal explants provides partial protection against the ex vivo 
retinal ganglion cell dendropathy, triggered by axotomy, in young wild-type mice. By the 
same methods of analyses, in vivo delivery of 670 nm light to aged wild-type and het 
mice partial provided protection against ex vivo RGC dendropathy in RGCs from wild-type 
mice and partial protection in RGCs from het mice.   
By immunohistochemistry, the transcription factor NFκB was found to be activated in 
RGCs from aged het mice treated with in vivo 670 nm light. The oxidative stress sensor, 
DJ1, was upregulated in RGCs from aged wild-type and het mice, by in vivo 670 nm light. 
The activation of the serine/threonine protein kinase, AKT, which plays a pivotal role in 
controlling cell survival and apoptosis, was decreased following in vivo 670 nm light 
treatment in aged wild-type RGCs.
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1.1 Autosomal dominant optic atrophy  
 Clinical presentation and prevalence  
Autosomal Dominant Optic Atrophy (ADOA) also known as Kjer’s Optic Atrophy was first 
described in 19 Danish families in 1959 by the Danish ophthalmologist Dr. Poul Kjer (Kjer, 
1959). The disease prevalence is estimated to be as high as 1 in 25,000 making it the 
most common cause of inherited blindness (Yu-Wai-Man et al., 2010). There is much 
clinical variation in ADOA ranging from a subclinical phenotype to those patients 
registered legally blind. ADOA patients predominantly experience visual defects however 
a small cohort develop additional extra-ocular symptoms giving rise to syndromic ADOA. 
The disease is characterized by a loss of retinal ganglion cells and subsequent atrophy of 
the optic nerve. The clinical presentation usually begins in childhood with a progressive 
bilateral loss of visual acuity (Kjer et al., 1983). The disease can be further characterized 
by colour vision defects, most commonly blue-yellow dyschromatopsia, centrocecal, 
central or paracentral visual field defects and temporal or diffuse optic nerve pallor with 
optic disc atrophy. 
 
Figure 1.1: A left fundus photograph of a patient with ADOA, showing temporal pallor.  
 
Chapter 1. Introduction 
3 
 
Approximately 20% of ADOA patients develop multi-system symptoms, most commonly 
sensorineural deafness. Other symptoms can also develop later in life including 
myopathy, peripheral neuropathy, paraplegia, cardiomyopathy and cataracts (Lenaers et 
al., 2012). 
 Disease pathology 
The pathology of ADOA has not yet been fully clarified, however, much progress has been 
made to this end. Histological examination of the eyes of ADOA patients suggested that 
the loss of visual acuity was due to the loss of retinal ganglion cells. One patient showed 
a reduction in the number of ganglion cells in the retina with the remainder displaying 
classical features of degeneration such as cytoplasmic vacuolization. In addition there 
was a loss in myelin density, pallor, axonal swelling and demyelination in the temporal 
aspect of the optic nerve (Johnston et al., 1979). In another post-mortem examination 
by Kjer et al (1983) there was heavy fibrosis of the ganglion cell layer of the retina, a 
reduced number of ganglion cells in the posterior part of the retina as well as partial 
atrophy of the optic nerve, however, the other cell layers of the retina were unaffected. 
In the majority of cases the degree of optic disc pallor is representative of the loss of 
visual acuity (Votruba et al., 1998).  
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Figure 1.2: Cross section of the retina. Photons are absorbed by the visual pigment of 
the photoreceptors. The light signal is translated into an electrical signal which is passed 
from the photoreceptors to ganglion cells via bipolar cells. The axons of the retinal 
ganglion cells form the optic nerve which sends the light signal to the brain. Information 
can also be passed from photoreceptors to bipolar cells via horizontal cells. Amacrine 
cells function in integrating the signal from bipolar cells to the ganglion cells.  
 Genetic components  
ADOA has a great degree of genetic heterogeneity as it has been associated with 
mutations in five different chromosomal loci, Optic atrophy 1, OPA3, OPA4, OPA5 and 
OPA7 found on chromosome 3q28, 19q13.2–q13.3, 18q12.2–q12.3, 22q12.1–q13.1 and 
11q14.1-q21 respectively (Chen et al.). There are also other forms of optic atrophy 
associated with mutations in OPA4 and OPA6, which respectively follow X-linked and 
recessive modes of inheritance (Eiberg et al., 2006). Leber’s Hereditary Optic Neuropathy 
is also a common cause of inherited optic atrophy displaying a similar phenotype to 
ADOA, however, it arises due to point mutations in mitochondrial DNA and therefore it 
is inherited maternally and predominantly affects males (Reynier et al., 2004). On the 
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other hand, ADOA follows an autosomal mode of inheritance and affects both males and 
females indiscriminately (Lenaers et al., 2012).  
 Mutations in the nuclear gene OPA1, which is located on the telomeric region of 
chromosome 3, has been found in 60-80% of patients and is thus the most common 
cause of ADOA. Mutations in OPA3, OPA5 and OPA7 have also been found in ADOA 
patients, albeit to a much lesser extent to OPA1, accounting for less than 1% of cases 
(Reynier et al., 2004), (Yu-Wai-Man et al., 2010). Numerous mutations in different 
regions of the OPA1 gene have been found in patients further extending the level of 
genetic heterogeneity of ADOA (Thiselton et al., 2002). To date, 230 pathogenic 
mutations have been found in OPA1 (Chen et al., 2013). 
 OPA1 spans approximately 100 kb and is comprised of 31 exons. Alternative splicing with 
exon 4b, 5b and 4 lead to the generation of eight transcripts and therefore eight different 
isoforms of the protein. Mutations found in patients with dominant optic atrophy have 
been found throughout the coding sequence of OPA1, the majority of which are located 
in exons 8-28. This region of the gene encodes for the GTPase domain (exon 8-15), the 
central dynamin domain (exon 16-24) and the C terminal region containing a coiled-coil 
domain (exon 25-28) (Delettre et al., 2002). 
 The mutations observed in OPA1 can be categorized into various types: nonsense, 
missense and splicing mutations (Delettre et al., 2002). Nonsense mutations, which can 
be found anywhere along the gene, arise due to the replacement of a nucleotide in the 
triplet code, which resultantly translates into a stop codon instead of an amino acid in 
the protein. Missense mutations which are predominantly located in the GTPase region 
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of the gene result from a change in a critical amino acid, giving rise to a malfunctioning 
protein. Splicing mutations are predominantly found in the GTPase region of the gene. 
They result from the replacement of a nucleotide in the splice site of the protein, leading 
to aberrant processing of the OPA1 transcript and possible skipping of an exon, which 
may contain amino acids critical for its function.  
Approximately half of these mutations result in a truncated version of OPA1 (Delettre et 
al., 2002). Truncation of the C terminal means the protein cannot interact with itself and 
other proteins resulting in haploinsufficiency of OPA1 (Olichon et al., 2007). The 
dominant mode of inheritance may, in part, be explained by the abundance of OPA1 
required in the retinal ganglion cells, meaning that the presence of one null allele could 
result in haploinsufficiency of OPA1, causing ADOA (Alexander et al., 2000). Non-
truncating mutations allow the mutant protein to compete with the wild-type for 
interaction with OPA1, itself, and other proteins. As the mutant protein lacks the vital 
GTPase activity this causes a dominant negative effect in the cell (Olichon et al., 2006). 
Although OPA1 expression is ubiquitous, it is most abundantly expressed in the brain and 
the retina, and to a lesser extent in the heart, liver, skeletal muscle and testis (Davies and 
Votruba, 2006). A wide range of tissues were examined by northern blot analysis and 
OPA1 transcripts were found in all tissues (Delettre et al., 2002). Predominant expression 
was noted in the ganglion cell layer of the retina above all other tissues in experiments 
carried out in rodents. The universal expression of OPA1 may explain the less common 
occurrence of extra ocular symptoms in syndromic ADOA.  
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1.2  OPA1 
 Protein structure  
OPA1 is a ubiquitously expressed dynamin related GTPase attached to the inner 
mitochondrial membrane. The protein is comprised of a mitochondrial leader sequence 
with a highly basic amino terminal coiled-coil (CC) domain, a central dynamin domain, a 
highly conserved GTPase domain and a carboxy terminal domain of unknown function 
(Davies and Votruba, 2006). The leader sequence enables the protein to locate to the 
mitochondrion, the coiled coil enables interaction with other proteins, the central 
domain regulates the GTPase activity of the protein and the function of the C terminal 
domain has yet to be determined (Satoh et al., 2003). Opa1 is unique from other dynamin 
related GTPases (Figure 1.3) in that the carboxy terminus lacks a GTPase effector domain 
(GED), a pleckstrin homology (PH) domain and a proline rich domain (PRD) (Alexander et 
al., 2000).  
 
 
Figure 1.3: A comparison between the structure of OPA1 and conventional Dynamins 
(Olichon et al., 2006). Opa1 is unique from other dynamin related GTPases in that the 
carboxy terminus lacks a pleckstrin homology domain and a proline rich domain. 
 
The size of the OPA1 gene varies between isoforms, ranging from 924-1015 amino acids 
in length. The molecular weight also varies, and isoforms can either be 88 or 93 kDa 
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proteins. It has been shown that the 93 kDa isoforms have a stronger association to the 
mitochondrial membrane than the 88 kDa isoforms. It was also found that the 93 kDa 
isoforms were mainly associated with the inner membrane while the 88 kDa isoforms 
were exclusively associated with the outer membrane. Exon 5b encodes much of the N 
terminal coiled coil domain and this exon is skipped in the 88 kDa isoforms. This suggests 
a requirement for this region in the binding of OPA1 to the inner membrane (Satoh et 
al., 2003). 
 OPA1 and mitochondrial fusion dynamics 
Opa1 has been found to play a vital role in mitochondrial fusion dynamics, a process by 
which mitochondria undergo continuous fusion and fission cycles maintaining 
equilibrium between interconnected networks or small individual units (Lee et al., 2004). 
Perturbing the balance between fusion and fission leads to an increase in ROS and a 
decrease in ATP production, events which favour cellular demise, most notably in highly 
energetic cells (Gray et al., 2013). In addition disruption to proteins involved in 
mitochondrial fusion dynamics have been implicated in neurodegenerative disorders, 
highlighting the importance of fusion dynamics for cell vitality (Twig and Shirihai, 2011).  
OPA1 is a profusion protein with its optimal functioning being dependent on its GTPase 
domain and the coiled-coil region at the C terminal (Cipolat et al., 2004). As mentioned 
previously, most pathogenic mutations in ADOA affect these two regions of the protein. 
Mutations in the GTPase domain or the Carboxy terminus result in globular shaped 
mitochondria in transfected cells. The observed globular shape is indicative of 
unopposed fission arising from aberrant fusion. 
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It is thought that the coiled-coil domain is necessary for the protein interactions 
responsible for mitochondrial fusion (Cipolat et al., 2004). Fusion of mitochondria 
requires the synchronized fusion of both the inner and outer membrane, to allow the 
exchange of mitochondrial matrix contents and mitochondrial elongation. This process 
relies on the coordinated functioning of profusion dynamin GTPases on the inner and 
outer mitochondrial membrane, OPA1 and Mfn1/Mfn2 respectively (Figure 1.4) (Song et 
al., 2009).  
Mitofusins; Mfn1 and Mfn2 are attached to the outer membrane with the GTPase 
domain and coiled-coil C terminal domain protruding into the cytosol. Fusion of the outer 
membrane of two adjacent mitochondria is facilitated by the interaction of the coiled-
coil region of mitofusin proteins on one mitochondrion with those on an adjacent 
mitochondrion (Chen and Chan, 2005). OPA1 on the other hand is attached to the inner 
mitochondrial membrane with the GTPase domain and coiled-coil region protruding into 
the intermembrane space and is involved in the fusion of the inner membrane. The 
precise mechanism by which OPA1 mediates inner membrane fusion is unknown. 
 
Figure 1.4: Opa1 is necessary for the fusion of fragmented mitochondria to create 
interconnected mitochondrial networks (Chen and Chan, 2005). OPA1 on the inner 
mitochondrial membrane works simultaneously with Mitofusins on the outer 
mitochondrial membrane to bring about mitochondrial fusion. 
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1.2.2.1 Mitochondrial membrane potential on the profusion function of OPA1  
There are 8 different isoforms of the protein, all of which can be further processed to 
form either short (S) or long (L) isoforms (Song et al., 2009). The L isoform is bound to 
the innermembrane and is required for innermembrane fusion. Processing of the L 
isoform of Opa1 involves constitutive cleavage by the intermembrane space AAA 
(ATPase associated with diverse cellular activities) protease YME1L at the protease 
cleavage site-S1 of the protein at exon 5 (Head et al., 2009). The resulting S isoform is a 
soluble protein due to the removal of the amino terminal transmembrane domain (Alavi 
and Fuhrmann, 2013). The soluble form is required to protect cells against death by 
apoptosis, upon exposure to stress (Sanjuán Szklarz and Scorrano, 2012). 
 The ratio of L to S isoforms must be kept constant to maintain the balance between 
fusion and fission (An et al., 2013). A decrease in mitochondrial membrane potential 
leads to inducible cleavage of OPA1L via the zinc metalloprotease OMA1 (Alavi and 
Fuhrmann, 2013). This inducible cleavage of additional L isoforms of OPA1 upsets the 
balance between L and S isoforms and results in the loss of function of OPA1 as a 
profusion protein. Another innermembrane protein, Hypoxia inducible domain family, 
member 1a (Higd1a), an antiapoptotic protein, interacts with OPA1 and prevents 
cleavage of the L isoform. The N-terminal domain of Opa1 is thought to be essential for 
the interaction with Higd1a as only the L isoforms can interact successfully with Higd1a. 
Further, cleavage of Opa1 into its soluble form and subsequent mitochondrial fission and 
cell death occurs in the absence of Higd-1a.   
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1.2.2.1 Mitochondrial dynamics and mitophagy 
Mitophagy is a quality control mechanism, whereby malfunctioning mitochondria are 
returned to the soma and eliminated from the cell by the autophagy system (Twig and 
Shirihai, 2011). Degradation of the mitochondria involves their engulfment into 
autophagosomes, which are subsequently fused with lysosomes to facilitate enzymatic 
demolition. 
 Mitophagy is essential for maintaining the quality of the mitochondria in the cell.  
Depolarized mitochondria undergo fission which is necessary to isolate damaged 
mitochondria from the mitochondrial population and facilitate their disposal by 
autophagy (Chen and Chan, 2009). The fate of the fragmented mitochondria is 
dependent on their cellular environment. They can be rescued by subsequent fusion with 
active mitochondria if unfavorable conditions are merely transitory. On the other hand, 
if the depolarized state is sustained OPA1 is cleaved and no longer able to carry out its 
profusion role.  
Mitochondria incapable of fusion are retained in a preautophagic pool and are degraded. 
Also, if insufficient OPA1 is available then the incidence of fusion events will decline, 
allowing autophagy of the fragmented mitochondria to prevail leading to apoptosis (Twig 
and Shirihai, 2011). The role of OPA1 in mitophagy involves an interaction with the 
proapoptotic protein Bnip3 in response to cellular stress. Retinal ganglion cells (RGCs) 
can be exposed to various stress inducers such as hypoxia in several ocular diseases. 
Mitophagy aims to restore homeostasis, however if cellular stress reaches threshold 
levels, OPA1 complexes may be disassembled and cell death will ensue.  
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With respect to ADOA, mutations in OPA1 may render the RGCs more vulnerable to 
stressors, hence reducing their resistance to demise (Landes et al., 2010). In a mouse 
model of ADOA in which Opa1 is mutated, there was an increase in the number of 
autophagosomes, with the most in the RGCs and the surrounding dendrites. The 
downregulation of OPA1 causes a decrease in membrane potential which leads to an 
increase in dysfunctional mitochondria that are targets for the competing actions of 
fusion and mitophagy. In the case of ADOA mitophagy appears to triumph, which is 
hypothesized to overburden the autophagy system, resulting in apoptosis of the RGCs 
(White et al., 2009).  
 General effects of the functional loss of OPA1  
ADOA is considered to be a mitochondriopathy as disruption to OPA1 leads to 
mitochondrial dysfunction, which ultimately gives rise to the disease phenotype. 
Homozygous inactivation of OPA1 causes embryonic lethality, suggesting a vital role for 
OPA1 in development (Davies et al., 2007). A loss of OPA1 in the cell results in 
mitochondrial fragmentation, decreased oxidative phosphorylation, a dissipation of the 
mitochondrial membrane potential and the initiation of apoptosis (Olichon et al., 2003). 
 OPA1 may be required for the maintenance of the protein levels and enzymatic activity 
of complex IV of the electron transport chain. Mice lacking opa1 in β islet cells were 
shown to have a significant decrease in the protein levels of all subunits of complex IV 
and a more minor decrease in a subunit of complex I. The remaining complexes were 
unaffected by the loss of opa1. The specific activity of Complex IV was likewise 
decreased, while no change was seen in that of the other ETC complexes. Interestingly, 
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Opa1 loss had no effect on mtDNA copy number, suggesting that the reduction in 
complex IV does not results from a reduction in mtDNA (Zhang et al., 2011). In mice 
heterozygous for Opa1, the activities of complex I and IV were found to be decreased 
from the wild-type, while all other complexes were unaffected. In contrast to the opa1 
null β islet cells, the mtDNA was markedly reduced in the heterozygous Opa1 mice (Chen 
et al., 2012). Furthermore, down regulation of Opa1 in primary cortical neurons lead to 
a reduction in the levels of reactive oxygen species (ROS). 
The levels of expression of pre and post synaptic proteins were reduced with the 
functional loss of Opa1, thereby, impairing the ability of the neurons to form new 
synapses (Bertholet et al., 2013). Opa1 loss also resulted in inhibition of dendritic growth 
essential for neuronal maturation. It is thought that expression of proteins involved in 
synaptogenesis is dependent on sufficient ROS levels, which are diminished with the loss 
of Opa1.  
 The role of OPA1 in apoptosis 
The loss of function of OPA1 has been extensively studied, yielding a wealth of 
information on the importance of this protein in maintaining mitochondrial integrity and 
cell viability. There appears to be interplay between mitochondrial morphology and 
apoptosis, however, the underlying molecular events with respect to the role of OPA1 
are less well understood.  
The structure of the cristae was found to be majorly disrupted in cells devoid of Opa1, 
which could be the central event leading to apoptosis (Olichon et al., 2003). 
Approximately 80% of cytochrome c is contained within the folds of the cristae and the 
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remainder is stored in the intermembrane space in a normal non apoptotic cell (Arnoult 
et al., 2005), (Martinou and Youle, 2006). It is thought that some isoforms of OPA1 such 
as that which contains exon 5b, form the cristae junctions supporting the sequestration 
of cytochrome c, therefore, when OPA1 expression is inhibited, cytochrome c may be 
released (Lenaers et al., 2009). Perturbations of the inner membrane structure allows 
the release of cytochrome c into the intermembrane space (Olichon et al., 2007). Cristae 
disorganization could occur prior to the dissipation of the membrane potential, which 
could open the cristae junctions allowing the release of cytochrome c, triggering 
apoptosis.  
Cell demise can be prevented by the overexpression of the anti-apoptotic protein Bcl2, 
suggesting that OPA1 is a target for pro or anti-apoptotic proteins (Olichon et al., 2007). 
The interaction of OPA1 with the anti-apoptotic protein Higd-1a has been shown to 
prevent cleavage of OPA1L; this in turn could prevent the release of cytochrome c into 
the cytosol. It is well known that the induction of the intrinsic apoptotic pathway requires 
the release of cytochrome c into the cytoplasm, and OPA1 is somehow crucial to 
counteract the intrinsic death signal (Alavi and Fuhrmann, 2013).  
The pro-apoptotic proteins Bax and Bak are mediators of the permeabilisation of the 
mitochondrial outer membrane facilitating the release of cytochrome c (Arnoult et al., 
2005). Opa1 is also released from the mitochondria and can be detected in the cytosol 
in apoptotic cells. Moreover, it is thought that the loss of OPA1 from the inner membrane 
after outer membrane permeabilisation inhibits fusion, allowing mitochondrial 
fragmentation to occur.  
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Lastly, the amount of cytochrome c required to activate the target caspases of the 
apoptosome has not been defined and may depend on cell type (Martinou and Youle, 
2006). The apoptosome itself can be activated by relatively small amounts of cytochrome 
c that could be released from the intermembrane pool during Bax/Bak mediated 
mitochondrial outer membrane permeabilisation (MOMP). In neurons (MOMP) can be 
reversed by antiapoptotic proteins, however, if the remaining cytochrome c is released 
from the cristae folds apoptosis could ensue.  
  The functional loss of OPA1 with respect to ADOA 
With respect to ADOA it is unknown as to why RGCs are exclusively affected by the 
functional loss of OPA1 considering that the protein is ubiquitously expressed. The 
highest levels of Opa1 RNA expression were found to occur in the retina and the brain 
however this does not explain the pathophysiology of ADOA (Alexander et al., 2000). The 
expression levels of OPA1 does not predominate in RGCs relative to other cells in the 
retina, nor is there a specific isoform expressed in RGCs, yet, other cells of the retina are 
unaffected by loss of function of OPA1 and the associated increase in apoptosis (Kamei 
et al., 2005). 
 If there is insufficient OPA1 available to maintain the structure of the cristae, 
cytochrome c could be available in the intermembrane space, in amounts sufficient to 
irreversibly trigger apoptosis. Therefore in the event of exposure to an apoptotic 
stimulus and the subsequent activation of Bax/Bak cell death would be inevitable. 
 The retinal ganglion cell may have high levels of antiapoptotic proteins to compensate 
for the increased exposure to apoptotic stimuli, which would make it more susceptible 
Chapter 1. Introduction 
16 
 
to Opa1 loss of function. Further, it was found that neurons can restore normal function 
after cytochrome c release if exposed to nerve growth factor (NGF). Opa1 deficient cells 
are thought to be lacking in the ROS dependent upregulation of proteins involved in cell 
growth and survival, rendering them unable to overcome apoptosis (Chen et al., 2012). 
  
Chapter 1. Introduction 
17 
 
1.3 Animal models of ADOA 
The availability of retinal tissue from patients with ADOA is low due to the scarcity of 
patients with the disease. Thus the creation of animal models is necessary to gain insight 
into the pathology of the disease, as well as testing the efficacy and safety of therapeutic 
intervention in statistically viable numbers. 
 Drosophila model of Opa1 deficiency  
An eye specific Opa1 mutant drosophila was generated by somatic mutagenesis, 
inactivating two copies of the Drosophila ortholog of OPA1, CG8479 (dOpa1) in the eye 
(Yarosh et al., 2008). Eye specific mutants were chosen due to the embryonic lethality of 
homozygous mutants and the lack of eye phenotype observed with the heterozygous 
mutants. The eyes in this model were found to be glossy due to decreased lens and 
pigment disposition by cone and pigment cells. They also had a rough phenotype due to 
failure of the cells within the ommatidium to develop and pattern properly, which may 
be due to defective apoptosis during development. The mitochondria were scarce and 
dysmorphic in mutant cells of this model, which may be caused by the increased ROS 
production and cell death also observed in these cells.  The glossy eye phenotype can be 
significantly reduced with the over expression of the antioxidant hSOD1 however no 
effect was observed on the rough eye phenotype. The observations in this model support 
the role of ROS in the pathogenesis of ADOA which would intuitively suggest that 
antioxidants would ameliorate the disease phenotype.  
This model may show the effects of Opa1 loss at a systemic level, however, the reliability 
of this model in uncovering the pathogenesis of ADOA is questionable. On the other 
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hand, the mouse is a suitable choice for a disease model due to the relative ease of 
genetic manipulation and the high homology to the human genome. 
 Opa1 null β-islet cell mouse  
To find out the role of Opa1 in specific tissues a conditional mouse strain must be 
generated, as homozygous null embryos are not viable. The islet cells were chosen due 
to the important role of oxidative phosphorylation in regulating glucose levels in the 
blood. To investigate the role of Opa1 in the pancreatic β-islet cell, Opa1 was deleted 
from these cells by introducing IoxP recombination sites before exon 10 and after exon 
13 in the Opa1 gene (Zhang et al., 2011). The intervening sequence which encodes for an 
essential G3 motif in the GTPase domain is excised, resulting in a dysfunctional Opa1 
protein. This model shows a reduction in the activity and the amount of Complex IV 
activity in the β-islet cells while there is no reduction in the copy number of mtDNA.  
There was no increase in apoptosis detected in these cells, however cell proliferation was 
found to be impaired. 
 Mouse model of RGC loss 
Genetic manipulation was employed to create a mouse model whereby RGCs are 
programmed to be removed after differentiation. This allows a more accurate 
investigation of the effects of RGC loss on optic nerve degeneration compared to a 
knockout model that merely prevents normal RGC development. The Pou4f2 gene which 
is required for the differentiation and survival of RGCs was knocked out in one allele by 
the insertion of floxed-lacZ-stop-diphtheria toxin A (dta) cassette in the creation of a 
heterozygotes mouse (White et al., 2009). This mouse was then crossed with mice with 
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a tamoxifen-inducible cre strain and the resultant mice were maintained as stock lines. 
Tamoxifen administration caused successful ablation of the RGCs. The retinas 
maintained their structural integrity while the model shows characteristic features of 
retinal degeneration. 
 Syndromic ADOA mouse model 
An Opa1 knock-in mouse carrying the recurrent OPA1c.2708_2711delTTAG mutation, 
described in patients was generated by deleting the four conserved TTAG base pairs in 
exon 27 of the murine Opa1 gene. The gene was integrated by homologous 
recombination at the Opa1 gene locus in embryonic stem cells which were subsequently 
injected into E3.5 blastocysts of C57Bl6/J mice. The Opa1+/- mice have one defective copy 
of Opa1 in which the last 58 amino acids are deleted due to the presence of a premature 
stop codon. A progressive loss of visual acuity can be observed in these mice which may 
be associated to the reduction in the COX activity in the retina. The RGC number was half 
that of control mice in this model between the ages of 9 and 16 months (Sarzi et al., 
2012).  The mice also displayed reduced auditory brain stem responses, locomotive and 
gait abnormalities and disorganised myofibres from both skeletal and cardiac muscle, 
consistent with the extraocular symptoms observed in ADOA plus patients (Sarzi et al., 
2012).  
 Main mouse models of ADOA 
There are two main mouse models of ADOA that have been published: the B6;C3-
Opa1Q285STOP Opa1 mutant mouse and the B6;C3-Opa1329-355del Opa1 mutant mouse 
(Davies et al., 2007), (Alavi et al., 2007). 
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1.3.5.1 B6;C3-Opa1329-355del 
The B6;C3-Opa1329-355del Opa1 mutant mouse was generated by screening an N-ethyl-N-
nitrosourea (ENU)-mutagenized DNA library of mouse DNA and identifying a splice site 
mutation in murine Opa1 intron 10: c.1065 + 5G → A (Alavi et al., 2007). A purebred 
C3HeB/FeJ mice carrying the Opa1enu/+ mutation were outcrossed with C57BI/6. 
Subsequent Opa1enu/+ mice were intercrossed to create a DOA mouse model with the splice 
site mutation identified in the Opa1 gene and wild-type littermate controls. The 
mutation in this model is close to three mutations found in DOA patients, namely c.1065 
+2T > C, c1065 + 2T > G and c.1065 + 3A > C. Mutations in this region of the Opa1 gene 
lead to an in-frame deletion of 27 amino acid residues in the dynamin GTPase domain, 
due to the skipping of exon 10. 
1.3.5.2  B6;C3-Opa1Q285STOP  
The B6;C3-Opa1Q285STOP mutant mouse model was generated by screening an ENU-
mutagenized DNA library of CH3 male mice for point mutations in Opa1  (Davies et al., 
2007). A heterozygous nonsense mutation in exon 8 was selected which codes for a C-T 
transition at 1051 bp. This introduces a stop codon in place of glutamine285, leading to 
the expression of a truncated protein at the start of the GTPase domain. This mutation 
is close to the mutation that is the most common cause of ADOA in humans at the 290 
amino acid. The Opa1 mutant mice line was then generated via in vitro fertilization of 
C57BI/6J females with mutant sperm. The founder generation was outcrossed to 
C57BI/6J up to the 4th generation and the heterozygous Opa1+/- mice were then 
intercrossed to create generation cohorts (Davies et al., 2007). This model shows 
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premature degeneration of the optic nerve and an increase in the presence of 
autophagosomes in the RGCs and their axons (White et al., 2009). 
1.3.5.3 Validity of B6;C3-Opa1Q285STOP  and B6;C3-Opa1329-355del as models of DOA 
Both models show a 50% reduction in Opa1 RNA in the retina and a 50% reduction in 
Opa1 protein in a number of different tissues, supporting the theory that 
haploinsufficiency is underlying the pathophysiology of DOA. 
 The B6;C3-Opa1Q285STOP mouse displays a loss in visual acuity noted at 12 months, which 
is consistent with the age at which dendropathy of RGCs begins to occur (Williams et al., 
2011).  Abnormalities in myelin distribution in the optic nerve reportedly began at 9 
months of age in this model and continued to 18 months (Davies et al., 2007). This is 
consistent with findings in older ADOA patients whereby demyelination was observed 
(Davies et al., 2007). 
The B6;C3-Opa1329-355del  appears to have a more severe phenotype showing total loss of 
large axons and  a significant loss of small axons of the RGCs which make up the optic 
nerve by the age of 8 months (Alavi et al., 2007). The findings suggest that large RGCs 
have an increased susceptibility to the Opa1 mutation. However, in some cases the loss 
of large axons may be due to the shrinkage of RGC axons that occurs prior to cell death. 
The axonal degeneration in the B6;C3-Opa1Q285STOP mice began at 9 months and the 
axonal counts were significantly reduced by 24 months (Davies et al., 2007). The RGC 
layer in the B6;C3-Opa1Q285STOP mouse was compared to littermate controls of up to 24 
months and revealed no difference in cell death between the two groups. Similarly there 
was no change in the retinal architecture or morphology in the mutants compared to the 
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controls, however, there was a significant increase in the number of autophagosomes in 
the soma of the RGCs and their axons.  
The B6;C3-Opa1329-355del  model shows a slight reduction in the number of RGCs in the 
mutant mice at 13 months which was exacerbated significantly by 23 months, suggesting 
a progressive loss of RGCs in the pathophysiology of ADOA (Alavi et al., 2007). 
Contrastingly, the B6;C3-Opa1Q285STOP model suggests that ADOA results from RGC 
dysfunction rather than cell loss, as visual function appears to be disrupted in the 
absence of RGC loss (Williams et al., 2011). Disruption to the visual pathway in these 
models was revealed by analysis of the visual evoked potentials which are suggestive of 
RGC loss or dysfunction.  
Further, in the B6;C3-Opa1Q285STOP  mouse model mitochondria were punctuated and 
dispersed throughout muscle explant cells (Davies et al., 2007). In cardiac cells of the 
same model, a reduction in ATP production, oxygen consumption and protein levels of 
COX, as well as a reduced resistance to oxidative stress was observed (Chen et al., 2012). 
 Selective dendropathy in the B6;C3-Opa1Q285STOP  mouse 
Exactly how defective mitochondrial fusion dynamics leads to RGC degeneration has as 
of yet failed to be established, however the B6;C3-Opa1Q285STOP  mice are providing 
invaluable insight into the underlying mechanisms of ADOA. 
The progressive dendritic atrophy in the RGCs of the B6;C3-Opa1Q285STOP mouse 
beginning from the ages of 10-15 months were localized to those synapsing in the 
sublamina b (ON layer) of the inner plexiform layer with dendrites synapsing in the outer 
OFF layer relatively unaffected (Williams et al., 2010b). These findings are suggestive of 
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a selective effect of the functional loss of Opa1 on On-Centre RGCs, which have different 
energy demands and neurotransmitter pathways to the resistant Off-Centre cells 
(Williams et al., 2010b). Findings from the B6;C3-Opa1Q285STOP  mouse suggests that RGC 
loss and optic nerve degeneration occurs secondary to the slow progressive dendritic 
pruning, causative of the insidious onset of ADOA. The pressing question, regarding the 
selective atrophy of the On-Centre RGCs remains unanswered. 
 A decrease in complex I and IV activities and an associated reduction in ATP production 
was found in the B6;C3-Opa1Q285STOP mouse (Chen et al., 2012). Due to the mitochondrial 
dysfunction seen in the absence of Opa1, the magnitude of energy demanded of the 
mitochondria in the RGCs to maintain their function should be considered. There is a 
large energy demand of RGCs due to the large dendritic field. Each process requires a 
plentiful supply of mitochondria along its length, in order to be sustained by the cell. 
Moreover, myelination of the RGC axon begins, merely as the nerve leaves the eye. This 
puts an additional strain on the energy resources of the cell as the relatively large 
unmyelinated portion of the axons reduces the conductive capacity of the axon, thereby 
increasing the amount of ATP needed to carry out the same function (Williams et al., 
2012). 
Furthermore, the loss of Opa1 and the consequential mitochondrial dysfunction have 
been shown to result in dysfunctional connectivity in the RGCs (Williams et al., 2012). 
The dendritic pruning seen in the B6;C3-Opa1Q285STOP  mouse is accompanied by  atrophy 
of  the synapses of the RGCs, as shown by decreased synaptic density and structural 
changes. It was also found that there was a decrease in glutamatergic synapses, while 
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the GABAergic synapses were unaffected by loss of Opa1. On-Centre cells synapse with 
bipolar cells via glutamatergic receptors, which have high energy requirements while 
their Off-Centre counterparts use GABAergic transmission which has a much lower 
energy demand. This finding supports previous findings for selective atrophy of On-
Centre RGCs and brings to attention, yet again, to the immense energy demands of the 
ON-centre RGCs. 
 Of note, the mitochondria within the synaptic button were found to be fragmented 
(Williams et al., 2012). As mentioned previously, the fate of fragmented mitochondria is 
dependent on the cellular environment, i.e. they can be rescued if optimal conditions are 
restored within the cell. However, with the unceasing energy demands of the On-Centre 
RGCs and an inadequate number of functioning mitochondria, it is inevitable that the 
mitochondria will be unable to elongate and will be thus, degraded. The cell may then 
begin to retract its processes to alleviate the energy burden of the cell, giving rise to the 
pruning of the dendrites that is seen in this model. 
If we could find a way to assist the mitochondria in meeting the, presently, 
unsurmountable challenge of providing adequate ATP to the On-Centre RGCs, then it 
may be possible for the RGCs to retain their dendrites. This in turn may prevent the 
deterioration of visual acuity seen in our model. 
1.3.6.1 RGC classification 
RGC subtypes have been found to have differential susceptibility to death in diseases 
associated with RGC degeneration such as glaucoma (Struebing et al., 2016). In ADOA 
ON-centre RGCs have an increased susceptibility to degeneration compared to OFF-
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centre RGCs (Williams et al., 2010b), therefore, it is also possible that further subclasses 
of RGCs are differentially susceptible to degeneration in ADOA. It is, therefore, important 
to be able to identify different RGC subtypes and be aware of the percentage of each 
type in each experimental group to avoid confounding the results. 
RGCs can be classified based on their electrophysiology, morphology, anatomy and 
genetics (Sun et al., 2002) (Baden et al., 2016). RGCs were first classified into ON-centre, 
OFF-centre and ON-OFF cells based on the response of the cells to light (Baden et al., 
2016). Based on their morphology, RGCs can be classified into four main groups, three 
different groups of monostratified cells (RGA, RGB and RGC) and a group of bistratified 
cells (RGD) (Sun et al., 2002). The monostratified cells are classified based on the size of 
their soma and dendritic field. RGA cells have a large soma and a large dendritic field, RGB 
cells have a small to medium sized soma and a small to medium sized dendritic field, and 
RGC cells have a small to medium sized and a medium sized dendritic field (Sun et al., 
2002). RGCs can be sub classified based on the morphology, with 10 subclasses of 
monostratified and 4 subclasses of bistratified cells identified in the mouse based on size 
shape and branching pattern (Coombs et al., 2006). RGCs in mice have been shown to 
project to at least 40 different targets, suggesting a large number of RGC subtypes, based 
on an anatomical classification (Baden et al., 2016). Further, populations of RGCs can be 
classified based on their genetic profile.  
The RGC classification system is based on RGCs from healthy adult and developing 
retinae (Tribble et al., 2014). Since RGC degeneration in the the B6;C3-Opa1Q285STOP  
mouse presents as a loss in dendrites and dendritic field size, therefore RGC classification 
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based on dendritic field size and branching density may be unreliable in this model. 
However, it is also possible to classify RGCs based on dendritic features that are more 
resistant to degeneration such as the more proximal dendritic structures, which remain 
intact during early stage RGC degeneration. It was found that RGCs can be classified 
based on the RGC soma and proximal dendritic field size, and primary dendrite thickness 
(Tribble et al., 2014). In addition, asymmetry in the proximal dendritic tree can be used 
to discriminate between different RGC subtypes. 
 Limited treatments for ADOA 
To date there is no effective treatment available for ADOA. Low visual aids can have some 
benefit in patients with severely decreased visual acuity, however, there is no effective 
means of reducing the severity of the symptoms of ADOA (Lenaers et al., 2012). 
 As the energy deficits appear to be responsible for the cell loss seen in ADOA, targeting 
the apparent dysfunctional ETC of the mitochondria to increase energy production 
seems like the most attractive treatment option. Idebenone is an ETC targeting drug that 
has been shown to have some therapeutic effects, however, these effects are not 
sufficient for the drug to be recognized as an effective treatment for optic neuropathies 
including ADOA. 
Idebenone is a benzoquinone, a synthetic analogue of Coenzyme Q10 which acts as an 
exogenous transporter of electrons through the electron transport chain in the 
mitochondria, thereby, increasing the rate of ATP production. Idebenone acts by 
transporting electrons directly to Complex III thereby bypassing Complex I which is 
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defective in ADOA. It is also an antioxidant which can counteract the increase in ROS 
produced as a result of the defect in complex I (Barboni et al., 2013).  
This shows the need to address other underlying features of ADOA as targets for 
therapeutic intervention, as the effects of bypassing the defective complex I appear to 
be clinically insufficient. A more effective treatment for ADOA is needed. As complex IV, 
which is downstream to complex I, has also been shown to be defective in this condition, 
targeting complex IV could bring about a greater yield of ATP production. As red light is 
hypothesised to upregulate the activities of complex IV, the possibility of irradiating the 
RGCs with 670 nm light could provide a simple non-invasive way of ameliorating the 
condition. 
1.4 The potential of red/NIR light therapy in retinal neurodegeneration 
 History of light therapy 
The therapeutic properties of light have been known since antiquity, as far back as 1400 
BC, where it was used by Hindus to treat skin disorders (Roelandts, 2002). The ancient 
Egyptians, Greeks and Romans were also reportedly aware of the beneficial effects of 
sunlight which they used to treat various ailments (McDonagh, 2001). The evidence for 
the use of phototherapy in those time, however, is purely anecdotal. It was not until 
1903 that the therapeutic power of light gained scientific recognition, when Niels Finsen 
was awarded the Nobel Prize in medicine for the discovery of UV light as a treatment for 
skin tuberculosis (lupus vulgaris) (Finsen, 1901).  
Red light was later found to have biostimulatory effects; an unintentional discovery 
made by Endre Mester, in 1967, who wanted to assess the ability of 694 nm lasers to 
Chapter 1. Introduction 
28 
 
cause carcinogenesis in mice (Mester et al., 1971). The mice in both the light-treated and 
untreated groups were shaved prior to laser exposure. The results found that the light-
treated group did not develop cancer, but more intriguingly, the hair grew back on the 
laser treated mice at a faster rate than the untreated group.  
In more recent times, there has been a surge in the use of red and near infrared (NIR) 
lasers and LEDs in clinical and preclinical research (Desmet et al., 2006). As red and NIR 
light have relatively long wavelengths, they have the advantage of a greater penetration 
depth over shorter wavelengths, making them an ideal choice for the treatment of neural 
tissue (Hartwig and Van Veen, 1979). In addition to light being able to penetrate into the 
tissue of interest, another requirement is that the photon energy corresponds to the 
absorption characteristics of the chromophores responsible for triggering the beneficial 
effects upon photoexcitation. It appears that red and NIR light correspond the absorption 
maxima of such chromophores as will be discussed later. For various reasons, LEDs are 
most commonly used as the light source in these studies. Most importantly, red/NIR LED 
therapy has been approved for use in humans and has been deemed as a non-significant 
risk by the U.S. Food and Drug Administration. Although shorter wavelengths of visible 
light and UV light are also employed for therapeutic purposes, their safety for use in 
humans, especially for the eye, is less clear (Rozanowska et al., 2009, Rozanowska, 2012). 
With the ultimate objective of exploring the efficacy of phototherapy as a treatment for 
neurodegeneration in the human retina, this review will focus only on the use of 
wavelengths that are least likely to cause adverse effects, that is red and NIR 
light(Barolet, 2008).  
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 The potential of red/NIR light as a treatment for 
neurodegeneration 
1.4.2.1 Evidence from in vitro studies 
Red and NIR light have been shown to provide protection against the deleterious effects 
of mitochondrial electron transport chain inhibitors and excitotoxic cell death in neurons 
in vitro (Wong-Riley et al., 2005, Ying et al., 2008a, Huang et al., 2014). Since impaired 
mitochondrial function and excitotoxicity are common causes of cell death in 
neurodegenerative conditions, the ability of red/NIR light to protect against these 
challenges in vitro has emphasized the potential of this therapy in various 
neurodegenerative conditions.     
1.4.2.2 The effects of red/NIR light in models of neurodegeneration 
Red/NIR light therapy has shown great potential in the treatment of acute 
neurodegenerative conditions, showing neuroprotective effects in rodent models of 
spinal cord injury, traumatic brain injury and stroke (Byrnes et al., 2005b, Wu et al., 2012, 
Xuan et al., 2015, Dong et al., 2015a, Oron et al., 2006, Giacci et al., 2014b).  
Furthermore, red light has been shown to have beneficial effects in animal models of 
some of the most prevalent neurodegenerative diseases. A reduction in cell loss and 
other markers of disease severity was seen with red/NIR light treatment, in rodent 
models of multiple sclerosis, Alzheimer’s and Parkinson’s disease (Muili et al., 2013, Muili 
et al., 2012, Purushothuman et al., 2015, Purushothuman et al., 2013, Oueslati et al., 
2015, Johnstone et al., 2014, Peoples et al., 2012b, Shaw et al., 2010).  
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1.4.2.3 The potential of red/NIR light as a successful treatment for neurodegeneration in 
humans 
While transcranial red/NIR light therapy is yielding remarkable results in numerous 
rodent models of neurodegeneration, the real question is how well these results will 
translate when applying this therapy to human patients.  
Interestingly, in a neurotoxin-induced monkey model of Parkinson’s disease, 670 nm 
light was delivered directly to the macaque midbrain using an implanted optical fibre 
which was activated over the period of time of 5-7 days when the neurotoxin precursor, 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), was injected (Darlot et al., 2016). 
The study found a reduction in clinically-assessed behavioural impairment with this 
method of red light delivery in this primate model as well as neuroprotection to the 
dopaminergic neurons of the substantia nigra. Although a more invasive method of 
delivery than transcranial red light treatment, no major adverse effects were observed 
following surgical implantation of the optical fibre. However, it would have been of great 
interest if the effects of transcranial light delivery were also tested in this model, for 
comparison.  
 Red light treatment in retinal degenerative diseases 
Since the retina is an extension of the CNS, the neuroprotective effects of red/NIR light, 
as discussed above, should also be observed in this tissue. In fact, irradiating the retina 
with red or NIR light seems more likely to be successful as a non-invasive treatment for 
human patients as the issue of tissue penetration is avoided. 
Chapter 1. Introduction 
31 
 
1.4.3.1 The safety of light treatment on the retina 
The greatest concern arising when aspiring to use red light therapy to treat retinal 
degeneration, is the potential retinal damage that may occur upon direct exposure of 
the retina to light with high levels of irradiance. The dangers of high levels of irradiance 
on the retina is highlighted in a study on anesthetised monkeys (Friedman and Kuwabara, 
1968). It was found that white light with a retinal irradiance of 270 mW/cm2 caused 
irreversible damage to the photoreceptors and retinal pigment epithelium. White light 
is made up of light of all wavelengths in the visible light spectrum, with light of shorter 
wavelengths and higher frequencies having a greater damaging effect on 
photoreceptors. Blue light, with a relatively short wavelength, was found to cause 
irreversible damage to S cones (Harwerth and Sperling, 1975).  While exposure to green 
and red light caused damage to M and L cones, respectively, the damage to these cones 
was reversible, with a full recovery of function seen after a few weeks. More recent 
studies on macaque monkey, however, have demonstrated that yellow light of 568 nm 
wavelength can cause retinal damage manifested as disruption of the retinal pigment 
epithelium at the dose below the Maximal Permissible Exposure established by the 
American National Standard Institute’s (ANSI) as a standard for the safe use of lasers 
(Hunter et al., 2012). 
Albeit transient and less severe than light of shorter wavelengths, damage to L cones 
upon exposures to high levels of red light would be a cause for concern when considering 
red light as a treatment for retinal degeneration. This concern has been addressed with 
numerous in vivo studies. These studies have shown that therapeutic effects were 
achieved, in the absence of retinal damage, when rodent retinas were exposed to 670 
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nm light with a therapeutically effective irradiance and exposure times (Albarracin et al., 
2013, Albarracin et al., 2011, Giacci et al., 2014a). Further, this included irradiance of 60 
mW/cm2 which is the highest irradiance level found in studies of in vivo models of retinal 
degeneration where positive results were achieved using 670 nm light. This 
demonstrates the safety of using 670 nm light as a treatment for retinal degeneration. 
In addition to photoreceptor damage, the possibility of photothermal damage to the 
retina and surrounding ocular structures evokes further concern when considering using 
light to treat retinal degeneration (Youssef et al., 2011). Comparing the effects of green, 
red and NIR laser light exposure on the temperature rise in the human choroid, it was 
found that the longer wavelengths led to a smaller degree of choroidal heating, due to 
the decrease in absorption by melanin with increasing wavelength (Vogel and 
Birngruber, 1992). The variation in choroidal heating between green and red 
wavelengths was minor compared with the difference between green and NIR 
wavelengths.  
Still the question remains as to which would be the optimal wavelength for use as a 
neuroprotective agent in the retina. Addressing this, the efficacy of red and NIR light 
were compared in a model of partial optic nerve transection (Giacci et al., 2014a). It was 
found that although protective effects were seen in retinae treated with both red and 
NIR light, 670 nm light was more effective in improving visual function compared with 
830 nm light. However, in a rat model of light induced retinal degeneration protective 
effects were observed with 670 nm light treatment, but no protection was seen with 830 
nm light (Giacci et al., 2014a). It is therefore not surprising that most studies testing the 
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effectiveness of phototherapy on neurodegeneration in the retina use red light at 670 
nm.  
1.4.3.2  670 nm light therapy in models of photoreceptor damage  
As discussed above, exposing the retina to bright light can cause photoreceptor damage, 
an event that can occur with excessive sunlight exposure or accidental exposure to high 
intensity artificial light sources. Models of light induced photoreceptor damage are also 
used to simulate retinal degenerative diseases, involving photoreceptor specific death. 
Emphasising the vast and diverse effects of light on biological tissue, irradiating the retina 
with red light provided protection against the structural damage to the outer retina and 
loss in photoreceptor function in a rat model of light induced photoreceptor 
degeneration (Albarracin et al., 2011). Methanol can also induce damaging effects on the 
retina causing photoreceptor toxicity due to the ability of its metabolite, formic acid, to 
inhibit cytochrome c oxidase, the terminal enzyme of the electron transport chain. In a 
rat model of methanol induced retinal toxicity, red light treatment brought about a 
significant recovery of rod and cone mediated function, in addition to preventing 
methanol induced changes to outer retinal morphology (Eells et al., 2003). These studies 
show the ability of red light to protect against loss in photoreceptor function, an event 
that would cause severe visual impairment and would otherwise be irreversible. 
1.4.3.3 The effects of red light on inflammation in the outer retina 
Inflammation in the retina has been implicated in many retinal diseases including age 
related macular degeneration (AMD) and diabetic retinopathy, and as such, looking at 
ways to alleviate inflammation in these conditions is thought to reduce the severity of 
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symptoms associated with these diseases (Whitcup et al., 2013). Also, an upregulation in 
inflammatory proteins has been observed following light damage in rats, demonstrating 
pathological features similar to “dry” AMD (Rutar et al., 2012). In addition to its ability to 
protect against light induced photoreceptor damage, red light treatment was found to 
reduce the complement propagation that occurs in the retina following light damage. 
Red light treatment was also tested in an aged genetic mouse model of AMD, the 
complement factor H knockout, which presents with reduced retinal function and 
increased inflammation (Begum et al., 2013). In contrast to most studies with red/NIR 
light where the light source was held directly in front of the animal, the environmental 
light was supplemented with red light for this study. Even though the red light exposure 
was indirect, the levels reaching the retina were sufficient to reduce inflammation in the 
outer retina, in this model. 
In addition to inflammation associated with disease pathology, inflammation increases 
in the retina with age. Red light was effective in reducing proinflammatory cytokines and 
a chronic marker of inflammation in the aged mouse retina, demonstrating the potential 
of red light to also alleviate the visual decline associated with normal aging 
(Kokkinopoulos et al., 2013). These studies draw attention to the ability of red light to 
produce anti-inflammatory effects associated with outer retinal degeneration, whether 
by induced damage, disease pathology or normal aging.  
1.4.3.3 The effects of red light on neurodegeneration in the inner retina  
Retinal ganglion cell (RGC) death and optic nerve degeneration are hallmarks of optic 
neuropathy, a frequent cause of vision loss, of which the causes are many.  Red light 
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therapy has been trialled in a rat model of diabetic retinopathy and positive outcomes 
have been reported. There was a significant reduction in the diabetes induced RGC death 
and a 50% improvement in the diabetes-induced reduction in ERG amplitude with 
exposure to red light (Tang et al., 2013a). Highlighting the beneficial effects of red light 
on the retinal vasculature, red light also prevented the diabetes-induced increase in 
leukostasis in the retinal vasculature, an event which is implicated in the pathogenesis 
of diabetic retinopathy. Further, the diabetes-induced increase in retinal expression of 
an adhesion molecule, essential for leukostasis, ICAM-1, was also prevented with red 
light. Similarly, in a model of secondary degeneration of RGCs, resulting from traumatic 
injury to the optic nerve, red light was found to be protective (Fitzgerald et al., 2010). 
The secondary damage, following partial optic nerve transection, normally leads to 
further loss of RGCs and visual function; however, normal visual function was restored 
with red light treatment(Fitzgerald et al., 2010). Furthermore, treatment with 670 nm 
light in a rat model of partial optic nerve transection resulted in improved vision 7 days 
post injury (Giacci et al., 2014a). Additionally, dendropathy of retinal ganglion cells, an 
event found to be associated with visual loss in experimental models of glaucoma and 
autosomal dominant optic atrophy, was partially prevented, in an axotomy model of 
neurodegeneration, with red light treatment (Beirne et al., 2016). Protection against RGC 
and optic nerve degeneration, arising from different conditions, appears to be possible 
with red light treatment. Since RGC dysfunction and optic nerve degeneration are 
common features among numerous other types of optic neuropathies red light has the 
potential to provide protection in these conditions also.  
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However, the successful outcomes achieved in the discussed experimental models were 
seen when red light was administered immediately after induced optic nerve injury, a 
treatment strategy that would be unachievable in a real life clinical setting. Although the 
therapeutic window of opportunity for red/NIR light therapy in models of traumatic optic 
neuropathy has not been explored, it has been assessed in other CNS injury models. NIR 
light therapy improved motor function in a rabbit model of embolic stroke when 
treatment was administered 6 hours post-embolization, but was ineffective when 
administered 12 hours post embolization (Lapchak et al., 2007). The findings show that 
neuroprotection can be achieved when red/NIR light is administered for up to 6 hours 
after the induced injury, showing the therapy to be applicable to a clinical setting. Other 
studies on animals demonstrated effectiveness of near-infrared light in a mouse model 
of traumatic brain injury when administered 4 hours after injury, with additional 
treatments administered at one and two days post injury(Xuan et al., 2016, Thunshelle 
and Hamblin, 2016). The transcranial treatment upregulated brain-derived neurotrophic 
factor (BDNF), improved neurological functions, reduced the size of the lesion, 
stimulated formation of new neurons and stimulated synaptogenenesis. There are also 
growing body of evidence suggesting that people affected by chronic traumatic brain 
injury or after stroke can benefit from transcranial irradiation with red/near-infrared 
light (Naeser et al., 2016, Hamblin et al., 2016) 
1.4.3.4 Red/NIR light as a therapy for patients with retinal disease 
The protective effects seen with red light treatment, in the absence of adverse effects, 
in numerous in vivo models of retinal degeneration, strongly suggest this non-invasive 
treatment should be trialled in patients with retinal degeneration. Progress to this end 
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has commenced with trials of red and NIR light therapy yielding promising results in 
patients with AMD. In one such study, a brief exposure of NIR light (780 nm), from a 
semiconductor laser diode, to AMD patients, twice per week for two weeks, resulted in 
a significant improvement in their visual acuity (Ivandic and Ivandic, 2008). This 
improvement in vision was seen in patients with both wet and dry AMD and was 
maintained for 3-36 months after treatment. Moreover, no adverse effects of the 
treatment were seen. In this study, the laser was applied transconjunctivally to the 
macula when the eye was in adduction. In another study looking at the effects of 
photobiomodulation on patients with dry AMD, the retina was irradiated through the 
pupil with red light (670 nm), from the FDA approved Warp 10 LED light source, 3 times 
per week for 6 weeks (Merry et al., 2013). The visual acuity and contrast sensitivity 
remained significantly improved for 12 months after treatment; however, the 
improvement in visual acuity began to decline after 4 months. The results provide vital 
information on the time at which patients may benefit from re-treatment, in addition to 
providing pilot data on the safety and effectiveness of 670 nm light from an LED source. 
Red/NIR light has also been trialled in diabetic macular edema and Leber’s hereditary 
optic neuropathy, however, there are no results available from these studies. A summary 
of all the studies using red/NIR light as a treatment intervention in conditions associated 
with neurodegeneration in the retina is available in Table 1. From all the studies listed, 
red/NIR light is showing the greatest potential as a treatment for AMD. Since positive 
outcomes have been observed in patients with AMD, this paves the way for the 
application of this therapy in other retinal degenerative conditions, particularly those 
where positive outcomes have been seen in preclinical studies. 
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Responsible 
party 
Last verified on 
ClinicalTrials.gov 
Condition 
Duration 
of 
treatment 
period 
Number 
of 
patients 
Duration of 
improved 
vision after 
treatment 
Status 
Harry T 
Whelan 
01/09/2013 
Diabetic 
Macular 
Edema 
3 months 20 
No results 
available 
Completed 
Ivandic and 
Ivandic 
2008 
N/A 
Wet and dry 
AMD 
2 weeks 203 
Up to 36 
months 
Completed and 
published(Ivandic 
and Ivandic, 
2008) 
Merry, 
Graham 
01/11/2011 
Non-
exudative 
Age-related 
Macular 
Degeneration 
6 weeks 9 
Up to 12 
months 
Completed and 
published(Merry 
et al., 2013) 
Merry et al., 
2016 
N/A 
Non-
exudative 
Age-related 
Macular 
Degeneration 
3 weeks 24 3 months 
Completed and 
published(Merry 
et al., 2016) 
University 
of Sydney 
01/06/2014 
Diabetic 
retinopathy 
4 weeks N/A N/A Planned 
LumiThera, 
Inc. 
01/04/2016 
Age-related 
Macular 
Degeneration 
3 weeks 30 N/A Planned 
Harry T 
Whelan 
01/09/2014 
Leber’s 
hereditary 
optic 
neuropathy 
3 months 4 N/A 
Terminated (0/4 
patients 
completed the 
study) 
Table 1.1: A summary of the completed, planned and terminated clinical trials, using 
red/NIR light as a treatment intervention in conditions associated with retinal 
neurodegeneration. The table includes the name of the organisation of person 
responsible for the trial, the date when the trial was last verified on Clinicaltrials.gov, the 
condition for which red/NIR light is being tested in, the duration of the red/NIR light 
treatment period, the duration of the improvement in vision after cessation of treatment 
and the status of the trial. 
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 The effects of red/NIR light on mitochondrial dysfunction 
Although the therapeutic benefits of red/NIR light therapy have been demonstrated in a 
number of different disease models, in addition to AMD patients, the underlying 
molecular mechanisms are less well understood (Desmet et al., 2006). The question is no 
longer whether or not light has biological effects, it is rather how these effects are 
mediated at a cellular and molecular level (Hamblin and Demidova, 2006).  
1.4.4.1 Cytochrome c Oxidase: the photoacceptor for red/NIR light 
Endeavors to uncover the underlying molecular mechanisms suggest a major role for 
cytochrome c oxidase (COX), which is the terminal enzyme of the electron transport 
chain, transferring electrons from cytochrome c to molecular oxygen (Chung et al., 2012), 
(Karu, 1999). 
COX is a large multicomponent protein, containing two copper centres (CuA and CuB) and 
two heme iron containing centres (heme a and heme a3), which absorbs photons in the 
red to NIR region of the electromagnetic spectrum (Karu, 1999). These transition metals 
are also the intermediate redox sites in the electron transfer pathway from cytochrome 
c to oxygen, a process which is coupled to the pumping of protons across the inner 
mitochondrial membrane. The electrons pass from cytochrome c to CuA then passed to 
heme a, from heme a to heme a3-CuB and finally to molecular oxygen.  
1.4.4.2 The absorption of photons by photoacceptors in COX  
One theory proposed to explain how photon energy is absorbed by COX, centres on its 
heme molecules (Zielke, 2014). Heme is comprised of a porphyrin ring with an iron atom 
at its centre that can continuously switch its oxidation states between ferrous (Fe2+) and 
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ferric (Fe3+) by accepting or donating an electron. The porphyrin ring is made up of four 
pyrrole rings that are connected through their carbon atoms via  bonds. The electrons 
in these  bonds are delocalised, moving back and forth from one configuration to 
another, creating resonance. Electrons, like photons, have a dual nature, behaving like 
particles or electromagnetic waves, thereby creating a resonating electromagnetic cloud 
in the porphyrin ring. Photons with similar wavelengths are absorbed by this cloud, 
increasing its energy. The energy from these photons causes photoexcitation of electrons 
of Fe2+, bringing them to an unstable higher energy level.  Upon absorption of sufficient 
energy, these electrons are released from the orbitals of Fe2+ causing the oxidation of 
Fe2+ to Fe3+. The oxidised iron atom can then accept electrons from cytochrome c, thus 
increasing the electron flux through the electron transport chain.  
Experimental evidence shows that red/NIR light has the ability to upregulate the 
enzymatic activity of complex IV, increase the mitochondrial membrane potential and 
increase ATP production (Karu, 2008, Hamblin and Demidova, 2006, Kokkinopoulos et 
al., 2013, Begum et al., 2013, Ferraresi et al., 2015a, Ferraresi et al., 2015b, Tina Karu and 
Hamblin, 2013). These mitochondrial specific effects of photobiomodulation may offer a 
partial explanation for its beneficial effects in neurodegenerative diseases associated 
with mitochondrial dysfunction. However, in genetic or toxin induced models of 
Parkinson’s disease, where loss of dopaminergic cells was triggered by complex I 
dysfunction, neuroprotective effects were seen with red/NIR light treatment. The 
absorption of photon energy by the heme group in complex IV may explain how 
photobiomodulation can increase ATP production when complex IV is inhibited, but fails 
to explain how this effect can be achieved in models with complex I inhibition.  
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It has been hypothesised by Zielke et al. that the electrons released in this oxidation 
process are free to reduce NAD+ and FAD, providing substrates for complex I and II, 
respectively, creating a closed circuit of electron transfer (Zielke, 2014). In the case of 
aberrant functioning of COX the flux of electrons through this closed circuit would 
maintain the proton pumping functions of complex I and III, thereby maintaining the 
electrochemical gradient across the mitochondrial membrane required for ATP 
synthesis. However, since oxygen is very electronegative it would be most likely that the 
released electrons would be readily accepted by the oxygen molecule bound to the 
reduced heme a3-CuB component of COX, reducing it to water. In the event of aberrant 
COX activity the released electron would most likely react with unbound oxygen 
molecules, forming reactive oxygen species. Therefore, how red/NIR provides 
neuroprotection against complex I dysfunction is not explained by its direct action on the 
COX. 
 The nitric oxide theory of Red/NIR light therapy 
1.4.5.1 The role of nitric oxide in mitochondrial respiration 
Nitric oxide (●NO) has important roles in the regulation of blood pressure and vasculature 
tone, however, excessive ●NO production, as seen in neurodegenerative diseases, can 
cause impairment of mitochondrial respiration and apoptosis (Zhao, 2005). 
Mitochondria harbor nitric oxide synthase (NOS) to produce NO, which they use to 
hinder respiration as an intrinsic mechanism to prevent oxygen from reaching 
precariously low levels (Barolet, 2008). ●NO, at low concentrations, competes with 
oxygen to bind to the reduced heme a3-CuB component of COX (Chung et al., 2012). This 
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prevents COX from reducing molecular oxygen, thus impairing the proton pumping 
abilities of the enzyme and essentially the energy production ability of the mitochondria. 
Additionally, ●NO was found to cause inhibition of complex I and II and IV-dependent 
respiration, in mitochondrial suspensions, where the inhibitory action of ●NO was found 
to be more profound at lower oxygen tensions (Cassina and Radi, 1996). Interestingly, 
this inhibitory action of ●NO was overcome by reoxygenation of mitochondrial 
suspensions for a mere 10 seconds, resulting in complete recovery of complex I and IV 
dependent oxygen consumption and a 50% recovery of complex II dependent 
respiration.  This shows that the inhibitory actions of ●NO are almost completely 
reversible upon restoration of normal oxygen levels. Therefore, this intrinsic mechanism 
would protect a tissue if the depleted oxygen supply were temporary, by putting the 
mitochondria in a state of conservation until the return of normal oxygen levels. 
However, prolonged inhibition of respiration would deplete ATP levels and bring about 
cell death (Kalogeris et al., 2012). 
1.4.5.2 The effects of red/NIR light on ●NO-mediated mitochondrial dysfunction 
Red/NIR light has been proposed to influence the photodissociation of ●NO from COX, 
thereby allowing oxygen to reclaim its binding site, permitting the ATP production 
process to resume (Chung et al., 2012). This would be most beneficial in pathological 
situations where ●NO levels are higher than normal physiological amounts, favouring the 
binding of ●NO rather than O2 to COX. Experiments have shown that irradiating cells with 
red/NIR light increases COX activity in normal healthy neurons and restores the activity 
in COX inhibited neurons (Wong-Riley et al., 2005). However, the increase in COX activity 
appears to be mediated by an increase in the expression of the proteins in the COX 
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complex, suggesting that a mechanism, additional to the disinhibition of COX, may also 
be involved(Lim et al., 2010). Furthermore, exposure of cells to an irreversible COX 
inhibitor was overcome by NIR light treatment, providing further support to the claim 
that restoration of activity is mediated by upregulating the expression of COX proteins 
(Wong-Riley et al., 2005). 
An indirect effect of red/NIR light on COX activity helps explain how beneficial effects are 
also seen in neurodegenerative conditions that are associated with impairment of other 
electron transport chain complexes. The absorption of photon energy from red/NIR light 
by COX may indeed have direct effects on the enzyme itself, however, this initial event 
may trigger further downstream events, which may have more far-reaching effects. As 
●NO is widely known for its function as an intercellular signaling molecule, the release of 
●NO upon red/NIR light exposure would increase its bioavailability, allowing it to function 
as a signaling molecule (Lohr et al., 2009). It has been suggested that ●NO intracellular 
signaling could play a role in the upregulation of COX proteins upon red/NIR light 
exposure. Intracellular signaling from the mitochondria to the nucleus may be triggered 
by other byproducts of mitochondrial respiration, levels of which may be altered by 
red/NIR light, therefore, will be discussed in more detail later in this review.  
1.4.5.3 The indirect effects of Red/NIR light on mitochondrial dysfunction 
The findings by Cassina and Radi suggest that increasing the delivery of oxygen to the 
mitochondria, as would occur with increased blood flow to the tissue, would improve 
mitochondrial function in tissues with ●NO-mediated mitochondrial electron transport 
chain inhibition (Cassina and Radi, 1996). It has been found that the exposure of blood 
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vessels to red light from an LED source can induce photorelaxation of blood vessels, an 
event that would increase blood flow and, in turn, oxygen delivery to the irradiated tissue 
(Plass et al., 2012). Exposure of porcine coronary arteries to red light caused their 
vasodilation, as measured by wall tension in the exposed vessels. Since nitric oxide is 
known to have a primary role in the regulation of vasculature tone, and NOS is activated 
upon absorption of visible light, the vasodilation effect seen upon red light exposure is 
thought to be mediated through nitric oxide (Samoilova et al., 2008).  Additionally, 
red/NIR light can trigger the photodissociation of ●NO from nitrosyl hemoglobin and 
nitrosyl myoglobin(Lohr et al., 2009). The ●NO released from hemoglobin in the blood 
would contribute to the vasodilation effects of red/NIR light. Depending on the 
physiological situation, photobiomodulation can either reduce or increase ●NO levels, 
however, the molecular events determining whether the effect will be an inhibitory or a 
stimulatory one are yet to be identified (Gavish et al., 2008). An increase in ●NO upon 
red light exposure would provide beneficial effects in conditions such as TBI, where 
increased cerebral blood flow could increase mitochondrial function in hypopxic cells 
(Figure 1.5) (Naeser et al., 2014). As mentioned earlier in the review, hypoxia can trigger 
inhibition of respiration through the binding of ●NO to COX. The phototdissociation of 
NO from COX in hypoxic tissue may not cause a significant improvement in mitochondrial 
function since there would be limited oxygen available to reclaim the binding site on 
COX. However, if combined with an increase in cerebral blood flow, the associated 
increase in oxygen levels would lead to a more substantial improvement in mitochondrial 
function. This proposes a partial explanation for the neuroprotective effects seen upon 
red/NIR light exposure.  
Chapter 1. Introduction 
45 
 
Figure 1.5: The direct and indirect actions of red/NIR light on nitric oxide improve 
mitochondrial function in neurons vulnerable to degeneration in acute 
neurodegenerative conditions such as TBI. Cerebral blood flow is reduced by traumatic 
brain injury, leading to tissue hypoxia. Increased activation of nitric oxide synthase in the 
mitochondria increases nitric oxide production which can bind to the oxygen binding site 
on complex IV to slow down oxygen consumption and ATP production. Red/NIR light is 
absorbed by nitric oxide synthase, triggering the production of nitric oxide which can 
cause vasodilation, increasing cerebral blood flow. Red/NIR light can also trigger the 
photodissociation of nitric oxide from the oxygen binding site of complex IV. Increased 
cerebral blood flow can increase the oxygen supply to the hypoxic tissue and displace 
nitric oxide from complex IV. The binging of oxygen to complex IV can increase oxidative 
phosphorylation, thereby increasing ATP production which promotes neuronal survival. 
 
1.4.5.4 The effects of red/NIR light on cellular function  
The ability of red/NIR light to increase free ●NO can have beneficial effects in cells where 
mitochondria are dysfunctional. Providing further support to this theory, it was found 
that red/NIR light was protective against hypoxia and re-oxygenation injury in cultured 
cardiomyocytes. The observed protection was dependent on an increase in ●NO as the 
protective effects were abolished in the presence of ●NO scavengers (Zhang et al., 2009). 
Further, it was observed that the increase in NO seen upon red/NIR exposure was 
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partially prevented by the non-selective inhibition of all isoforms of NOS. Of note, there 
are three isoforms of NOS: Neuronal NOS (nNOS), which is expressed in the central 
nervous system and plays a role in synaptic plasticity and central regulation of blood 
pressure, endothelial NOS (eNOS), which is mostly expressed in endothelial cells and 
primarily functions in controlling blood pressure, and inducible NOS (iNOS), which can be 
expressed in many cell types in response to cytokines and other agents to generate large 
amounts of ●NO(Förstermann and Sessa, 2012). The findings show that the increase in 
●NO by red/NIR light is mediated in part by its action on NOS, however, the exact isoform 
of NOS responsible for the protective effects has not been determined. The source of the 
remaining NO could be that which is released during the photodisociation of ●NO from 
COX in the mitochondria as discussed above.  
This in vitro model of cardiac ischemia provides useful insight into how red/NIR light 
mediates its effects via ●NO in ischemic conditions. Since the experiment was done in 
vitro, the observed protective effects most likely arose from the local effects of an 
increase in intracellular ●NO rather than an indirect effect of ●NO by increasing blood 
flow to the ischemic tissue. Although reperfusion is essential to limit cell death after 
hypoxia, paradoxically, this event itself causes further cell death due to excess ROS 
production (Keszler et al., 2014). The increase in free ●NO upon red/NIR light exposure 
would increase its availability to bind to COX and cause the reversible S-nitrosation of 
Complex I, events which would slow down the reactivation of the electron transport 
chain during the crucial initial stages of reperfusion (Chouchani et al., 2013). In this 
particular pathological situation red/NIR light, administered upon reoxygenation, could 
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reduce the harmful levels of ROS produced during reperfusion injury by reversibly 
inhibiting the electron transport chain.  
Contrastingly, in an in vivo model of cerebral ischemia, where excess ●NO production is 
said to be associated with neurotoxic effects, red/NIR light has been shown to have the 
ability to reduce the levels of ●NO by down-regulating the activity and expression of all 
isoforms of NOS (Leung et al., 2002).  Both studies focus on ●NO to explore the underlying 
mechanism responsible for the protective effect of red/NIR light in models of ischemia, 
yet, in these examples, the effects on ●NO were found to be conflicting. The respective 
increase and decrease in ●NO levels seen upon red/NIR light irradiation in the discussed 
models, was dependent on the respective activation and inhibition of NOS. Although 
theories have been proposed to explain the increase in NOS activity in response to 
red/NIR light irradiation, how red/NIR light inhibits NOS activity is less clear. Since the 
expression of the three isoforms of NOS showed a similar trend to the specific activities 
of the NOS enzymes in response to red/NIR light, red/NIR light must be somehow 
suppressing the expression of NOS, but the mechanism responsible for this effect is 
unknown(Leung et al., 2002).     
This observed dual effect of red/NIR light on intracellular ●NO levels has great relevance 
in the field of neurodegenerative conditions. ●NO at physiological amounts confers 
neuroprotection, however, if produced in excess, ●NO has neurotoxic effects (Calabrese 
et al., 2007). In the in vivo model of cerebral ischemia mentioned above the light was 
administered immediately after middle cerebral artery occlusion, but the levels of NOS 
activity were not measured until 4 days post injury, the time at which the NOS levels 
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peaked before returning to pre-injury levels. In the in vitro model of cardiac ischemia the 
light was also administered immediately after hypoxia but the ●NO levels were measured 
after just 2 hours of reoxygenation. It is possible, therefore, that red/NIR light triggers an 
initial increase in ●NO levels, sufficient to reduce ROS production and bring about the 
observed cytoprotective effects. Furthermore, as the cell is then in a state of elevated 
●NO levels and reduced ROS levels this may be sufficient to switch off the endogenous 
trigger that induces the increased expression of NOS and the subsequent delayed surge 
in ●NO levels, which only contribute to the toxic effects at that late stage of ischemia. 
However, as shown in Figure 1.6, low levels of ●NO are produced during the early stages 
of ischemia to induce neuroprotective effects in the absence of red/NIR light, yet an 
increase in ●NO is responsible for the neuroprotective effects achieved with red/NIR light 
in the in vitro model of ischemia. Therefore, how does the ●NO produced by red/NIR light 
provide further neuroprotective effects in the early stages of ischemia? Also unanswered 
is how the increase in ●NO  by red/NIR light and the associated reduction in ROS 
production would downregulate the delayed surge in NO production in the later stages 
of ischemia when the ●NO produced in the absence of red/NIR light fails to do so. 
There is much evidence to show that ●NO acts as a neuroprotective agent through its 
various cellular effects. One such effect is the induction of the signaling molecule cyclic 
guanosine 3’,5’-monophosphate (cGMP), a molecule with a key role in vasodilation and 
mitochondrial biogenesis (Tengan et al., 2012). Mitochondrial biogenesis has been found 
to occur in response to red/NIR light irradiation (Nguyen et al., 2014). Diseases with a 
mitochondrial origin such as Leber’s hereditary optic neuropathy, retinitis pigmentosa 
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and autosomal dominant optic atrophy would benefit from the associated increase in 
mitochondrial biogenesis, as a way of supporting neuronal survival.  
Figure 1.6: A proposed explanation for the observed dual effect of red/NIR light on NO 
in models of ischemia. Red/NIR light is absorbed by nitric oxide synthase triggering the 
production of nitric oxide. The photodissociation of nitric oxide from nitrosyl 
haemoglobin is also triggered by red/NIR light. Low levels of nitric oxide produced by 
red/NIR light can lead to neuroprotective effects in the early stages of ischemia. This may 
somehow inhibit the endogenous trigger that causes an increased expression in nitric 
oxide synthase, leading to the production of toxic levels of nitric oxide that contribute to 
neurodegeneration during late stage ischemia. However, low levels of nitric oxide are 
also produced in the early stages of ischemia in the absence of red/NIR light, yet this has 
no effect on downregulating the delayed surge in nitric oxide production. 
1.4.5.5 The effects of reactive nitrogen species on mitochondrial function 
There is much evidence to show that ●NO, at higher doses, is toxic to neurons; however, 
this NO-mediated toxicity is not produced by ●NO alone, but by the formation of reactive 
nitrogen species (RNS) (Lipton et al., 1993). As a by-product of mitochondrial respiration 
the superoxide radical anion (O2●―) is formed when electrons from Complex I or III are 
transferred to oxygen molecules instead of their respective substrates: ubiquinone and 
cytochrome c (Lenaz, 2001). If the amount of superoxide produced in the cell increases 
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to a level that would exceeds the antioxidant capacity of the cell, oxidative stress will 
result. In that pro-oxidant state, the production of ●NO can cause the generation of 
additional cytotoxic compounds.  The reaction of NO with the superoxide radical anion 
(O2●―) leads to the generation of the powerful oxidant peroxynitrite (ONOO―), which 
causes detrimental effects in the cell, through its interactions with lipids, proteins and 
DNA (Lipton et al., 1993).  
Nitric oxide, superoxide and peroxynitrite are often generated in excess during 
inflammatory and pathological conditions, contributing to the associated toxic effects 
(Rubbo et al., 1994). Peroxynitrite can induce mitochondrial dysfunction and cell death 
in neurons by its ability to inhibit many mitochondrial proteins including complex I, II and 
IV, and ATP synthase. It can also increase mitochondrial proton permeability, an effect 
which may be caused by lipid peroxidation (Brown and Borutaite, 2004). Impairment of 
normal mitochondrial function causes depletion of ATP and generation of free radicals, 
causing cellular dysfunction and further oxidative stress. Peroxynitrite has been found to 
be involved in the pathogenesis of many neurodegenerative disorders (Torreilles et al., 
1999). Since the formation of peroxynitrite depends on the availability of ●NO, inhibition 
of nitric oxide synthase activity, as was found to occur in cerebral ischemic-rats irradiated 
with red light, may reduce the amount of peroxynitrite produced and the associated 
deleterious effects in neurodegenerative disorders (Leung et al., 2002).  
 Red/NIR light in the mitochondrial signaling pathway 
Causing further controversy in the efforts to uncover the underlying molecular 
mechanism of red/NIR light therapy, is the effect that it has on ROS and RNS production. 
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It is also uncertain whether an increase or a decrease in these molecules, in the cell, in 
response to red/NIR light exposure would be the most therapeutically beneficial. In some 
physiological situations red light mediates its therapeutic effects by increasing levels of 
free radicals but in other circumstances by reducing the levels of free radicals. 
Consequently, a further look at the molecular effects of free radicals in 
neurodegeneration is required to uncover the underlying mechanism of red/NIR therapy. 
1.4.6.1 The role of ROS and RNS in neurodegeneration 
Postmortem analysis of the brains of patients with various neurodegenerative diseases 
shows an increase in ROS and RNS in the affected brain regions (Andersen, 2004, Aslan 
and Ozben, 2004). It is known that these reactive species can cause oxidative and 
nitrative damage to cellular components thereby having toxic effects on the cell (Tafur 
and Mills, 2008). It may be deduced from this association that the increase in ROS and 
RNS is contributing to cellular death and that an antioxidant may be beneficial in such 
conditions. Since red/NIR light has been found to be protective in models of such 
conditions it could, therefore, be possible that the therapeutic benefits of red/NIR light 
could be due, in part, to an antioxidant effect. One possible mechanism of providing the 
antioxidant protection is the photodissociation of ●NO, which at low concentrations can 
exert an antioxidant effect (Niziolek et al., 2003a, Niziolek et al., 2003b, Niziolek et al., 
2005, Niziolek et al., 2006).  
Because red/NIR light has been found to increase the activity of the electron transport 
chain, and ROS/RNS production is a byproduct of such activity, sometimes it is presumed 
that red/NIR light increases ROS production. It can be argued, however, that by removing 
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NO-mediated inhibition of COX, the electron flow is restored and therefore the likelihood 
of donating an electron from Complex I or III to oxygen (which results in generation of 
superoxide radical anion) is reduced (Lenaz, 2001). Thus by enabling the electron flow in 
the electron transport chain, the risk of formation of superoxide is decreased. 
Investigation into the effects of red/NIR light on ROS production by various groups 
provides inconsistent results as some found a reduction in ROS upon irradiation while 
others found that ROS was, in fact, upregulated (Tafur and Mills, 2008). Regardless of the 
effect of red/NIR light on ROS levels, it is unclear whether an antioxidant or pro-oxidant 
effect would be most beneficial when employing red/NIR light as a neuroprotective 
agent. Regulated ROS production could trigger signaling pathways involved in cell 
protection, but unregulated ROS production could result in cellular damage and cell 
death (Zorov et al., 2014). In addition, when ROS levels are too low this also has 
detrimental effects for the cell. The concept that lower, non-toxic levels of ROS are 
essential for promoting cell survival by inducing an adaptive responses is called 
mitochondrial hormesis or mitohormesis (Ristow and Schmeisser, 2014). Exposure to 
red/NIR light may trigger a transient increase in ROS levels, sufficient to induce this 
adaptive response and provide neuroprotective effects. This explanation seems plausible 
in situations where light is administered as a pre-treatment as the cells could employ this 
adaptive response to protect against a subsequent injury-induced increase in ROS levels. 
However, if the cell is already in a state of elevated ROS levels, as in many pathological 
situations, it is unclear as to how an additional increase in ROS by red/NIR light would 
provide neuroprotective effects. From the current literature, it is clear that the 
mechanism for the effect of red/NIR light on ROS production, in addition to the cellular 
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mechanisms responsible for balancing the ROS levels required for maintaining optimal 
mitochondrial and cellular function are not fully understood. However, since maintaining 
redox homeostasis is paramount for the optimal functioning of the cell and neuronal 
survival, we suggest that the exposure to red/NIR light may restore redox homeostasis, 
in pathological conditions where it is perturbed. Therefore, in cells with elevated ROS 
levels, red/NIR light may cause mild cellular stress by an unknown mechanism that may 
induce an adaptive response, which includes the upregulation of genes with a role in 
redox homeostasis. We suggest that the observed increase in ●NO upon red/NIR light 
irradiation, by the various mechanisms discussed in section 5, may facilitate the 
production of peroxynitrite through the reaction of ●NO with ROS. The elevated RNS 
levels may induce an adaptive response by triggering a different signaling pathway to 
that which is triggered by ROS. 
1.4.6.2  ROS/RNS as signalling intermediates 
The upregulation of ROS and RNS, such as peroxynitrite, are thought to promote cell 
viability and increase proliferation owing to their ability to function as signal 
intermediates (Figure 1.7). ROS, which is produced by the ETC complexes as a byproduct 
of cellular respiration permits communication from the mitochondria to the rest of the 
cell. This mitochondrial signal transduction can activate various signaling pathways 
resulting in the expression of a plethora of genes including those involved either directly 
or indirectly in the suppression of apoptosis, cell survival or cell proliferation. Curiously, 
among the genes affected by red/NIR light irradiation were those with roles in anti-
oxidation(Tafur and Mills, 2008). 
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Figure 1.7: The upregulation of ROS or RNS by red/NIR light triggers the translocation 
of the transcription factor NFκB to the nucleus, enabling NFκB to alter gene expression. 
Red/NIR light is absorbed by ETC complex IV leading to the photodissociation of nitric 
oxide from the oxygen binding site of complex IV allowing oxygen to bind to complex IV 
and accept electrons from complex IV, increasing complex IV activity. This increases the 
electron flux across the entire electron transport chain and increases ROS production 
from complex I and III. The free nitric oxide can react with superoxides to produce 
peroxynitrite. ROS and peroxynirtite can trigger the dissociation of the inhibitor of κB 
from NFκB, allowing NFκB to translocate to the nucleus where it can alter gene 
expression of target genes such as those with roles in cell survival and restoring redox 
homeostasis.  
1.4.6.3 The mitochondrial signalling pathway 
ROS is thought to mediate its protective effect via the activation of the redox sensitive 
transcription factor nuclear factor κ-light-chain-enhancer of activated B cells (NFκB) 
which is proposed to be sensitive to an increase in ROS generation. In support of this 
theory it was found that an increase in ROS production by mitochondrial inhibitors 
brought about a concurrent increase in NFκB, while the exposure to antioxidants reduced 
the NFκB activation (Chen et al., 2011). NFκB can both induce and repress gene 
expression by binding to ĸB elements in the promoter and enhancer regions of the gene. 
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This transcription factor has been shown to induce the expression of numerous genes 
with functions in cell survival, the stress response and inflammation (Chen et al., 2011). 
When superoxides are produced in the mitochondria they are metabolized to H2O2 which 
is thought to activate NFκB by triggering the dissociation of inhibitor of ĸB kinase from 
NFκB. This allows NFκB to translocate to the nucleus where it can alter gene expression 
(Figure 1.6) (Gloire et al., 2006). Many of the genes upregulated by NFκB play a role in 
the immune response, inducing pro-inflammatory genes at the onset of inflammation 
and anti-inflammatory genes during the resolution of inflammation(Lawrence, 2009).  
Therefore, depending on the context, ROS can both activate and inhibit NFκB signaling 
(Morgan and Liu, 2011). It is no surprise that the results obtained appear to be 
inconsistent with varying cell type and cellular environment at the time of exposure to 
red/NIR light. This may provide some explanation for the differential results that have 
been observed with the use of red/NIR light therapy in different cell types. For example, 
irradiation of traumatized muscle tissue with red light therapy reduced the levels of ROS 
and NFĸB activation, and the associated increase in the expression of proinflammatory 
genes (Rizzi et al., 2006). On the other hand, NIR light has been shown to induce ROS 
production and NFĸB activation in murine embryonic fibroblasts (Chen et al., 2011).  
In a similar fashion to ROS, peroxynitrite production triggers this stress response, causing 
the up or downregulation of cell signaling cascades in a cell dependent manner (Liaudet 
et al., 2009). Peroxynitrite signaling is mediated by tyrosine nitration of proteins, 
particularly those involved in phosphotyrosine-dependent signaling. The oxidant is also 
involved in signaling via mitogen activated protein kinase, protein kinase B and C, NFĸB 
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and the insulin receptor. Of note, these pathways which converge on the upregulation 
of mediators of cell survival, growth and proliferation are also activated by other stress 
stimuli such as ROS.  
It is also possible that nuclear factor erythroid-2 like 2 (Nrf2) may be playing a role in the 
underlying molecular mechanism of red/NIR light therapy, due to its role in eliciting an 
adaptive response to oxidative and nitrostrative stress, in a similar manner to NFκB. The 
Nrf2/Keap1/ARE pathway plays a major role in the regulation of cellular redox 
homeostasis by regulating the transcription of over 100 genes including those with roles 
in promoting cell survival, antioxidant production and inhibition of inflammation (David 
et al., 2017). Under normal cellular conditions Nrf2 is covalently bound to cysteine 
residues on Keap1 in the cytoplasm, leading to ubquitination and degradation of Nrf2. 
Nrf2 is thus prevented from translocating to the nucleus and initiating transcription of 
its gene targets (David et al., 2017). In the presence of oxidative stress, however, ROS 
modifies the cysteine residues on Keap1, preventing the binding of Keap1 to Nrf2, 
thereby allowing Nrf2 to translocate to the nucleus and induce transcription by binding 
to antioxidant response element (ARE) in the promoter element of its target genes 
(Figure 1.8).  
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Figure 1.8: Nrf2 activation by oxidative stress (Facecchia et al., 2011). Under normal 
conditions Nrf2 is sequestered in the cytoplasm by covalent bonding with the cysteine 
residues on Keap1, preventing Nrf2 from translocating to the nucleus. In the presence of 
oxidative stress, the cysteine residues on Keap1 are modified, preventing the binging to 
Nrf2. Nuclear translocation of Nrf2 can then occur allowing Nrf2 to bind to the ARE in the 
promoter element of target genes and initiate gene transcription.  
 
Another potential molecular effector of red/NRI light is DJ1, a redox responsive protein 
that increases its expression upon oxidative stress(Ariga et al., 2013). The specific 
functions of DJ1 and the mechanism of activation remain unclear. It is known, however, 
that oxidative stress induces the upregulation of endogenous DJ1, an effect that is 
associated with an increase in the cellular defense mechanism against oxidative 
stress(Lev et al., 2008). Its subcellular distribution also contributes to its protective 
effects. Under normal cellular conditions DJ1 is localised to the cytoplasm as a 
homodimer (Björkblom et al., 2014). During oxidative stress, the dimer is disrupted and 
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the DJ1 monomer translocates to the mitochondria and nucleus where it can instigate 
various effects including its antioxidant function and cytoprotective activity.  
It is thought that DJ1 is mediating some of its protective effects via the Nrf2 pathway (Im 
et al., 2012). In support of this finding, activation of the Nrf2 pathway was found to be a 
critical mechanism by which DJ-1 upregulates antioxidant enzymes and promotes 
cryoprotection in an in vitro model of hypoxia/re-oxygenation (Yan et al., 2015). DJ1 has 
also been shown to be involved in the modulation of the Akt (protein kinase B) pathway, 
which is also a major neuroprotective pathway triggered in response to oxidative stress 
(Aleyasin et al., 2010). Therefore, Akt is another potential molecular effector of red/NIR 
light that may be responsible, in part, for the neuroprotective effects.  
The PI3K-Akt signaling pathway is a critical pathway involved in promoting neuronal 
survival, which is activated by various mechanism(Brunet et al., 2001). Oxidative stress 
is one such mechanism by which this pathway is activated in neurons (Uranga et al., 
2013). Akt activation requires recruitment to the plasma membrane and subsequent 
phosphorylation of two key amino acids, Thr303 and Ser473(Song et al., 2005). Upon 
phosphorylation, it translocates to the nucleus and cytoplasm where it phosphorylates 
various target proteins to promote neuroprotection (Uranga et al., 2013).  
In support of the theory that red/NIR light causes upregulation in the expression of genes 
associated with cell survival, is the increased neuroprotective effects observed when 
red/NIR light is administered before the induced injury in models of neurodegeneration, 
compared to when administered after injury (Ying et al., 2008b). This suggests that 
red/NIR light could be mediating its protective effects by instigating the production of 
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ROS/RNS at levels sufficient to cause the upregulation of stress response genes, via the 
pathways discussed above, with negligible damage to the irradiated tissue. If the same 
tissue was subsequently exposed to a toxic agent, the cell would be equipped with the 
appropriate defense mechanisms to cope with such an insult. The destructive effects to 
the tissue in such an instance would be remarkably less, such as is seen in various 
pretreatment models (Rutar et al., 2012, Albarracin and Valter, 2012, Albarracin et al., 
2013). This knowledge could be exploited in neurodegenerative diseases with a pre-
symptomatic phase. The observation demonstrates that red/NIR light therapy would be 
most effective as a preventative therapeutic treatment, administered before the onset 
of clinical symptoms and irreversible damage. With respect to retinal degenerative 
disease this preventative treatment approach would be particularly relevant in inherited 
optic neuropathies such as Leber’s hereditary optic neuropathy. Individuals with a LHON-
causing mtDNA pathogenic variant could be monitored so that treatment with red/NIR 
light could begin upon detection of pre-symptomatic abnormalities as a pre-treatment 
for the clinical symptoms. In the event of a more acute neurodegenerative condition such 
as TBI, exploiting the enhanced therapeutic effects of red/NIR light observed when used 
as a pretreatment would not be feasible. Therefore, the neuroprotective potential of 
red/NIR light therapy, as seen in the pre-treated animal models, may be somewhat 
limited in a real life clinical setting.  
 The effects of red/NIR light on the anti-inflammatory response 
Peroxynitrite and ROS are also produced by macrophages during inflammation, which is 
responsible for the cytotoxic effects (Kang et al., 2002). Red/NIR light has shown the 
ability to reduce the presence of these reactive species in irradiated tissues, thereby 
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attenuating some of the cytotoxic effects of the inflammatory response. Furthermore, 
modulation of the immune response itself was seen in many studies with red/NIR light 
treatment (Begum et al., 2013, Kokkinopoulos et al., 2013, Gavish et al., 2008).  Yet, how 
red/NIR light mediates this anti-inflammatory effect is poorly understood.  
Mitochondria play a major role in the activation of the inflammasome, a molecular 
platform that activates proapoptotic proteins, cytokines and other mediators of 
inflammation upon detection of infectious agents or cellular damage (Green et al., 2011). 
ROS can similarly activate the inflammasome.  The production of mitochondrially-
derived ROS is known to increase when mitochondria are dysfunctional. Decreased 
electron flux through the electron transport chain reduces the ability of COX to fully 
reduce oxygen to water, thereby increasing the formation of ROS. The action of red/NIR 
light in improving the functions of the mitochondrial electron transport chain could 
reduce the amount of ROS generated, which may reduce the activation of the 
inflammasome. Alternatively, the mitochondrial signal transduction triggered by an 
increase in ROS/RNS as discussed above, could also upregulate the expression of anti-
inflammatory or antioxidants proteins, to either directly or indirectly dampen the 
inflammatory response. However, it has been found that low level laser irradiation (LLLI) 
can reduce the gene expression of anti-inflammatory cytokines as well as pro-
inflammatory cytokines (Gavish et al., 2008). In this particular situation LPS was used to 
elicit an inflammatory like phenotype, triggering the expression of pro-inflammatory 
cytokines in addition to the anti-inflammatory cytokine, IL-10. The anti-inflammatory 
cytokine is also triggered during the inflammatory response to limit the host immune 
response, thereby minimising the damage caused to the affected tissue during the 
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inflammatory response (Iyer and Cheng, 2012). The findings demonstrate that LLLI is able 
to dampen the entire inflammatory response as oppose to specifically downregulating 
proinflammatory cytokines, suggesting that red/NIR light may be acting further 
upstream, influencing factors governing the inflammatory response. Also, there appears 
to be a correlation between the inflammatory level in the tissue and the extent of the 
inhibition of the inflammatory response (Gavish et al., 2008). It was found that LLLI had 
little effect on the inflammatory response at low levels of inflammation, but produced a 
potent anti-inflammatory effect at high levels of inflammation (Gavish et al., 2008). This 
shows an ability of red/NIR light to restore homeostasis in the tissue. In fact, ROS is 
produced by the microglia itself and plays an important role in the induction of pro-
inflammatory genes (Innamorato et al., 2009). Therefore, restoring the redox balance in 
microglia may facilitate the transition of the microglia from an activated to a resting 
state.  
It has been suggested that the mitochondrial dysfunction seen in many 
neurodegenerative diseases not only affects neurons, but also the microglia (Ferger et 
al., 2010). Experimental findings have shown that complex I inhibition in microglia 
inhibited the IL-4 mediated reduction in pro-inflammatory cytokines and the secretion 
of the neuroprotective insulin-like growth factor-1. The inflammatory response triggered 
by pathogens or damaged neurons functions to protect the neural tissue, but if this 
response is not attenuated the response would switch from a protective one to a 
deleterious one (Ramesh et al., 2013). When activated, microglia secrete anti-
inflammatory cytokines, in addition to pro-inflammatory cytokines to control the 
inflammatory response, preventing unnecessary damage to neural tissue. Electron 
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transport deficiencies in microglia appear to perturb the anti-inflammatory arm of the 
immune response (Ferger et al., 2010). Since red/NIR light has been shown to improve 
the function of the electron transport chain in neurons, it can be suggested that a similar 
effect would be seen in microglia with mitochondrial dysfunction.   
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1.5 Hypothesis  
Since red/NIR light has been found to improve mitochondrial function and increase ATP 
production, we hypothesise that 670 nm light will restore normal mitochondrial 
bioenergetics in the B6;C3-Opa1Q285STOP mouse and thereby prevent the associated 
neurodegeneration. In particular, as red/NIR light has been found to provide 
neuroprotective effects in numerous models of neurodegenerative conditions we 
hypothesis that 670 nm light therapy will prevent the dendropathy that occurs in an 
axotomy model of neurodegeneration. We also hypothesise that 670 nm light will 
prevent the progressive dendropathy that begins at 12 months in the B6;C3-Opa1Q285STOP 
mouse. Finally, we hypothesise that 670 nm light produces non-toxic levels of ROS in the 
neuron that are sufficient to trigger the activation of the NFκB pathway and other 
signalling pathways to promote cell survival and prevent RGC degeneration. 
1.6 General aims 
Overall aim: To test the effectiveness of 670 nm light therapy in models of RGC 
degeneration 
Specific aims: 
1. To determine whether 670 nm light can improve the energy producing ability of 
the mitochondria in retinae from aged wild-type and B6;C3-Opa1Q285STOP (het) 
mice. 
2. To test the effects of 670 nm light, delivered post axotomy to the retinal explant, 
on ex vivo RGC dendropathy. 
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3. To test the effects of 670 nm light treatment, delivered in vivo, prior to axotomy, 
on ex vivo RGC dendropathy in the entire population of wild-type RGCs and in the 
ON-centre RGCs from wild-type and het mice.  
4. To explore the effects of 670 nm light on NFκB activation and associated effects 
on microglial activation in RGCs from wild-type and het mice. 
5. To explore the effects of 670 nm light on other transcription factors and signaling 
intermediates that are upregulated in response to oxidative and nitrostrative 
stress in wild-type and het mice. 
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2.1 General methods 
 Wild-type and Opa1+/- Mice 
Mice were kept in a 12 hour light (10 lux) / 12 hour light-dark cycle with food and water 
available ad libitum. Breeding, maintenance and all experimental procedures were in 
compliance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision 
Research and were approved by the Home Office. The mutant strain, B6; C3-Opa1Q285STOP 
has been described in detail elsewhere (Davies et al., 2007). The mice were crossed with 
C57BI6/JCrl mice to move the mutation to a C57BI/6JCrl background (F1) and the 
experiments were performed on mice bred to F7 generation.  
 Genotyping 
DNA was extracted from mouse ear tissue obtained from ear mark identification 
procedure. Mouse ear tissue was lysed at 100°C for 5 minutes with 50 mM NaOH before 
being neutralised with 10 mM Tris. The genotyping of mutant mice involved two separate 
PCR reactions with two sets of primers. The forward primer was identical for both 
reactions amplifying wild-type and mutant alleles (F1: 5′- CTCTTCATGTATCTGTGGTC-3′). Two 
reverse primers were used to specifically amplify either the wild-type or mutant allele (R 
Wt: 5′ TTACCCGTGGTAGGTGATCATG-3′ and R Mut: 5′-TTACCCGTGGTAGGTGATCATA-3′). For each 
reaction 1 µl of DNA was amplified with 1.25 µl (10 µM primer) in a 20 µl reaction mix 
(BioMix Red; Bioline, UK). PCR reactions were ran on TC-512 Techne Thermal Cycler 
(Techne Inc., US) under the following conditions; denaturation for 5 minutes at 94°C 
followed by 35 cycles of denaturation (1 minute at 94°C), annealing (1 minute at 55°C) 
and elongation (1 minute at 72°C) and a final elongation for 10 minutes at 72 °C. PCR 
products were separated by 1% agarose gel electrophoresis in TAE (Tris-borate-EDTA) 
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buffer. 100 bp ladder was added to the gel to allow the size of the PCR products to be 
determined.  
 Retinal Dissection 
Mice were sacrificed by cervical dislocation. Eyes were immediately enucleated, 
transferred to a culture dish with ice cold Hanks’ balanced salt solution (Invitrogen) and 
put on ice. A hole was made in the cornea, just above the limbus using a fine needle 
which allowed for a cut to be made in the cornea. Ophthalmic scissors were used to cut 
around the cornea, removing the cornea from the eye. Ophthalmic forceps were then 
employed to pull the lens out of the eye. In aged animals the action of pulling the lens 
removed most of the vitreous from the eye without damaging the retina, but in younger 
animals scissors were required to cut the vitreous from the lens to avoid retinal damage. 
The retina was carefully peeled apart from the sclera, after which care was taken to 
remove the remaining vitreous using an ophthalmic forceps and scissors. Four radial cuts 
were made in the retina, towards the optic nerve head, to enable flat mounting onto a 
0.4 µm pore PTFE membrane culture plate insert (Sigma). A cut tip 3 mL pasture pipette 
was used to transfer the retina from the culture dish to the insert and a 1 mL fine tip 
transfer pipette was then used to carefully remove the excess solution surrounding the 
retina on the insert. Finally, the retina was gently unfolded with an ophthalmic forceps 
leaving a flattened out 4 leaf clover structure, with the ganglion cell layer facing up 
(Figure 2.1). The insert was placed in pre-warmed Neurobasal A media (Invitrogen) and 
transferred to an incubator at 37 °C, 5% CO2 for the required ex vivo period.   
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Figure 2.1: Mouse retina on a culture insert post dissection, flattened by four cuts 
towards the optic nerve head.  
 
 DiOlistic labelling of retinal ganglion cells  
2.1.4.1 Preparation of DiI and DiO coated tungsten particles 
Bullets of 1,10-dioleyl-3,3,3,3 tetramethylindocarbocyanine methanesulphonate (DiO) 
(Invitrogen) or 3,3’dihexadecyloxacarbocyanine perchlorate (DiI) coated tungsten 
particles were prepared prior to retinal preparation modified from Gan et al., 2000, with 
the modified protocol described here (Gan et al., 2000). In a fume cupboard, 100 mg of 
tungsten particles (1.7 µm) were spread out evenly on two glass slides. In an Eppendorf 
tube, 4 mg DiI or 8 mg of DiO was weighed out and protected from light with aluminium 
foil. Each was suspended in 100 µl of dichloromethylene, in a fumehood, and the solution 
was pipetted onto the tungsten particles. Dichloromethylene evaporated leaving dried 
DiI or DiO coated tungsten particles, which were then transferred onto filter paper and 
broken up into a fine powder using a razor blade. The powder was funnelled into a length 
of tubing (Bio-Rad) and left on a rotator (Bio-Rad) overnight, allowing the powder to 
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evenly coat the inside of the tubing. The particle coated tubing was stored in the dark 
and cut into lengths of 1.2 cm prior to use.   
2.1.4.2  Preparation of retinae to enable visualisation of RGCs 
Retinae were shot once at 100 psi using a Helios gene gun (Bio-Rad) 3 cm from the retina 
through a 3 µm pore size, high pore density cell culture insert (Milipore) to block clumps 
of tungsten from coming in contact with the retina. Diolistically labelled retinae were 
incubated in pre-warmed Neurobasal A for 25 minutes at 37 °C, 5% CO2 to facilitate dye 
diffusion before transferring to 4% paraformaldehyde (PFA) for 35 minutes, for fixation. 
The fixed retinas were then stained with TO-PRO (Invitrogen) (1:500) for 5 minutes 
before washing three times in PBS. Retinae were then mounted onto a glass slide and 
coverslipped with Prolong Gold Antifade Reagent (Invitrogen) and left in the dark at room 
temperature for 1 hour.  Finally, an airtight seal was made around the retina before 
storing in the dark at 4 oC.  
To assess the dendritic complexity at baseline, a group of animals were assigned to a 0 
hour group, indicating that retinas were diolistically labelled immediately after 
dissection. A second group was placed in culture for 8 hours and a third group was 
cultured for 16 hours before diolistically labelling, to examine the dendritic complexity 
as function of time and treatment.  
 Analysis of RGC dendritic complexity 
Fluorescent images were collected within 24 hours of labelling. RGCs were identified as 
having their soma located in the ganglion cell layer, their dendrites stratifying across the 
inner plexiform layer and a distinct axon projecting towards the optic nerve. Images were 
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acquired with a Zeiss LSM 510 confocal microscope (Carl Zeiss, Ltd, UK), using a 20X (0.8 
NA) objective lens, 543 nm excitation and BP 565-615 nm emission filter for DiI, 488 nm 
excitation and BP 500-530 nm emission filter for DiO and 633 excitation and 651-704 
emission spectral window for TO-PRO.  
 Images stacks were collected each 1 µm distance along the Z-plane, from the ganglion 
cell layer to the inner nuclear layer, producing a reconstructed 3-dimensional image. 
Cells were masked using a Fiji plugin prior to tracing. Dendrites were traced using the Fiji 
plugin, Simple Neurite Tracer, to facilitate Sholl analysis. Sholl analysis (Sholl, 1953) gives 
a quantitative measure of dendritic complexity, counting the number of dendritic 
intersections with concentric rings placed at 10 µm intervals from the soma to the most 
peripheral dendrite (Sholl, 1953).  
The area under the Sholl curve (AUC) was obtained by the trapezoidal method whereby 
the Sholl curve was divided into trapezoids with a 10 µm base and the sum of the area 
of each trapezoid from 10 µm to the distance of the most peripheral dendrite was 
calculated.  
The total dendritic length of each RGC was obtained by collecting the length of each 
dendrite measured in Simple Neurite Tracer and calculating the sum of all the dendrites. 
The dendritic field area of the RGC was obtained by connecting the ends of each dendrite 
using a polygon tool in Fiji.  
  Chapter 2. Materials and Methods 
71 
 
2.2 Exposure of the retinal explant to 670 nm light 
 Animals used  
Twenty five wild-type, 9 week old, male C57 BL/6J mice were used as the source of retinal 
explants. Each mouse contributed a maximum of one retina per experimental condition. 
Mice were kept in a 12 hour light (4.88 lux of warm white fluorescent lighting with an 
irradiance of 0.7 µW/cm2) / 12 hour light-dark cycle with food and water available ad 
libitum. Maintenance and all experimental procedures were in compliance with the 
ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and were 
approved by the Home Office, UK. 
 Ex vivo treatment of wild-type retinae with 670 nm light  
Mice were killed by cervical dislocation under 275 lux of warm white fluorescent light, 
providing total irradiance of 74 µW/ cm2 and an irradiance of 2.8 µW/cm2 in the 600-780 
nm range of the electromagnetic spectrum, as measured using a JETI Specboss 1201 
spectroradiometer (JETI Technische Instrumente GmbH, Jena, Germany). Retinae were 
then dissected under 676 lux of warm white fluorescent light, providing a total irradiance 
of 250 µW/ cm2 and an irradiance of 130 µW/cm2 in the red range. Retinae were 
dissected as described previously and flat mounted onto a 0.4 µm pore PTFE membrane 
culture plate insert (Williams et al., 2011). One retina per mouse was assigned to sham 
treatment and the other to light treatment. The insert was placed in a 6-well plate 
containing pre-warmed Neurobasal A media (Invitrogen) at 37 °C. 
Red light was delivered to the retinae from a WARP 10 light source (Quantum devices, 
Inc., Wisconsin, USA), immediately after flat mounting. Red light-treated retinae were 
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exposed to 670 nm with a bandwidth of 30 nm (full width half maximum, FWHM) light 
with a radiant exposure of 31.7 J/cm², delivered by 6 sequential 88 second exposures of 
the WARP 10 light device, over a 10 minute period, at room temperature (Figure 2.2). 
The parameters for 670 nm light delivery were chosen based on an experiment by Liang 
et al., 2006 where 670 nm light rescued primary visual cortical neurons from apoptosis 
(Liang et al., 2006). Sham treated retinae were placed at room temperature, in a separate 
room to the light treatment. Upon cessation of the treatment, the retinae were labelled 
using DiOlistics, either immediately or after an ex vivo period of 8 or 16 hours in a dark 
incubator, at 37 °C. In the majority of cases, both retinae from a single mouse were 
assigned to the same time point; one to light treatment and one to sham treatment. Also, 
the retina assigned to light treatment was alternated between the first and second eye 
that was dissected, to account for any effect on dissection time on the ex vivo 
dendropathy. 
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Figure 2.2: Treatment of the mouse retinal explant with 670 nm light. (A) The WARP 
10 light device was placed directly under the flat mounted retina in a 6-well plate, 
containing Neurobasal A media. A total radiant exposure of 26.4 J/cm2 was delivered 
over a 10 minute period, from 6 serial 88 second exposures of 670 nm light. There was a 
period of 5 seconds between each exposure. (B) The emission spectrum of the WARP 10 
light device was measured with a diffuser, 1 cm from the light source. Peak wavelength: 
670 nm. FWHM: 30 nm. 
 
2.3 In vivo treatment of 12-15 month old wild-type and het mice with 670 
nm light  
The mice were divided into 4 experimental groups; WT sham (n=15), WT light (n=16), Het 
sham (n=11), Het light (n=11). Light treated animals were exposed to 4.4 J/cm2 of 670 
nm light from a WARP 10 light source (Quantum devices, Inc.), which was delivered over 
88 seconds. A JETI Specboss 1201 spectroradiometer (JETI Technische Instrumente 
GmbH, Jena, Germany) was used to measure the irradiance at the level of the eye cornea. 
Two devices were required to ensure that the radiant exposure delivered to each eye, 
over the 88 seconds was 4.4 J/cm2 (Figure 2.3). Light treated mice were light adapted for 
30 minutes prior to 670 nm light exposure. The sham treated animals were subjected to 
the same level of handling as the light treated groups to account for any effect of stress 
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that may be experienced by the animal upon restraint. The mice were treated daily for 5 
consecutive days.  
On the fifth day, the final light or sham treatment was administered 30 minutes before 
culling by cervical dislocation. Thirty minutes was allowed between the final treatment 
and axotomy as it has been shown that the expression of genes which are induced by 
nitric oxide signalling peaks 30 minutes after nitric oxide exposure in cultured cells 
(Hemish et al., 2003).  
 
 
Figure 2.3: Light and sham treatment in vivo. (A) Mice assigned to the light treatment 
group were scruffed in front of two WARP 10 light devices for 88 seconds, positioned as 
such, ensuring that an irradiance of approximately 50 mW/cm2 is reaching the cornea. 
(B) The sham treated mice were scruffed in front of the light source for 88 seconds to 
ensure the level of stress was uniform throughout the experimental groups. 
 
2.4 In vivo treatment of 21-26 month old wild-type and Opa1 (+/-) mice with 
670 nm light  
Het mice and their wild-type littermate aged between 21 and 26 months were selected 
for the study. Five wild-type mice were assigned to a sham treatment group (Wild-type 
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sham). Ten mice heterozygous for Opa1 randomly assigned to either a sham treatment 
group (Het sham) or a light treatment group (Het light). Light treated animals were 
exposed to a single WARP 10 for 88 seconds twice daily at 9am and again at 6pm (Figure 
2.4B). Measurements were taken with the JETI Specboss 1201 spectroradiometer, taking 
into account the angle of the eyes relative to the light device (Figure 2.4C-D. An 
irradiance of 10 mW/cm2 was measured when the spectroradiometer was placed 1 cm 
from the light device, at the angle of the mouse eye. To increase the amount of 670 nm 
light reaching each eye from a single WARP 10 device, an aluminium foil dome was 
created to reflect some of the 670 nm light back to the eye. The irradiance of the light 
reaching the eye increased to approximately 19.7 mW/cm2, with the use aluminium foil 
dome placed around the spectroradiometer. Thus a foil dome was placed around the 
head of the mouse during red light exposure, to increase the irradiance reaching each 
eye. 
Sham treatment entailed scruffing in front of a light device for 88 seconds, while the 
device remained off (Figure 2.4A). Equal handling of all animals was ensured to account 
for the effect of stress on the results obtained.  
  Chapter 2. Materials and Methods 
76 
 
Figure 2.4: In vivo treatment of 21-26 month old wild-type and het with 670 nm light- 
treated (A) and sham treated (B) mice positioned with their eyes 1 cm from the light 
source. The mouse head: showing the width of the head and the position of the eyes (C). 
The angle of the mouse eyes (yellow) relative to the surface of the light (Zhang et al.) (D).  
On the seventh day of the trial the mice received one final treatment prior to sacrificing 
by cervical dislocation. Eyes from an untreated 9 week old wild-type mouse were fixed-
frozen and stored to be used as controls for microglial activation (Untreated wild-type). 
2.5 Immunohistochemistry 
Immunohistochemistry was done to look at the effect of 670 nm light on microglial 
activation in the GCL and IPL of very aged het mice. This technique was also employed to 
explore the effect of 670 nm light on the activation or upregulation of transcription 
factors or signalling intermediates that are upregulated in response to oxidative and 
nitrostrative stress in aged wild-type and het mice.   
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 Preparation of eyes for Immunohistochemical analysis  
Mice were sacrificed by cervical dislocation and the eyes were immediately enucleated 
and washed in PBS before being placed in 1 mL of 4% PFA and left overnight at 4 oC. The 
eyes were transferred to PFA in less than 30 seconds after death. After fixation the eyes 
were cryoprotected by transferring to a 5% sucrose solution for 1 hour, a 15% sucrose 
solution until the eye sank to the bottom of the Eppendorf tube and finally to a 30% 
sucrose solution for a time sufficient to allow the eye to sink. The eyes were then placed 
in an OCT filled cryomould and transferred to melting isopentane (-160 oC) until frozen 
and stored at -80o C.  The orientation of the eye was noted and labelled on the mould.   
 2.5.3 Preparation of eyes for COX/SDH assay 
Of the of 21-26 month old wild-type and het mice treated with 670 nm light or sham, 
one eye was prepared for immunohistochemical analysis, as described above, and other 
eye was prepared for a COX/SDH assay. One eye from each mouse was transferred 
rapidly upon death to an Eppendorf tube and immediately placed in a canister containing 
liquid nitrogen. The eyes were then transferred to the -80 freezer for storage. 
 Immunostaining procedure 
Sagittal sections of 10 µm thickness were cut from fixed-frozen eyes using a Leica 3050 S 
cryostat and collected on Superfrost Plus Adhesion Slides (Thermo Scientific). Four 
consecutive sections were placed on each slide and the slides were numbered so that 
the region of the retina being used for each staining protocol could be approximately 
known. Sections were allowed to air dry overnight at room temperature before storage 
at -20 oC until required. 
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Sections were selected from each mouse containing comparable regions of the retina by 
selecting slides labelled with the same number from each mouse. The staining protocol 
was done three times for each antigen and each slide chosen was 5 slides apart from the 
others to ensure that 3 different regions of the retina were examined per mouse for each 
antigen. 
 The sections were adjusted to room temperature for 20 minutes before rehydrating in 
0.1 M PBS for a further 5 minutes. The excess moisture around the sections was wiped 
off and the tissue sections were encircled with a hydrophobic barrier using a PAP pen. 
Non-specific binding sites were blocked with 10% fetal calf serum (FCS) (Abcam Ltd, 
Cambridge, UK) in 0.1 M PBS containing 1% TritonX100 and 1% Tween for 1 hour at room 
temperature. Sections were then washed three times with 0.1 M Triton-Tween PBS, for 
5 minutes each with rocking, before incubation with the primary antibody diluted in 5% 
FCS in 0.1M Triton-Tween PBS, overnight at 4 oC. Following three washes in 0.1 M Triton-
Tween PBS the secondary antibodies, diluted in 0.1 M Triton-Tween PBS with 5% FCS, 
were applied to the sections and left for 2 hours at room temperature. The primary and 
secondary antibody dilutions for each antigen used are listed in Table 2.5. Sections were 
washed three times in 0.1 M Triton-Tween PBS, as for the primary antibody, to remove 
excess secondary antibody. Finally sections were stained with Hoechst 33342, 
trihydrochloride, trihydrate, nuclear stain, diluted to 1:1000 in 0.1 M PBS for 5 minutes 
at room temperature before coverslipping using Prolong Gold Antifade Reagent 
(Invitrogen). Sections selected for no primary and no secondary antibody controls were 
shown identical treatment to the test samples, with the exception of the addition of 5% 
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FCS in 0.1 M Triton-Tween PBS in place of the primary and secondary antibody, 
respectively. 
For co-staining of two antigens a double staining protocol was used. This staining 
protocol was identical to the immuno staining protocol described above with the 
exception that two primary antibodies were applied to the sections simultaneously. Two 
secondary antibodies were then applied to the sections simultaneously, with care taken 
to avoid cross reaction of the secondary antibody with a non-specific primary antibody. 
For some stains, heat-induced epitope retrieval was required for successful antigen 
staining. Sections were placed in a large glass beaker filled with 10 mM sodium citrate 
buffer pH 6.0 and transferred to a heat block for 15 minutes. 
Antigen of 
interest 
Primary 
antibody  
Primary 
antibody 
dilution 
Secondary 
antibody 
Secondary 
antibody 
dilution 
Antigen 
retrieval 
Nrf2 Rabbit Anti-Nrf2 
(cat no. ab31163; 
Abcam Ltd, 
Cambridge, UK) 
1 in 100 
IHC 
Goat Anti-
Rabbit IgG 
H&L (Alexa 
Fluor® 
488) 
1 in 500 None 
NfkB Rabbit Anti-NF-
kB p65 (phospho 
S536) antibody 
(cat no. ab86299; 
Abcam Ltd, 
Cambridge, UK) 
1 in 150 
IHC 
Goat Anti-
Rabbit IgG 
H&L (Alexa 
Fluor® 
488) 
1 in 500 None 
Cytochrome 
c oxidase 
Mouse Anti-COX-
IV cat no. 
ab33985; Abcam 
Ltd, Cambridge, 
UK) 
1 in 100 
IHC 
Goat Anti-
Mouse IgG 
H&L (Alexa 
Fluor® 
594) 
1 in 200 Sodium 
citrate 
buffer 
(pH 6.0)  
D-J1 Rabbit Anti-
PARK7/DJ1 (cat 
no. ab18257; 
1 in 500 
IHC 
Goat Anti-
Rabbit IgG 
H&L (Alexa 
1 in 500 None 
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Abcam Ltd, 
Cambridge, UK)  
Fluor® 
488) 
3-
nitrotyrosine 
Rabbit Anti-
Nitrotyrosine 
antibody (cat no. 
N0409; Sigma-
Aldrich, UK) 
1 in 200 
IHC 
Goat Anti-
Rabbit IgG 
H&L (Alexa 
Fluor® 
488) 
1 in 500 Sodium 
citrate 
buffer 
(pH 6.0)  
MDA  Rabbit Anti-
Malondialdehyde 
cat no. ab6463; 
Abcam Ltd, 
Cambridge, UK) 
1 in 200 
IHC 
Goat Anti-
Rabbit IgG 
H&L (Alexa 
Fluor® 
488) 
1 in 500 None 
iNOS Rabbit Anti-iNOS 
antibody (cat no. 
ab3523; Abcam 
Ltd, Cambridge, 
UK) 
1 in 200 
IHC 
Goat Anti-
Rabbit IgG 
H&L (Alexa 
Fluor® 
488) 
1 in 200 Sodium 
citrate 
buffer 
(pH 6.0)  
Iba-1 Goat Anti Iba1 
(cat no. ab5076; 
Abcam Ltd, 
Cambridge, UK) 
1 in 500 
IHC 
Donkey 
Anti-Goat 
IgG H&L 
(Alexa 
Fluor® 
488) 
1 in 500 None 
Akt1/2/3 Rabbit Anti-
AKT1/2/3 
antibody (cat no. 
ab126811; 
Abcam Ltd, 
Cambridge, UK) ) 
1 in 1000 
WB 
Anti-
Rabbit- 
peroxidase 
antibody 
produced 
in goat 
(Sigma) 
1 in 1000 None 
p-Akt Anti-phospho-
Akt (pSer473) 
antibody 
produced in 
rabbit 
(cat no. 
SAB4504331-
100UG; Sigma)  
 
1 in 100 
IHC 
1 in 750 
WB 
Goat Anti-
Rabbit IgG 
H&L (Alexa 
Fluor® 
488) 
 
Anti-
Rabbit- 
peroxidase 
antibody 
produced 
in goat 
(Sigma) 
1 in 500 
IHC 
 
 
 
 
1 in 1000 
WB 
Sodium 
citrate 
buffer 
(pH 6.0) 
Actin Monoclonal Anti-
β-Actin, 
1 in 2000 
WB 
Anti-
mouse 
1 in 2000 None 
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produced in  
mouse (cat no. 
A1978; Sigma) 
IgG-
peroxidase 
antibody 
produced 
in rabbit 
(cat no. 
A9044; 
Sigma) 
Table 2.1: Working conditions for each antigen used in immuniohistochemical staining 
of fixed-frozen 10 µm retinal sections and western blot analysis. Table includes the 
primary antibody that was chosen to detect each antigen of interest, the primary 
antibody dilution, the secondary antibody used to detect the primary antibody and the 
dilution required. For some antigens, retinal sections were treated with sodium citrated 
buffer (pH 6.0) for 15 minutes prior to commencement of the staining protocol.  
 
2.6 2.6 Imaging and Fluorescence quantification 
 Fluorescence microscopy 
Images were acquired using an upright fluorescence microscope (Leica WETZLAR 
DM6000B) with selective FITC filter sets (excitation/emission 495/519 nm), a Rhodamine 
non-selective filter set (excitation/emission 552/578 nm) and a DAPI filter set 
(excitation/emission 359/461 nm). The experimental group to which the sections 
belonged was unknown to the experimenter. Three sections were imaged from each 
mouse with three images taken per section, one from the centre and two from the 
periphery using a DFC350 FX camera and a 20X magnification lens. All images were 
acquired with the same gain, intensity and exposure time. Controls for the primary and 
secondary antibodies were used to set the gain, intensity and exposure time, ensuring 
that minimal fluorescence was detected in samples controlling for autofluorescence and 
non-specific binding of the secondary antibody. This ensured that the images taken 
contained true fluorescence from the antigen of interest only.  
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 Confocal microscopy  
Images were acquired using a Zeiss LSM 510 confocal microscope (Carl Zeiss, Ltd, UK) 
using a 20X (0.8 NA) objective lens, 488 nm excitation and BP 500-530 nm emission filter 
for Alexa Fluor 488, 594 nm excitation and BP 599-702 nm emission filter for Alexa Fluor 
594 and 350 nm excitation and BP 411-480 nm for Hoechst 33342. Images of 60 X 
magnification were acquired using a 40X (0.8 NA) objective lens with a zoom value of 1.5. 
Three sections were imaged from each mouse with one images taken per section. All 
images were acquired with the same gain, intensity and exposure time.  
 Fluorescence quantification 
Fluorescence quantification was performed using Fiji software. To measure the average 
fluorescence in the GCL, RGB images with a range of 0-255 for each channel were 
converted into binary mode and the green and blue channels were split. The green 
channel was selected and a rectangular box of fixed area was placed on four different 
regions of the area corresponding to the retinal ganglion cell layer and the mean grey 
value within each rectangular box was calculated. The mean grey value within the 
rectangular box was calculated to give the average grey value for all the pixels occupied 
by the green marker in the selected region.  
To measure the nuclear-cytoplasmic ratio of fluorescent markers in the RGCs, the 
integrated density values were then obtained for the cytoplasmic and nuclear region of 
RGCs and the ratio between the two was calculated. To measure the integrated density 
of the RGC nuclei in ImageJ, the blue and green channels were split and the blue channel 
was overexposed to reveal all the RGCs (Figure 2.5A-B). The threshold function was used 
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to create a binary image to separate the RGC nuclei from the background (Figure 2.5C). 
A wand tracing tool was used to select and record the area occupied by each nuclei in 
the RGC layer and its position on the image (Figure 2.5D). Finally the regions of interest, 
recorded from the RGC nuclei in the blue channel, were pasted onto the areas 
corresponding to the RGC nuclei in the green channel, allowing the integrated density 
values for the antigen of interested in the RGC nuclear region to be measured. The 
integrated density of the GCL was measured by drawing around the nuclei with a polygon 
tool; the polygon created was approximately 16 µm in height, the approximate average 
diameter of the RGC soma. The integrated density value of the RGC nuclei was subtracted 
from the integrated density value for the GCL region, giving the integrated density values 
for the RGC cytoplasmic region. The ratio between the integrated density of the nuclear 
region and the cytoplasmic region of the GCL layer was then calculated. 
 
Figure 2.5: Method for calculation of the nuclear-cytoplasmic ratio of fluorescence in 
RGCs. The blue and green channels were split and the blue channel, showing the nuclear 
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stain was selected (A). The blue channel was over exposed (B) and the threshold function 
was used to create a binary image (C). A wand tracing tool was used to select and record 
the area of each nuclei (D). The green channel was then selected (E) and the area 
recorded for each nuclei was pasted onto the green channel, allowing the integrated 
density values for the antigen of interest in the nuclear region to be measured (F). Arrows 
indicate the selected nuclear region. Scale bars represent 100 µm (A-C and E) and 50 µm 
(D and F). 
 Western blotting 
Western blot analysis was used to verify the results of the immunohistochemistry in 
Chapter 6. Mice were sacrificed by cervical dislocation 30 minutes after the final light or 
sham treatment. The retinae were rapidly removed and placed in 5 µL of phosphatase 
inhibitor cocktail and 5 µL of protease inhibitor cocktail (Abcam) and immediately 
transferred to liquid nitrogen. Retinae were stored at -80 until required. Three mice per 
experimental group were used for each antibody and two retinae from each mouse were 
pooled together to produce a single sample. Each sample contained enough protein to 
do the western blot twice. 
20 µg of total protein was separated on a 10% SDS–PAGE gel and transferred to a 
nitrocellulose membrane (0.2 μm) (Bio-Rad laboratories, Hertfordshire, UK). Protein 
samples were incubated with blocking buffer (5% bovine serum albumen in 1X Tris-
buffered saline with 0.5% Tween20- pH 7.2–7.4) for 1 h at room temperature. After 
washing in wash buffer (1X Tris-buffered saline with 0.5% Tween), the primary antibodies 
(rabbit Anti-AKT1/2/3 antibody (1:1000), rabbit Anti p-Akt (1in 750) and mouse Anti-actin 
(1:2000)) were applied to the respective samples in blocking buffer and were incubated 
overnight at 4 oC on a mini orbital shaker SO5 (Stuart Scientific, Stratfordshire, UK). After 
washing three times for 10 minutes each in wash buffer, horseradish peroxidase 
conjugated secondary antibodies were applied to the samples goat anti-rabbit t at 
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1:1000 for Akt and p-Akt, and rabbit anti-mouse at 1:2000 for Actin. The samples were 
incubated with the secondary antibodies for 2 h at room temperature. The blots were 
developed using the enhanced chemiluminescence detection kit (Biological Industries, 
Lichfield, UK) and ChemiDOc XRS+ System (Bio-Rad laboratories, Hertfordshire, UK). 
Bands were quantified using Image Lab software (Bio-Rad laboratories, Hertfordshire, 
UK) and normalized to actin. The normalised values for p-Akt and Akt were then used to 
calculate the p-Akt/Akt ratio.  
2.7 MTT assay on the retinal flat mount 
 Reagents used   
2.7.1.1 Acidified isopropanol 
In the fume cupboard, 3.33 µl of 37% HCL was added to each 1mL isopropanol to make 
up the required volume of acidified isopropanol with a molarity of 0.04 M. This was done 
one week prior to use and stored at room temperature. 
2.7.1.2 MTT stock solution 
A 5 mg/mL stock solution with was made by diluting MTT powder in 0.1M PBS. The 
solution was passed through a 2 µm pore sterile filter into a sterile 15 mL falcon tube. 
The falcon tube was foil wrap to protect the solution from light and store in the fridge 
for up to 4 days before use. 
2.7.1.3 Culture medium 
Neurobasal A medium without phenol red was used to avoid any potential interference 
of phenol red with the absorbance readings in the final assay. 
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2.7.1.4 Triton X 10 
TritonX100 was diluted to 1 in 10 in PBS at room temperature to make the solution less 
viscous allowing the required volumes for the assay to be accurately measured. 
 Original MTT protocol prior to modifications 
Mice were killed by cervical dislocation. Both eyes were removed and placed in ice cold 
Hanks buffered saline solution. The retinae were dissected and flat mounted onto a 
membrane culture insert and placed in a 6-well plate containing 1 mL of pre-warmed 
Neurobasal A medium, as described previously, before being transferred to a at 37 oC 
incubator for the required time.  
After the incubation period, 110 µL of 5mg/mL (MTT) 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) solution was added to the well containing the insert, 
comprising 10% of the culture medium giving a final concentration of 0.5 mg/mL MTT in 
each well. The plate was gently swirled to ensure a uniform concentration of MTT within 
the well. The plate was then returned to the incubator for 2 hours at 37 oC to allow the 
reduction of MTT to formazan by active mitochondrial enzymes. 
To control for formazan production in the absence of viable cells, a retina was treated 
with TritonX10 to kill all retinal cells before treatment with MTT, representing 0% cell 
viability. This was achieved by the addition of 100 µL of Triton X 10 directly on top of the 
retina which was then left in the incubator at 37 oC for 30 minutes. 
After the MTT incubation period the insert containing the retina was removed from the 
well and washed with PBS for 5 minutes to remove any traces of MTT whilst taking care 
not to remove any formazan. Efforts were made to and protecting from light during all 
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stages of the assay, as light has the potential to cause an accelerated spontaneous of 
MTT. The insert containing the retina was transferred to a clean well to which 1 mL 
acidified isopropanol was added. The plate was before put on shaker for 15 minutes to 
dissolve the formazan crystals. The absorbance of the formazan crystal solution was read 
at 570 nm in triplicate. A reading was also taken at 690 nm as a reference for each 
sample, which was subtracted from each reading obtained at 570 nm. 
2.8 Measuring oxygen consumption in the retinal explant using the Seahorse 
XF Analyzer 
 Original protocol for preparation of retinal explants for use in the 
Seahorse XF analyser 
Mouse retinal explants were flat mounted 16 hours prior to measuring oxygen 
consumption. A 20 µl drop of chicken plasma was pipetted onto nylon inserts and the 
retinal explant was centred onto the insert before 20 µl of thrombin was added to fix 
slices within an O2 permeable clot. The slices were transferred to a 6 well plate 
positioned with the slices facing up. The slices were covered with pre-warmed 
Neurobasal A at 37 °C, 1 ml was sufficient to cover the slice. The plates were then 
transferred to an incubator at 37 °C and 5% CO2.  
 Modified protocol for preparation of retinal punches for use in the 
Seahorse XF analyser 
Mouse retinae were explanted and three 1 mm tissue punches were taken from regions 
adjacent to the optic nerve. This was to ensure that the readings were taken from the 
central retina to avoid central to peripheral variations. The retinal punches were placed 
off centre on the nylon insert and placed in ice cold Ames’ medium (pH 7.4) and placed 
in an igloo with ice. The inserts were positioned off centre so as to place the retinal punch 
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directly under the O2 sensor. Ames’ solution buffered with 10 mM HEPES was chosen as 
this medium is optimal for retinal tissue. Retinas remained on in ice cold Ames’ medium 
until the inserts were placed into the wells of the microplate.  
 XF24 microplate-based respirometry 
Respirometry of retinal explants was performed using an XF24 Extracellular Flux Analyzer 
(Seahorse Bioscience, Billerica, MA). Explants on nylon inserts were individually inserted 
face down into 16 wells of 24-well XF Islet Capture Microplates that contained 675 µl of 
Neurobasal A. Eight wells contained inserts but no slices to control for oxygen 
consumption and extracellular acidification rate. The wide end of a 20 µl pipette tip was 
used to ensure inserts are even in wells. Once the transfer of inserts was complete, slices 
in XF Islet Capture Microplates were incubated in a CO2-free incubator at 37°C for 1hr to 
allow temperature and pH equilibration. Slices were then loaded into the XF24 and 
further equilibrated for 15 min by three 3 min mix, 2 min wait cycles prior to the first 
measurement. XF assays consisted of 3 min mix, 3 min wait, and 2 min measurement 
cycles and were performed at 37°C as described (Wu et al., 2007). Using this protocol, it 
was possible to calculate an O2 consumption rate every 8 minutes. Compounds of 
interest prepared in Neurobasal A medium (75 μl) were preloaded into reagent delivery 
chambers A, B, C, and D at 10X, 11X, 12X, and 13X the final working concentration, 
respectively, and injected sequentially at intervals of 24 minutes, with the first addition 
occurring after 24 minutes and the final addition occurring after 96 minutes. Chambers 
A, B, C and D contained oilgomycin, FCCP, Rotenone and Antimycin A, respectively. 
2.9 Statistical analyses  
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The Kolmogorov-Smirnov test was performed in SPSS to test for normality in the data. 
Normally distributed data were analysed using an unpaired t-test in Excel. Non-
parametric data were analysed using the Mann Whitney-U test using the SPSS program. 
p values less of than 0.05 were considered statistically significant. 
Chapter 3. Modification of cell based assays to assess the effect of 670 nm light on 
mitochondrial bioenergetics in the retinal explant  
90 
 
Chapter 3. Modification of cell based assays to 
assess the effect of 670 nm light on mitochondrial 
bioenergetics in the retinal explant  
 
 
 
 
 
 
 
 
 
 
 
Chapter 3. Modification of cell based assays to assess the effect of 670 nm light on 
mitochondrial bioenergetics in the retinal explant  
91 
 
3.1 Introduction  
Although great progress has been made in uncovering the molecular mechanism 
responsible for the beneficial effects of 670 nm light, there remains, yet, much 
controversy and unclarity surrounding this area of research. One of the theories available 
for the beneficial effects of 670 nm light in neurodegenerative diseases is the increase in 
Complex IV activity and the restoration of the ATP producing capacities of the 
mitochondria of cells with defective mitochondrial proteins. Bioenergetic deficiencies 
have been found in the het mouse model, namely, a reduction in ATP production and 
oxygen consumption, a reduction in the protein levels of Complex IV and a decrease in 
the enzymatic activities of Complex I and IV (Chen et al., 2012). RGCs are highly 
metabolically active and it is hypothesised that the exclusive degeneration of RGCs in 
ADOA is due to their inability to survive with a reduced capacity to produce ATP. As 
perturbations in mitochondrial activity are detremental for RGC function, normal 
mitochondrial activity must be sustained to support the function and survival of the 
RGCs. We hypothesis that  670 nm light will provide beneficial effects to the 
degeneration prone RGCs by improving mitochondrial bioenergetics.  
Complex IV activity can be measured using the COX/SDH assay. Since many of the 
beneicial effects of 670 nm light are thought to occur downstream of absorbtion of 
photon energy at complex IV, we thought exploring the direct effects of 670 nm light on 
the enzymatic activity of this complex would be a suitable initial experiment. 
Mitochondrial electron transport chain activity can be assessed by monitoring the 
reduction of MTT to formazan. Learning of the effects of 670 nm light on mitochondrial 
activity or reductive capacity would provide a basic understanding of whether or not 670 
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nm light can influence mitochondrial function in retinae from het mice; however, the 
exact components of mitochondrial function altered by 670 nm light would not be 
identified. A more precise exploration of the effects of 670 nm light on mitochondrial 
bioenergetics would enable a more detailed analyisis of the effects of 670 nm light on 
retinal mitochondria. The Seahores XF cell mito stress test measures key parameters of 
mitochondrial function, including ATP production, proton leak, maximal respiration, 
spare respiratory capacity and non-mitochondrial respiration, by directly measuring 
oxygen consumption and cytoplasmic glycolysis.  
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3.2 Experimental design   
 COX/SDH assay 
The cytochrome c oxidase/succinate dehydrogenase (COX/SDH) assay can be used to 
measure COX or ETC complex IV activity. The catalytic subunits of COX are encoded by 
mitochondrial DNA, therefore their correct synthesis is dependent on mtDNA integrity 
(Ross, 2011). Whereas the subunits of SDH are encoded by nuclear DNA, therefore the 
proper synthesis of this complex is unaffected by mtDNA mutations.  
It was of interest look at the effects of 670 nm light on complex IV activity in in het mice 
as complex IV activity has been found to be reduced in this model. Very aged mice were 
chosen for this experiment to test whether or not 670 nm light could produce beneficial 
effects at the end stage of the disease. Wild-type and het mice were selected in numbers 
sufficient to have a minimum of five mice in each of the following experimental groups: 
wild-type sham treated, het sham treated and het 670 nm light treated. The mice were 
aged until all mice were a minimum of 21 months old to test whether or not 670 nm light 
could provide therapeutic effects in the very advanced stages of disease in the het 
mouse. 
Thus we treated 21-26 month old het mice (n=6) with 670 nm light twice daily for 7 
consecutive days as described in Chapter 2.4. A group of 21-26 month old wild-type (n=5) 
and het mice (n=4) were sham treated as a control. After the final treatment the mice 
were killed by cervical dislocation and one eye from each mouse was flash frozen. The 
second eye was prepared for exploration of the effects of 670 nm light on microglial 
activation in very aged mice (Chapter 6). 
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Due to freezer failure the flash frozen tissue was no longer suitable for the assay 
COX/SDH assay so there are no results for this experiment. 
 The MTT assay   
The MTT reduction assay is a cell viability assay based on the presence of active 
mitochondrial enzymes. Mitochondrially active viable cells can reduce MTT, which is a 
yellow solution, into formazan crystals, which are a purple, water insoluble product, in 
the presence of a mitochondrial reducing molecule, most likely NADH (Riss et al., 2016). 
NADPH oxidase is also another molecule responsible for MTT reduction. The amount of 
formazan produced, which absorbs maximally at 570 nm, is considered to be 
proportional to the number of viable cells, since mitochondrial activity is related to the 
number of viable cells in most cell populations.  
It was most useful to test the effects of 670 nm light on mitochondrial activity at a time 
when Opa1-related degeneration was present. As degeneration in the het mouse 
presents as significant dendropathy at 12-15 months, the effects of 670 nm light on 
mitochondrial activity were tested het mice of that age. Therefore, the mice were treated 
in vivo before culling and explanting the retinae, and the analysis was done on the retinal 
explant. However, the MTT assay is designed for use in in vitro studies, thus it was first 
necessary to modify the assay for use in the retinal explant.  
The degeneration in the het mouse is subtle at 12-15 months, indicating that the Opa1 
mutation produces a mild phenotype. In order to find significant differences between 
both wild-type and het mice, and sham and light treated mice, with a feasible number of 
retinae, it was necessary to allow the retinae to degenerate ex vivo to maximise the 
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chances of significance being reached between the experimental groups. Significant ex 
vivo dendropathy has been shown to begin to occur in mouse retinal explants after 6 
hours and progresses over 3 days (Binley et al., 2016). Sixteen hours was chosen as a 
suitable time for monitoring the changes in mitochondrial activity between wild-type and 
het retinae and sham and light treatment. This was considered the ideal time point as 
the effects of the Opa1 mutation would be exaggerated and the ex vivo degeneration in 
the retinae could be allowed to occur overnight ready for analysis the following morning. 
 Oxygen consumption measurements 
Similar to the MTT assay, it was decided that 16 hours ex vivo would be a suitable time 
point for measuring oxygen consumption in the retinal explant. As the nearest available 
Seahorse XF24 analyser was in Swansea University, a 16 hour ex vivo time point was 
considered most suitable for practical reasons. Retinal dissection was done the evening 
before the assay and retinae were transported to Swansea at 9am the following morning. 
The time of dissection and transport were carefully considered to ensure that the assay 
would commence approximately 16 hours post axotomy.   
Since there is decreased oxygen consumption in vivo in the het mouse, it was 
hypothesised that there would also be decreased oxygen consumption compared to 
wild-type after 16 hours ex vivo. A statistical reduction in oxygen consumption after 16 
hours would provide an ideal platform to test the effects of 670 nm light on this 
parameter.  
Of note, the retinae were placed in suboptimal conditions for transport which may have 
compromised the tissue quality at the time of the assay. In particular, the 6 well plate 
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containing the retinae was removed from the incubator and placed in a Styrofoam 
insulated box that was lined with cotton wool sheets and packed with heat packs at 37 ° 
C before sealing.  
The Seahorse mito stress test kit is used to yield information on various parameters of 
mitochondrial respiration by the sequential addition of modulators of different 
components of the electron transport chain, by measuring oxygen consumption (Figure 
3.1). Basal respiration shows the energy demand of the cell under normal physiological 
conditions, maximal respiration occurs when you use an uncoupler so the proton can 
freely cross the membrane following the concentration gradient so there is no proton 
gradient to allow for ATP synthesis, spare respiratory capacity demonstrates how well 
the cell would cope with an increased energy demand, non-mitochondrial “respiration” 
is the oxygen consumption that remains after the inhibition of the electron transport 
chain such as generation of superoxide which would be converted to hydrogen peroxide. 
   
Figure 3.1: An exemplary result from the Seahorse mito stress test on cells in vitro. 
Three readings are taken for the oxygen consumption that results from basal respiration. 
Another three readings are taken after the addition of oligomycin to show the decrease 
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in oxygen consumption following the inhibition of ATP synthase. The uncoupler FCCP is 
then added to uncouple oxidative phosphorylation from ATP synthesis, allowing the 
protons to flow through the mitochondrial inner membrane, from the intermembrane 
space back into the matrix, before they can be used to fuel ATP production by ATP 
synthase. Three readings are taken following FCCP addition to show the oxygen 
consumption at the maximal respiration ability of the mitochondria. The mitochondrial 
spare capacity is the difference in between the oxidative phosphorylation thar occurs 
under basal conditions for ATP production and that which occurs when oxidative 
phosphorylation is driven to maximum levels The addition of the complex III inhibitor 
Antimycin A and the complex I inhibitor Rotenone completely supresses oxidative 
phosphorylation. Three final readings are taken after the addition of Antimycin A and 
Rotenone to determine the oxygen consumption that occurs in the absence of 
mitochondrial respiration. The proton leak refers to the oxygen consumption that occurs 
from mitochondrial respiration under basal conditions that does not result from ATP 
production. 
 
The Seahorse XF analysers are designed for use with monolayers of cells, cells in 
suspension or isolated mitochondria, consequently, the assay required modification and 
optimisation for use in the retinal explant. This assay was previously modified for the 
measurement of oxygen consumption in both cultured and acute hippocampal slices 
with some success  (Schuh et al., 2011). The hippocampal slices used were 200 µm in 
thickness, which is the approximate thickness of the mouse retina. The medium used for 
the culture of hippocampal slices, artificial cerebospinal fluid, was also used as the assay 
medium, therefore we used retinal explant culture medium, neurobasal A, as the assay 
medium in our protocol. Plasma and thrombin were used to fix the slices to the nylon 
insert for measurements on acute hippocampal slices but were not required in the 
protocol for the cultured hippocampal slices. As the explants were to be placed in culture 
for only 16 hours, plasma and thrombin were used in the initial test of this assay on the 
retinal explant to avoid any potential movement of the tissue during oxygen 
consumption measurements. The concentrations of mito stress test compounds used in 
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the reference paper were used as the starting point in the optimisation process. Four 
different concentrations of each compound were tested in attempt to find the optimal 
concentration for use in the retinal explant. As the retinal explant has a much larger 
surface area than the hippocampal slices, three different concentrations above those 
used for the hippocampal slices were selected for testing in the retinal explant (Table 
3.1). 
 
 
 Oligomycin FCCP Antimycin A & 
Rotenone 
Starting 
concentration from 
reference paper 
(Concentration 1) 
1 µg/ml 1 and 5 µM 10 µM 
Concentration 2 
 
2 µg/ml 2 µM 20 µM 
Concentration 3 
 
5 µg/ml 5 µM 30 µM 
Concentration 4 
 
10 µg/ml 10 µM 40 µM 
Table 3.1: The concentrations of the mito stress test compounds chosen as a starting 
point for the optimisation of the assay for use in the retinal explant. Four different 
concentration of each drug were tested as a starting point for the Seahorse assay 
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3.3 Results 
 Modification of the cell based cell MTT used to assess cell viability 
in the retinal explant 
Incubation of the retinal explant with 0.5 mg/mL MTT for 2.5 hours resulted in a dense 
covering of formazan crystals on the retinal explant at different time points up to 24 
hours after flat mounting (Figure 3.2A-D). The absorbance at 570 nm of the solubilised 
formazan crystals, produced by active mitochondria, decreased rapidly as a function of 
time ex vivo (Figure 3.2E). Assessment of the cell viability of RGCs was required from the 
MTT assay, yet the resulting formazan crystals were formed by the cells of the entire 
retina. Therefore, visualisation of the formazan crystals around the RGC nuclei was 
necessary to show the metabolic activity and viability of these cells by the MTT assay.  
The concentration of MTT appeared to be too high at 0.5 mg/mL to allow the 
visualisation of formazan crystal formation around the RGC nuclei. Consequently, the 
concentration of MTT was reduced to 0.25 mg/mL and the incubation time of the retina 
with MTT was reduced to 30 minutes. Figure 3.3A shows the formazan formation on the 
retinal explant when treated with 0.25 mg/mL MTT for 30 minutes. Using this 
concentration made it possible to visualise the reduction in mitochondrial activity in the 
explant over time ex vivo as shown by the decrease in the purple formazan product on 
the retinal explant from 0 to 48 hours ex vivo (Figure 3.3A-E). This concentration was 
more suitable to assess whether the formazan crystals can be seen surrounding the RGC 
nuclei, using confocal microscopy.  
Reflective light was used to image the formazan crystals, using Topro as a nuclear counter 
stain. The results were inconclusive as it was difficult to pick up the reflective light signal 
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from the RGC layer. In some areas there was some reflected light signal detected around 
the RGC nuclei however the background signal was very high. 
 
Figure 3.2: Optimisation of the MTT assay to detect reductions in mitochondrial 
reductive capacity in the retinal explant. The formazan crystal formation on the retinal 
explant after incubation with 0.5 mg/mL MTT for 2.5 hours immediately after explanting 
(n=1) (A), 1 hour after explanting (n=1) (B), 3 hours after explanting (n=1) (C) and 24 hours 
after explanting (n=1) (D). E: The formazan formation on a retina which was treated with 
TritonX100, to cause almost 100% cell death before incubation with 0.5 mg/mL MTT for 
2.5 hours (n=1). F: The absorbance readings of solubilised formazan crystals formed by 
retinae after various ex vivo culture periods. 
 
 
 
Chapter 3. Modification of cell based assays to assess the effect of 670 nm light on 
mitochondrial bioenergetics in the retinal explant  
101 
 
 
Figure 3.3: Further optimisation of the cell based MTT assay for use on the retinal 
explant. The explant treated with 0.25 mg/mL MTT immediately after flat mounting 
(n=1) (A), treated with 0.25 mg/mL MTT 1 hour after flat mounting (n=1) (B), treated with 
0.25 mg/mL MTT 16 hour after flat mounting (n=1) (C), treated with 0.25 mg/mL MTT 48 
hours after flat mounting (n=1) (D), treated with 0.25 mg/mL MTT 1 week after flat 
mounting (n=1) (E) and treated with 0.25 mg/mL MTT after treatment with TritonX100, 
representing as close as possible to 100% cell death (n=1) (F). Images D and E were over 
exposed, showing the area of the retina with formazan crystals in purple and the 
unstained area of the retina in white. 
 
The MTT assay was found to have the ability to detect changes in mitochondrial reductive 
capacity in the retinal explant as observed by the progressive decrease in formazan 
formation in the explant as it degenerates over time ex vivo. Since we were unable to 
image the formazan crystals surrounding the RGC mitochondria, we were unable to 
determine the portion of the formazan that was produced exclusively by the RGCs. 
Therefore, the assay was used to detect changes in the mitochondrial activity of the 
entire retinal explant.  
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During the optimisation process much variability was found between the results of the 
MTT assay in retinae at the same ex vivo timepoints. It was noticed that ex vivo time 
points past 16 hours produced the most variable results with the MTT assay. However, a 
maximum of two retinae were used at each time point in the optimisation stages. To test 
the reproducibility of this assay on the retinal explant, five retinae each were used at 
time zero and at 16 hours ex vivo, with one retina from each mouse assigned to the 0 
hour time point and the other to the 16 hour timepoint. The standard concentration of 
0.5 mg/mL MTT was used for this experiment. The mean and standard deviation for the 
absorbance values at time zero was 0.593 ± 0.125, which was reduced to 0.396 ± 0.142 
when the assay was done after 16 hours ex vivo (Figure 3.4). The average absorbance 
value of 5 retinae was reduced from that obtained at 0 hours ex vivo to that obtained 
after 16 hours ex vivo. This reduction was in accordance with the reduction in cell viability 
that occurs over this time. From this result it was concluded that the MTT assay was 
sensitive enough to detect changes in cell viability in the retinal explant. 
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Figure 3.4: Investigating the viability of the wild-type retinal explant from 0 to 16 hours 
ex vivo, based on the mitochondrial reductive capacity, as determined by the MTT 
assay. The average absorbance of formazan at 570 nm was measured in retinal explants 
treated with MTT at 0 (n=5) and 16 (n=5) hours after flat mounting. Error bars represent 
SEM. 
 
The MTT assay was then used to explore differences in the cell viability of the retinal 
explant from wild-type and het mice after 16 hours ex vivo. The assay was also employed 
to look at the effect of 670 nm light on mitochondrial reductive capacity in aged wild-
type and het mice. Retinae from wild-type and het mice were treated in vivo with 670 
nm light, for 5 consecutive days, and the effects on the cell viability of the retinal explant 
after 16 hours ex vivo was monitored. There were no significant differences between any 
of the groups investigated, using three mice per experimental group (Figure 3.5).  
Further, no trend emerged to show that 670 nm light can increase mitochondrial activity 
in either wild-type and het retinae. Also, there was no decrease in mitochondrial activity 
in the het retinae, showing an inability of the MTT assay to detect differences between 
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wild-type and het retinae or sham treated and light treated retinae. This pilot experiment 
was therefore not pursued further. 
 
Figure 3.5: Mitochondrial reductive capacity was unchanged in retinal explants from 
het mice after 16 hours ex vivo compared to wild-type. Similarly, in vivo treatment with 
670 nm light had no effect on the mitochondrial reductive capacity of wild-type or het 
retinae, when assayed after 16 hours ex vivo. The average absorbance of formazan at 
570 nm of retinae from sham treated wild-type (n=5), light treated wild-type (n=6), sham 
treated het (n=4) and light treated het (n=4) mice is presented. Error bars represent SEM. 
 
 Development of a method to measure oxygen consumption in the 
retinal explant using the Seahorse XF analyser 
As the retina is almost the same diameter as the microchamber of the Seahorse XF24 
Islet cell microplate, it was thought that the design would be suitable for measuring 
oxygen consumption of the entire retinal explant (Figure 3.6A-C). Plasma and thrombin 
were used to prevent the retina moving during measurements by creating an oxygen 
permeable tissue clot between the retina and the porous nylon insert (Figure 3.6B-C). 
Different concentrations of compounds from the mitochondrial stress test (oligomycin, 
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FCCP, rotenone and antimycin A) were tested to find the best concentration of each for 
use on the retinal explant. The basal rate of oxygen consumption was very low for a large 
piece of tissue such as the retina (Figure 3.7). Additionally, there was only a minor effect 
of oligomycin and FCCP in most of the retinae, however, the respective decrease and 
increase in oxygen consumption was not as steep as that seen with a monolayers of cells 
(Figure 3.1). All concentrations of rotenone and antimycin A were found to be ineffective 
in supressing mitochondrial respiration as the oxygen consumption rates began to rise 
after the addition of the uncoupler, FCCP, and continued to rise despite the addition of 
the Complex I inhibitor, rotenone, and the Complex III inhibitor, antimycin A. 
 
Figure 3.6: Preparation of the retinal flat mount for measurement of oxygen 
consumption using the Seahorse XF Analyser and the Seahorse XF24 Islet Capture 
Microplate. The nylon insert (A), 10 µl of chicken plasma placed on the nylon insert (B), 
the retina flat-mounted onto the nylon insert (C), the 6 well plate containing the retina 
atop the nylon insert and neurobasal A medium (D), the bottom of the Islet Capture 
Microplate (E) and a diagram of the retina attached to the nylon insert placed in the Islet 
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Capture Microplate for the creation of a transient microchamber with the retractable 
probe (F).  
 
 
 
Figure 3.7: The oxygen consumption rates of whole retinal flatmounts measured using 
the Seahorse XF Analyser. Three measurements were taken for basal respiration before 
the addition of oligomycin, FCCP, rotenone and antimycin A at the times indicated by the 
arrows. Each plot shows the oxygen consumption over time for one retinal explant. 
 
The use of 20 µL of plasma and thrombin, as used previously to adhere the retina to the 
nylon insert, appeared to be too large of a volume for the retina, therefore, smaller 
volumes of 5 µL and 10 µL were tested (Figure 3.8A-B). Furthermore, as the tissue clot 
was formed prior to incubation of the explant for 16 hours, the effect of this condition 
on oxygen consumption measurements was examined (Figure 3.8). The baseline oxygen 
consumption measurements were, on average, higher in retinas not fixed to the nylon 
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insert with plasma and thrombin. Further, some retinae treated with 10 µL of plasma 
and thrombin had negative oxygen consumption readings. Based on this result, the use 
of plasma and thrombin on the retinal explant either caused a disruption to the oxygen 
consumption readings during the assay or the incubation of the retina with plasma and 
thrombin for 16 hours compromised the viability of the retinal explant leading to low 
oxygen consumption rates. However, even without the use of plasma and thrombin, the 
response of the retinae to the mitochondrial stress test compound was limited. This 
highlighted the possibility that waiting 16 hours between explanting the retina and 
measuring the oxygen consumption compromised the ability of the retina to respond to 
the mitochondrial stress test compound. 
 
Figure 3.8: A comparison of the effect of 10 µl plasma/thrombin, 5 µl plasma/thrombin 
or no plasma/thrombin on the oxygen consumption rates of whole retinal flatmounts 
as measured using the Seahorse XF analyser. Three measurements were taken for basal 
respiration before the addition of oligomycin, FCCP, rotenone and antimycin A at the 
times indicated by the arrows. 
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The MTT assay was employed to assess the viability of the retinal explant at the time of 
oxygen consumption measurements, taking into consideration the 15 hour incubation 
period at 37 °C in a 5% CO2 incubator and 1 hour transport conditions. The retina was 
incubated for 15 hours in a 37 °C 5% CO2 incubator then the 6-well plate was transferred 
to a sealed polystyrene box containing a heat pack at 37 °C and an inner insulating layer 
of cotton wool sheets. After an hour the plate was removed and an MTT assay was done. 
Figure 3.9D shows the cell viability of the retina represented by the formazan formation 
after normal 16 hour incubation conditions and Figure 3.9E shows the cell viability of the 
retina after 15 hours normal incubation conditions and one hour of simulated transport 
conditions. The large region of the retina without formazan crystals was indicative of a 
substantial loss in the number of viable cells with active mitochondria, in retinae where 
transport conditions were simulated (Figure 3.9E). A 16 hour incubation period with the 
additional challenge of the suboptimal transport conditions were found to have too of 
severe an effect on cell viability to be suitable for an assay where optimally functioning 
mitochondria are required.  
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3.9: The MTT assay revealed that 16 hours ex vivo and suboptimal culture conditions 
prior to the seahorse assay severely reduced mitochondrial function in the retinal 
explants. A: The retinal flat mount treated with MTT immediately after flat-mounting. B: 
The retinal flat mount treated with MTT 1 week after flat mounting. The image was over 
exposed, showing the area of the retina with formazan crystals in purple and the 
unstained area of the retina in white. C: The retinal flat mount treated with MTT after 
TritonX100 treatment to represent 100% retinal cell death. D: The retinal flat mount 
treated with MTT 16 hours after flat mounting under normal tissue culture conditions. E: 
The retinal flat mount treated with MTT 16 hours after flat mounting under normal tissue 
culture conditions for 15 hours and simulated transport conditions for an hour. 
 
The measurement of oxygen consumption on the retinal explant was then tested 2 hours 
after explanting the retina, with one hour of transport conditions included in this 
incubation period (Figure 3.10A). Examination of the condition of the retinal 
wholemount on the nylon insert after completion of the assay revealed that although 
the flatmounts had cuts to allow the media to flow unimpeded through the porous insert 
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into the microchamber at the beginning of the assay, the entire insert was covered with 
retinal tissue upon cessation of the assay (Figure 3.10B). This uncovered a potential 
limitation of the protocol as the tissue itself may have restricted fresh media being 
delivered to the microchamber before each measurement, which may have limited the 
oxygen consumption capacity of the explant in the previous tests. To address this 
concern, the retina was cut into thirds to ensure that a fresh supply of media could enter 
the microchamber after each oxygen consumption measurement (Figure 3.10C). 
The basal oxygen consumption rates in many of the samples were between 200 and 500 
pmol O2 (Figure 3.10A). Of those samples, the majority showed a response to the 
mitochondrial stress test compound; the oxygen consumption decreased after the 
addition of the inhibitor of ATP synthase, oligomycin, increased after the addition of the 
mitochondrial membrane uncoupler, FCCP, began to rapidly decrease after the addition 
of the complex I inhibitor, rotenone, and continued to decrease after the addition of the 
Complex III inhibitor, antimycin A. However, with the exception of two samples, the 
response to oligomycin and FCCP was weak compared to that which occurs when the 
assay is done using cell monolayers. The retina appeared to respond appropriately to 
rotenone, as the oxygen consumption rates were brought down below basal respiration 
rates. The effect of antimycin A is unclear as the oxygen consumption rate continued to 
decrease with each measurement after the addition of rotenone, but the rate of the 
decrease remained unchanged after the addition of antimycin A.  
The high oxygen consumption rate after the addition of oligomycin indicates that much 
of the oxygen consumption in these retinal samples is due to non-mitochondrial 
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respiration. It is also possible that the concentration of oligomycin used was too low or 
the time allotted for the inhibition of ATP synthase was too short. The high oxygen 
consumption levels after the addition of rotenone and antimycin A were a further 
indication of high non-mitochondrial respiration levels in the retinal samples. 
 
Figure 3.10: The oxygen consumption rates of retinal flatmount thirds were measured 
using the Seahorse XF Analyser. A: Three measurements were taken for basal respiration 
before the addition of oligomycin, FCCP, rotenone and antimycin A at the times indicated 
by the arrows. B: The whole retinal flatmount after the assay. C: The retinal flatmount 
third placed on the nylon insert.  
 
It was thought that the amount of tissue used to measure retinal oxygen consumption 
was too large as the concentration of compound used in the assay is dependent on the 
number of cells, therefore decreasing the tissue size will increase the likelihood of seeing 
standard changes in the oxygen consumption rate in response to the compound. The 
method from the paper using hippocampal slices was used as our starting point because 
the slices were approximately 200 µm in thickness, which is the approximate thickness 
of the mouse retina. However, comparing our method to that used to measure oxygen 
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consumption in hippocampal slices using Seahorse XF technology, the area of the retinal 
section, with an area of 3.2 mm2, was much greater than that of the hippocampal slice, 
with an area of 0.33 mm (Schuh et al., 2011). 
 It was possible to cut the retina into 8 radial sections with an approximate area of 1.2 
mm each, which was 3.6 times larger than the hippocampal slice. The drug 
concentrations used for hippocampal slices were then adjusted to achieve a 3.6 times 
larger concentration for the retinal section. Two concentrations higher and two 
concentrations lower than the concentration predicted to be suitable for the retinal 
section were tested (Table 3.2).  
Drug Concentration 
hippocampal 
slice titration 
Predicted 
suitable 
concentration 
for retina 
(3.6X) 
Rep1 Rep2 Rep3 Rep4 
Oligomycin 3 µM 11 µM 5 µM 10 
µM 
15 
µM 
20 
µM 
FCCP <5 µM 11, 14 or 18 
µM 
5 µM 10 
µM 
15 
µM 
20 
µM 
Rotenone Not tested 36 µM 10 
µM 
20 
µM 
30 
µM 
40 
µM 
Antimycin 
A 
10 µM 36 µM 10 
µM 
20 
µM 
30 
µM 
40 
µM 
Table 3.2: Predicted suitable drug concentrations for use on retinal sections, based on 
reference paper. The optimisation of the best concentration of compound to use on the 
retinal explant was tested using two concentrations above and two concentrations 
below the concentration predicted to be suitable for a retinal section of 1.2 mm in area. 
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The protocol used in the preceding attempts had taken three measurements after each 
drug injection, with each measurement taking 8 minutes. This may not have been 
sufficient time for a molecule with such a high molecular weight such as oligomycin 
(790.523113 g/mol) (exact mass, Pubchem) to penetrate a large tissue section. Schuh et 
al. 2011 has shown that the OCR continues to decrease after the addition of oligomycin 
for up to 9 measurements (Schuh et al., 2011). FCCP (254.041545 g/mol) has a lower 
molecular weight and may not need as many measurements. Also, since the OCR 
increased after the first measurement of FCCP but steadily decreased with subsequent 
measurements, fewer measurements may be sufficient (Schuh et al., 2011). Antimycin A 
(548.273381 g/mol) has been shown to decrease OCR using the protocol from our 
previous attempt, however, since it has a relatively large molecular weight and the 
decrease seen was not as steep as expected, an additional measurement was added.  
The Seahorse XF Analyser simultaneously records changes in oxygen consumption and 
pH rate to monitor rates of respiration and glycolysis, respectively. A pH of between 8 
and 9 was recorded in the samples which may be responsible for the limited effect of the 
drugs. The tissue, which should be maintained at pH 7.4, may not have responded to the 
drug a such a high pH. The assay medium Neurobasal A, which is buffered with sodium 
bicarbonate, was not suitable for use for the Seahorse assay which is done in a CO2 free 
incubator.  The Neurobasal A medium was replaced by non-buffered Seahorse assay 
medium supplemented with 25 mM glucose and 0.23 mM pyruvate. Furthermore, the 
potential movement of the smaller retinal section during oxygen consumption 
measurements raised concerns about increasing variability in the readings. The effect of 
using plasma and thrombin on the sections was therefore explored again; the findings 
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showing a negative effect of plasma and thrombin on the baseline oxygen consumption 
levels, as rates of those treated with plasma and thrombin were mainly lower that those 
without (Figure 3.11).  
There were no effects of oligomycin or antimycin A in any of the samples. There was a 
subtle increase in oxygen consumption after the addition of FCCP in most samples and a 
transient decrease in oxygen consumption after the addition of rotenone. Reducing the 
tissue size and increasing the concentrations of compound used reduced the success of 
the mitochondrial stress test assay compared to the previous attempt. The oxygen 
consumption rates decreased steadily over time, a trend which was minimally altered by 
the addition of high concentrations of mitochondrial compound. Curiously, the oxygen 
consumption readings rapidly increase or decrease in some retinal samples after 
approximately 25 minutes. This event coincides with the addition of oligomycin, as a 
rapid and transient change in oxygen consumption readings is seen between the final 
measurement of basal respiration and the first reading after the addition of oligomycin.   
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Figure 3.11: Plasma/thrombin reduced the oxygen consumption rates of retinal 
flatmount eights as measured using the Seahorse XF analyser. Three measurements 
were taken for basal respiration before the addition of varying concentrations (as shown 
in the table) of oligomycin, FCCP, rotenone and antimycin A at the times indicated by the 
arrows.  
 
The publication of a paper to measure the oxygen consumption in the retinal explant 
showed some success in using the mitochondrial stress test compound on the retinal 
explant (Kooragayala et al., 2015). The adapted method has been described in detail in 
Chapter 2 using 1 mm retinal punches. Of note, three punches each were taken from the 
central and peripheral retina. The retinal punches were placed off centre onto the nylon 
insert and placed in ice cold Ames’ medium pH 7.4 and placed in an igloo with ice for 
transport. The inserts were positioned so as to place the retinal punch directly under the 
O2 sensor. As some studies omit oligomycin from their protocol the assay was tested 
adding the uncoupler, FCCP, directly after the basal respiration measurements, and 
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compared the result to the effect of adding the uncoupler after the addition of 
oligomycin.  
The effect on the oxygen consumption measurements of the placement of the retinal 
punch on the insert was also investigated, with some peripheral retinal punches placed 
with the GCL facing down and others with the GCL facing up (Figure 3.12B). Following 
this method, oligomycin and FCCP failed to have any effect on the oxygen consumption 
levels of the retinal punches (Figure 3.12). The rates declined steadily with an increase in 
this rate of decline after the addition of rotenone in some of the samples. The results 
from the published paper were not replicated indicating that the transport conditions 
for the retinae may have compromised the mitochondrial function of the retinal cells as 
seen by their inability to respond to the mitochondrial stress test compound 
(Kooragayala et al., 2015). 
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Figure 3.12: The mito stress test compounds did not have an appropriate effect on 
oxygen consumption rates in retinal punches of 1 mm in diameter, as measured using 
the Seahorse XF Analyser. Three measurements were taken for basal respiration before 
the addition of oligomycin, FCCP and rotenone at the times indicated by the arrows: 
central retinal punches (A) and peripheral retinal punches (B). Three measurements were 
taken for basal respiration before the addition of FCCP and rotenone at the times 
indicated by the arrows (C).   
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3.4 Discussion 
 Modification of the cell based cell viability assay MTT for use in the 
retinal explant 
Dendropathy is associated with a loss in visual acuity in the het mouse, in the absence of 
apoptosis (Williams et al., 2010a). The MTT assay was therefore employed to explore the 
effects of 670 nm light on the more subtle reductions in mitochondrial activity.  
The energy demands in the inner segment of photoreceptor cells, the outer plexiform 
layer and the nerve fibre layer are greater than in the inner plexiform layer and ganglion 
cell layer. This is denoted by the density of the distribution of cytochrome c oxidase and 
the active energy consuming-enzyme Na+K+ATPase in these layers (Wong-Riley, 2010). 
As the readings from the MTT assay reflected the mitochondrial activity of the entire 
population of retinal cells, the majority of the formazan produced was most likely due to 
the mitochondrial activity of the retinal cells other than RGCs. To overcome this 
confounding factor, we sought to quantify the formazan produced exclusively from 
RGCs.  
Unfortunately, endeavours to quantify the extent of formazan crystal formation 
surrounding the nuclei in the ganglion cell layer, required for the specific quantification 
of mitochondrial activity of RGCs, were not met with success. Whilst not equipped to 
yield information on mitochondrial activity from RGCs only, the assay was capable of 
detecting reductions in mitochondrial activity over time ex vivo from the entire retina, as 
shown by a progressive decrease in formazan production from 0 to 48 hours ex vivo 
(Figure 3.3). However, high variability was observed between readings at the same time 
point, therefore large numbers of retinae were predicted to be required for detecting 
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statistically significant differences between groups. Using 5 retinae per group, the assay 
was capable of detecting a difference in mitochondrial activity from the entire explant 
between 0 and 16 hours ex vivo, however this difference was not statistically significant 
(Figure 3.4). This result showed that the assay was capable of detecting reductions in 
mitochondrial reductive capacity but would most likely not be the most feasible in terms 
of the amount of tissue required to achieve statistically meaningful results.  
The pilot study carried out to see if it was possible to detect differences in mitochondrial 
activity between wild-type and het retinae in response to 670 nm light treatment and 
provide pilot data to perform a sample size calculation to determine how many retinae 
would be required to achieve statistically significant differences between groups. The 
pilot study, found there to be no reduction in mitochondrial activity in het retinae or an 
increase in either wild-type or het  retinae when pre-treated with 670 nm light (Figure 
3.5). Since this pilot study had 5 retinae per experimental group but revealed no 
emerging trend, it was deemed that it was not worthwhile investing more retinae into 
this assay.  
The results revealed that there is high variability between retinae of the same genotype, 
in terms of mitochondrial activity. This has important implications when testing the 
effects of a therapy that targets mitochondria as each retina may respond differently to 
the same treatment. Additionally, the dendropathy, that is associated with the mutation 
in Opa1, may vary in terms of severity between mice. The method of analysis used to 
test the effectiveness of 670 nm light in the het mouse must, therefore, be most accurate 
so that it limits the variability to that produced by the biological situation. 
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 Development of a method to measure oxygen consumption in the 
retinal explant using the Seahorse 
The most success was achieved with the Seahorse assay when retinal thirds were assayed 
approximately 2 hours after explantation (Figure 3.10). Dividing the retina into 8 radial 
sections had a negative effect on the oxygen consumption measurements (Figure 3.11), 
with most basal rates of oxygen consumption measurements of retinal thirds showing 
readings of 200-500 pmol O2/min and measurements of retinal eighths showing readings 
of 0-100 pmol O2/min. The tissue was also much more responsive to the mitochondrial 
stress test compounds when retinal thirds were used compared to retinal eighths. Thus 
using a retinal section large enough to cover most of the nylon insert yet not large 
enough to impede the flow of media into the microchamber, proved to be the most 
appropriately sized retinal section for this assay (Figure 3.10C). Endeavours to improve 
on the result achieved using retinal thirds by using less tissue, increasing the 
concentrations of compounds and increasing the time allowed for the compounds to 
penetrate the tissue were not successful as these modifications to the protocol abolished 
the effects of the mito stress test compounds (Figure 3.11). This implies that sectioning 
the retina into eight radial sections before placing in culture for 2 hours compromised 
the ability of the mitochondria to respond to the compounds, therefore sections of this 
size proved to be less suitable than retinal thirds.  
Despite all efforts to optimise the Seahorse assay for use in the retinal explant, the 
practical challenges which prevented using freshly explanted retinae compromised the 
careful consideration of all other factors. This was proven in the final test which followed 
a published protocol that was successful in measuring oxygen consumption in the retinal 
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explant with somewhat appropriate responses to the mito stress test compounds 
(Kooragayala et al., 2015). The published protocol used fresh retinae, yet achieved less 
than ideal responses to some of the mito stress test compounds, bringing to light the 
additional challenges faced when tissue was placed in suboptimal culture conditions 
before commencement of the assay. This shows that if the assay were to be used for the 
assessment of the effects of 670 nm light on oxygen consumption in the retina, the 
freshest tissue possible would be required before attempting to address other limiting 
factors.  
Chapter 4. Red light therapy in an axotomy model of neurodegeneration  
122 
 
Chapter 4. Red light treatment in an axotomy 
model of neurodegeneration 
 
 
 
 
 
 
 
 
Chapter 4. Red light therapy in an axotomy model of neurodegeneration  
123 
 
4.1 Introduction 
Evidence is continually mounting in support of the potential of red and near infrared 
(NIR) light therapy to provide protective effects in various neurodegenerative diseases 
including Parkinson’s disease and multiple sclerosis (Fitzgerald et al., 2013, Byrnes et al., 
2005a, Wu et al., 2012, Xuan et al., 2015, Naeser and Hamblin, 2011, Naeser and 
Hamblin, 2015, Dong et al., 2015b, Ando and Hamblin, 2013, Nivaldo A. Parizotto and 
Hamblin, 2013). Red/NIR light therapy has also shown great potential in the treatment 
of the more acute neurodegenerative conditions such as stroke, spinal cord injury and 
traumatic brain injury (Fitzgerald et al., 2013, Byrnes et al., 2005a, Wu et al., 2012, Xuan 
et al., 2015, Naeser and Hamblin, 2011, Naeser and Hamblin, 2015, Dong et al., 2015b, 
Ando and Hamblin, 2013, Nivaldo A. Parizotto and Hamblin, 2013). 
Since longer wavelengths have the ability to penetrate deeper than shorter wavelengths, 
NIR light is the preferred choice for irradiating brain tissue (Jagdeo et al., 2012). When 
irradiating the retina, however, the issue of tissue penetration, when using shorter 
wavelengths, is avoided. Consequently, the beneficial effects of red light have been 
reported in the retina. Treatment with 670 nm light has provided protection against cell 
loss in various rodent models of photoreceptor damage whilst demonstrating the safety 
of using 670 nm light with an irradiance of 60 mW/cm2 on this light sensitive tissue 
(Albarracin et al., 2013, Albarracin et al., 2011). Also, 670 nm light provided protection 
in other models retinal damage or dysfunction (Peoples et al., 2012a, Tang et al., 2013b, 
Barbosa et al., 2014, Natoli et al., 2013). In particular, treatment with 670 nm light in a 
rat model of partial axotomy (optic nerve transection) resulted in improved vision, 7 days 
post injury (Giacci et al., 2014a).   
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Apoptosis, the primary mechanism of retinal ganglion cell (RGC) death following 
axotomy, is not detectable until 3-4 days after axotomy, in vivo (Magharious et al., 2011). 
RGC dendritic pruning, as characterized by a reduction in dendritic complexity, reduced 
dendritic arbor area and shrinkage of dendrites, has been observed in mouse models of 
both glaucoma and Alzheimer’s disease and this event has been suggested to precede 
cell loss (Berry et al., 2015, Votruba et al., 2012, Williams et al., 2013b).   
Until recently, the mechanisms by which dendrites are eliminated from the neuron were 
largely unknown. Newly emerging data has provided some mechanistic insight into this 
process. The findings of one such study has suggested that dendrite degeneration occurs 
in a process independent of apoptosis involving a local loss of mitochondrial membrane 
potential and ATP decline, which precede dendrite loss (Ikegami and Koike, 2003). 
Inflammation is, likewise, thought to play a prominent role in this process, as an increase 
in the pro-inflammatory cytokine, interferon γ, and an upregulation in complement 
proteins were found to be associated with the dendritic pruning that occurs in 
neurodegenerative diseases and neural injury (Kim et al., 2002, Stephan et al., 2012). 
Other findings have shown the inhibition of mTOR, the key signal integrator for a variety 
of extracellular signals including growth factors, to be involved in dendritic pruning (Di 
Polo, 2015). Notably, cellular stressors such as low ATP levels and inflammation have 
been shown to inhibit mTOR, and optic nerve lesion has been shown to bring about the 
inhibition of an mTOR complex, an event which has been shown to coincide with 
dendritic retraction.  
Red/NIR light, which is absorbed by complex IV of the mitochondrial electron transport 
chain, has been shown to upregulate the enzymatic activity of complex IV, increase the 
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mitochondrial membrane potential and increase ATP production (Karu, 2008, Hamblin 
and Demidova, 2006, Kokkinopoulos et al., 2013, Begum et al., 2013, Ferraresi et al., 
2015a, Ferraresi et al., 2015b, Tina Karu and Hamblin, 2013). Red light was also found to 
have an anti-inflammatory effect as markers of inflammation, including complement 
proteins, were significantly reduced in the outer retina following 670 nm light treatment 
(Kokkinopoulos et al., 2013, Begum et al., 2013, Fernandes et al., 2015, Rutar et al., 2012, 
Calaza et al., 2015). Additionally, red/NIR light was found to modify cell growth by 
modulating the Akt/mTOR signaling pathway in cancer cells (Sperandio et al., 2013). In 
fact, the PI3K/Akt/mTOR pathway, which is involved with cell growth, proliferation, 
differentiation and survival, has been reported to be one of the most studied pathways 
that is influenced by red/NIR light (Sonis et al., 2016). 
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4.2 Experimental design 
Since many of the mechanisms proposed to be involved in the dendritic pruning process 
are potential therapeutic targets of the molecular mechanism responsible for the 
beneficial effects of 670 nm light, we have hypothesised that 670 nm light can delay the 
dendritic pruning that is initiated upon axotomy. To test this hypothesis we used an ex 
vivo model of dendritic pruning in the mouse retinal explant. Explanting the retina which 
involves axotomy of the entire population of RGCs by complete severing of their axons, 
is rapidly followed by pruning of the RGC dendrites (Di Polo, 2015). The retinal explant, 
consequently, provides a platform upon which to test the effects of 670 nm light on 
dendritic pruning in a substantially shorter timeframe than would be possible in the 
models of RGC degeneration, mentioned in the introduction. The effect of 670 nm light 
on the RGC dendritic pruning in the retinal explant was monitored at 40 minutes, 8 hours 
and 16 hours post axotomy. Changes in RGC dendritic morphology over time were 
investigated by employing various methods to analyze dendritic complexity, including 
Sholl analysis, area under the Sholl curve, the maximum peak of the Sholl curve, average 
total dendritic length and average dendritic field area. 
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4.3 Results 
A total of 31 retinae out of 50 included RGCs with fluorescent labeling that allowed for 
accurate tracing of their dendrites (Figure 4.1).  
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Figure 4.1: Representative images of RGCs from sham and light treated retinae over 
time ex vivo. The main image shows the Z-projected tracing of the Diolistically labelled 
RGC and inset is the original confocal image of the Diolistically labelled RGC. Scale bars 
represent 100 µm. Arrows indicate the axon. 
Tracing of the RGC dendrites facilitated Sholl analysis to be done. Sholl analysis is a 
method used to analyze dendritic morphology, which gives information on the 
functionality of the neuron and its ability communicate effectively with other cells 
(Langhammer et al., 2010). Since dendrites are the main regions of information input 
into neurons, reductions in the number of dendrites could hinder the ability of the RCG 
to receive information from the preceding bipolar and amacrine cells. Changes in 
dendritic morphology are associated with malfunction in neurons, as seen in 
neurodegenerative diseases. Sholl analysis enables the monitoring of these changes 
quantitatively by producing the data in the form of a Sholl profile. Although 3D tracings 
of the RGCs were obtained, the Sholl analysis was done in 2D on the Z-projected tracings 
of RGCs, which have a planar stratification of dendrites.  Of note, it is also possible to do 
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Sholl Analysis in 3D, which is more appropriate in studies on non-planar neurons where 
2D Sholls may introduce error (Binley et al., 2014). 
 In this experiment, the Sholl profile, which illustrates the number of intersections of 
dendrites with concentric rings placed at each 10 µm distance from the cell soma, of 
RGCs from sham treated retinae showed a downward and leftward shift after both 8 and 
16 hours ex vivo, indicating a loss of RGC dendritic complexity over time (Figure 4.2A-B). 
In retinae treated with red light, the leftward shift in the RGC Sholl profile over time was 
less profound (Figure 4.2C-D). There was a statistically significant reduction in the 
number of dendritic intersections at 70, 90 and 130 µm from the soma after 8 hours 
(p<0.05) and at 30 (p<0.05), 40 (p<0.01), 50 (p<0.05), 60-70 (p<0.01) and 80-110 µm 
(p<0.05) after 16 hours ex vivo for sham-treated retinae.  In contrast, RGCs from light 
treated retinae had no statistically significant reductions in the number of dendritic 
intersections at any point on the Sholl curve after 8 or 16 hours. However, there was no 
statistically significant reduction between sham- and light-treated RGCs after 16 hours 
ex vivo (Figure 4.2F). 
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Figure 4.2: Treatment with 670 nm light prevents statistically significant reductions in 
various points on the Sholl plot of RGCs after 8 and 16 hours ex vivo. The Sholl profiles 
of sham-treated RGCs after 8 hours (A) and after 16 hours (B) ex vivo. The Sholl profiles 
of light-treated RGCs after 8 hours (C) and 16 hours (D) ex vivo. At 40 minute sham (17 
RGCs from 5 mice), 8 hours sham (13 RGCs from 4 mice), 16 hours sham (17 RGCs from 
5 mice), 40 minutes light (19 RGCs from 6 mice), 8 hours light (15 RGCs from 7 mice) and 
16 hours light (13 RGCs from 4 mice) were used * p<0.05, ** p<0.01; Mann-Whitney U 
test. Error bars represent SEM. 
 
The Sholl profile suggests that there is a difference in the areas under the Sholl curves 
and the maximum number of dendritic intersections in the Sholl plot of sham treated 
and light treated RGCs.  For statistical comparison, however, it was necessary to compare 
the Sholl profiles of the individual RGCs used to create the Sholl plots in Figure 4.2. This 
was achieved by doing subsequent analysis on the Sholl plot of each cell, allowing 
statistical comparisons to be made. 
The average area under the Sholl curves was calculated by the trapezoidal method. The 
average area under the Sholl curves of RGCs from sham treated retinae was reduced by 
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39% after 8 hours ex vivo (p=0.018) and by 43% after 16 hours (p=0.007) (Figure 4.3A). 
For light-treated retinae the values were reduced by 17% after 8 hours and by 18% after 
16 hours but none of the differences were significant (p=0.286 and p=0.223, respectively) 
(Figure 4.3A). 
The average maximum peak of the Sholl curves for RGCs from sham-treated retinae was 
significantly reduced from 24.4 intersections at 40 minutes to 17.1 intersections at 8 
hours (p=0.005) and to 15.1 intersections at 16 hours (p=0.001) (Figure 4.3B). In RGCs 
from light-treated retinae, the average maximum peak of the Sholl curves was reduced 
from 23.0 at 40 minutes to only 22.0 intersections after 8 hours and to 18.3 intersections 
after 16 hours (p=0.986 and p=0.136, respectively) (Figure 4.3B).  
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Figure 4.3: Treatment with 670 nm light partially prevents reductions in the Area under 
the Sholl curve and the peak of the Sholl curve of RGCs after 8 and 16 hours ex vivo. 
The effect of time ex vivo, up to 16 hours, on the average area under the Sholl curves (A) 
and average maximum Sholl peaks (B) of sham and light treated RGCs. At 40 minute sham 
(17 RGCs from 5 mice), 8 hours sham (13 RGCs from 4 mice), 16 hours sham (17 RGCs 
from 5 mice), 40 minutes light (19 RGCs from 6 mice), 8 hours light (15 RGCs from 7 mice) 
and 16 hours light (13 RGCs from 4 mice) were used. * p<0.05, ** p<0.01, *** p<0.001; 
Mann-Whitney U test. Error bars represent SEM. 
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To further investigate the effects of red light on RGC dendrites after axotomy, 
measurements of dendritic field area and total dendritic length, which are additional 
measures of RGC dendritic complexity were obtained. Dendritic field area provides 
information on how widely the cell spreads over the retina and relates to the size of its 
receptive field. Since RGCs are the final neurons in the visual pathway before the light 
signal is transmitted to the brain, a reduction in the area of the RGC dendritic field could 
diminish photosensitivity, impeding the entire visual process. Similarly, since total 
dendritic length has been found to be positively correlated with whole-neuron 
capacitance (Gertler et al., 2008), a decrease in this parameter could negatively impact 
on the ability of the cell to reach the threshold for electrical stimulation, thereby 
reducing the likelihood of an action potential being formed. 
The average dendritic field area for RGCs from sham-treated retinae decreased 
significantly from 31204 µm2 at 40 minutes to 17402 µm2 after 16 hours ex vivo 
(p=0.019). Contrastingly, where retinae were treated with 670 nm light, the RGCs did not 
experience a statistically significant reduction in their average dendritic field area (28971 
to 22540 µm2, p=0.195) (Figure 4.4B).  
A statistically significant decrease in the average total dendritic length was also seen in 
RGCs from sham treated retinae, from 3007 µm at 40 minutes to 1851 µm at 8 hours 
(p=0.038) and to 1640 µm at 16 hours (p=0.006). The values for dendritic length 
decreased from 2943 µm to 2430 µm after 8 hours (p=0.286) and 2362 after 16 hours 
(p=0.170), in RGCs that were exposed to 670 nm light, but the differences were not 
statistically significant (Figure 4.5B). 
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Although the average total dendritic field area of red light-treated retinae was 30% 
greater than in the sham-treated retinae after 16 hours, the difference was not 
statistically significant (p=0.385). To determine the number of retinae required to obtain 
a statistically significant difference between red light and sham-treated retinae after 16 
hours, a sample size calculation was done. It was determined that 40 additional retinae 
would be required for the sham-treated group and 61 for the red light-treated group to 
achieve a statistically significant difference in the dendritic field area between sham and 
red light-treated retinae after 16 hours at 0.8 power. 
 
 
Figure 4.4: Treatment with 670 nm light prevented the reduction in the dendritic field 
area of RGCs after 16 hours. The effect of time ex vivo, up to 16 hours, on the average 
dendritic field area of light and sham treated RGCs. (A) The Z-projected image of an RGC 
showing the dendritic field area measurement using a concave polygon tool in ImageJ. 
(B) Stars indicate statistically significant reductions in the average dendritic field area, 
occurring ex vivo at the times indicated in the legends. At 40 minute sham (17 RGCs from 
5 mice), 8 hours sham (13 RGCs from 4 mice), 16 hours sham (17 RGCs from 5 mice), 40 
minutes light (19 RGCs from 6 mice), 8 hours light (15 RGCs from 7 mice) and 16 hours 
light (13 RGCs from 4 mice) were used. * p<0.05; Mann-Whitney U test. Error bars 
represent SEM. Arrow indicates the axon. Scale bar represents 100 µm.  
 
Chapter 4. Red light therapy in an axotomy model of neurodegeneration  
135 
 
 
Figure 4.5: Treatment with 670 nm light prevented the reductions in total dendritic 
length of RGCs from RGCs after 8 and 16 hours ex vivo. The effect of time ex vivo, up to 
16 hours, on the average dendritic field length of RGCs from sham and light treated 
retinae. (A) A 3-D image of an RGC tracing used to calculate dendritic field length 
measurements. (B) Stars indicate statistically significant reductions in the average 
dendritic field length, occurring ex vivo at the times indicated in the legends. At 40 
minute sham (17 RGCs from 5 mice), 8 hours sham (13 RGCs from 4 mice), 16 hours sham 
(17 RGCs from 5 mice), 40 minutes light (19 RGCs from 6 mice), 8 hours light (15 RGCs 
from 7 mice) and 16 hours light (13 RGCs from 4 mice) were used. ** p<0.01; Mann-
Whitney U test. Error bars represent SEM. Arrow indicates the axon.  
 
In summary, the statistically significant reductions in the number of RGC dendritic 
intersections at various points on the Sholl plot were observed after 8 and 16 hours in 
sham-treated retinae but were not seen in red light-treated retinae. Treatment with red 
light also prevented a statistically significant reduction to the area under the Sholl curve 
and to the peak of the Sholl curve. The results for average dendritic field area and 
average total dendritic length measurements were consistent with Sholl analysis data, 
showing the ability of 670 nm light to prevent statistically significant decreases in further 
parameters of dendritic complexity. Red light prevented statistically significant 
reductions in the total loss of dendrites form the entire RGC dendritic arbor, the total 
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area of the dendritic field and the loss of dendrites from the most densely branched 
region of the RGC dendritic arbor.  
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4.4 Discussion 
Herein we report, for the first time, of the ability of 670 nm light to prevent the dendritic 
pruning that occurs upon axonal injury. In this study, we investigated the effect of 670 
nm light on RGC dendritic pruning which occurs in the mouse retinal explant upon 
axotomy of the optic nerve. This degeneration was detectable by analysis of dendritic 
morphology after 8 hours and again after 16 hours, where statistically significant 
decreases from initial values were observed in sham-treated explants. Sholl analysis 
revealed statistically significant reductions in the number of dendritic intersections at 
various points of the Sholl curve after both 8 and 16 hours. The area under the Sholl 
curve, the average peak of the fitted Sholl curve, the average total dendritic length and 
average dendritic field area after 16 hours also showed statistically significant reductions 
from the values at 40 minutes by 40.56% (p<0.008), 33.9% (p<0.007), 45.43% (p<0.006), 
and 44.23% (p<0.019), respectively. Our results have demonstrated that 670 nm light can 
prevent the statistically significant reductions in these measurements up to 16 hours 
post axotomy, since the reductions seen in RGCs from light treated retinae were smaller 
and not statistically significant. The results revealed that rapid intervention with 670 nm 
light, when administered immediately after the acute optic nerve lesion, axotomy, 
prevented significant neuronal damage.  
Although 670 nm light prevents statistically significant reductions from 0 to 16 hours ex 
vivo, the lack of statistical significance between the sham- and light-treated retinae after 
16 hours ex vivo restricts the conclusions that can be made from this experiment. There 
is a reduction in each parameter in sham-treated retinae after 16 hours compared to 
light-treated retinae, however with the numbers of cells used statistical significance was 
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not achieved. It was not possible to obtain the cell numbers required to achieve 
statistical significance based on the power calculation due to limited resources. However, 
since the results were not based on a particular RGC subtype it may be possible to reduce 
the number of cells required in future experiments by classifying cells based the proximal 
dendrites (Tribble et al., 2014). Genetic identification of RGC subtypes can also be used 
to selectively label a particular cell type, thereby reducing the numbers of retinae 
required (Huberman et al., 2009). However, there may be limitations to this method 
when labelling degenerating cells due to possible changes in gene expression during 
degeneration. 
Evidence has been gathered, suggestive of a role for dendritic abnormalities in the 
pathology associated with the initial clinical symptoms of a range of neurodegenerative 
diseases (Di Polo, 2015). Degeneration of RGCs is a hallmark of devastating retinal 
degenerative diseases such as glaucoma and autosomal dominant optic atrophy (ADOA). 
A progressive degeneration of the RGCs in such diseases coincides with deterioration in 
visual acuity, eventually resulting in blindness. In experimental glaucoma, dendritic 
pruning has been suggested to precede selective loss of RGCs (Liu et al., 2010, Williams 
et al., 2013a, Pavlidis et al., 2003).  Also in ADOA, dendritic pruning was found to begin 
at a time when a loss in visual acuity was observed, in a mouse model of the disease 
(Williams et al., 2010a).   
The effect of changes to the dendritic morphology of neurons has also been observed in 
some of the most common and debilitating, neurodegenerative diseases, including 
Alzheimer’s disease. In the postmortem brains of Alzheimer’s disease patients, there was 
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a marked decrease in the number of dendritic branches in the majority of neurons from 
the visual and acoustic cortices compared to normal controls (Baloyannis, 2009). In 
addition, there was a 45% decrease in the dendritic field area compared with controls in 
these neurons. Alterations in dendritic morphology has also been found in Parkinson’s 
disease (Bertram and Tanzi, 2005).  In the substantia nigra pars compacta of post mortem 
tissue from Parkinson’s disease patients, there was a severe reduction in the dendritic 
length of dopaminergic type I neurons compared with healthy controls (Patt et al., 1991). 
Similarly, in post mortem tissue from patients with multiple sclerosis (MS), a loss in 
dendritic arborization was observed in cortical lesions (Peterson et al., 2001). This 
pathology was thought to contribute to the clinical symptoms of MS by decreasing the 
synaptic input to the cortex. Since these relatively subtle changes to the neurons are 
thought play a role in the clinical symptoms, mild beneficial effect on the survival ability 
of the dendrites could translate into a significant clinical effect. Delaying the dendritic 
pruning that occurs in the early stages of these neurodegenerative diseases could delay 
the onset of clinical symptoms, thereby providing an invaluable improvement to the 
quality of life of patients.  
The pathology for the initial symptoms in the discussed diseases appears to be due to a 
loss of dendrites as opposed to cell death. Moreover, dendritic degeneration appears to 
occur via a process independent of neuronal loss. It was found that the inhibition of pro-
apoptotic proteins was sufficient to delay neuronal somal death while failing to have any 
preventative effect on dendritic pruning (Koike et al., 2008). Therefore, looking at ways 
of preventing dendritic pruning may require a unique approach and may also be a more 
fruitful treatment strategy than merely endeavoring to keep dysfunctional cells alive. As 
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we have found that 670 nm light can prevent axotomy induced dendritic pruning in RGCs 
this therapy may be of greater benefit than an anti-apoptotic therapy. 
Our understanding of the pathology of neurodegenerative diseases seems to be 
changing from one of progressive cell loss to one whereby more subtle alterations in the 
dendritic morphology are associated with the initial clinical symptoms. The alterations 
to the dendritic morphology reported in the aforesaid neurodegenerative diseases were 
similar to those changes observed in the current experiment after 16 hours post 
axotomy, in the retinal explant. Since rapid intervention with 670 nm light treatment 
prevented such statistically significant alterations in the dendritic morphology for up to 
16 hours ex vivo, it is possible that it may prevent or slow down the changes to the 
dendrites associated with the pathology of the said neurodegenerative diseases.   
Chapter 5. The effects of 670 nm light treatment in vivo on dendropathy in the retinal 
explant from aged wild-type and Opa1(+/-) mice 
141 
 
Chapter 5. The effects of 670 nm light treatment in vivo on dendropathy in the retinal 
explant from aged wild-type and Opa1(+/-) mice 
142 
 
Chapter 5. The effect of 670 nm light treatment in 
vivo on dendropathy in the retinal explant from 
aged wild-type and het mice 
 
 
 
 
 
 
 
 
 
Chapter 5. The effects of 670 nm light treatment in vivo on dendropathy in the retinal 
explant from aged wild-type and Opa1(+/-) mice 
143 
 
5.1 Introduction 
We have shown in the previous chapter that 670 nm light was partially effective in 
preventing axotomy-induced dendropathy in RGCs from young wild-type mice. However, 
the dendritic pruning associated with the initial clinical symptoms of neurodegenerative 
diseases, discussed in 3.4, begins at an advanced age. It has been shown that treatment 
with 670 nm light has the potential to protect against age related degeneration in the 
outer retina as suggested by the increase in ATP production, a decrease in the expression 
of a marker of oxidative stress and a reduction in the expression in a marker of 
inflammation, in the outer retina of aged mice (Gkotsi et al., 2014, Begum et al., 2013). 
However, the effects of 670 nm light in aged mice has not yet been explored in RGCs. It 
is therefore worth testing if 670 nm light can provide protection against dendropathy in 
RGCs from aged mice, similar to those effects achieved in the retinae from young wild-
type mice.  
As described in Chapter 1, the mutation in Opa1 in the het mouse leads to progressive 
pruning of the RGC dendrites, which occurs predominantly in the ON-centre sub-type, 
beginning at 12 months (Williams et al., 2010a).  The commencement of dendropathy at 
this age suggests a gradual loss in the ability of RGCs, particularly ON-centre RGCs, to 
cope with the effects of the mutation in Opa1. When the mice reach 12 months, the long 
battle for survival is eventually lost by the RGCs as they succumb to their suboptimal 
cellular environment, which results in an impaired ability to maintain their dendrites. 
Since 670 nm light has been shown to improve mitochondrial bioenergetics and ATP 
production, and the exclusive susceptibility of RGCs to degeneration in ADOA has being 
theorised to be due to the high energy demands of this cell type; we hypothesise that 
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670 nm light will be effective in preventing RGC dendritic pruning in retinae from het  
mice.   
Chapter 5. The effects of 670 nm light treatment in vivo on dendropathy in the retinal 
explant from aged wild-type and Opa1(+/-) mice 
145 
 
5.2 Experimental design 
The dendropathy seen to occur in the het mouse progresses slowly, from mild at 12-15 
month months to severe after 20 months(Williams et al., 2010a). As dendropathy in vivo 
progresses slowly over many months, treatment would be required for several months 
to allow differences between sham- and light-treated RGCs to be detected. With a more 
acute model of RGC dendritic pruning available in the retinal explant, whereby significant 
dendritic pruning occurs in less than 24 hours, we have an opportunity to test 670 nm 
light treatment in the het mouse in a much shorter timeframe.  
As described in the previous chapter, the post axotomy treatment provided only partial 
protection against ex vivo dendropathy in young wild-type mice. It has been suggested 
that red/NIR light triggers a stress response, upregulating pro-survival pathways; 
therefore applying 670 nm light to the cells prior to trauma would enhance their ability 
to survive during a subsequent trauma. This theory has been discussed in the final 
paragraph of 1.6.3 with evidence to show that pre-treatment with red/NIR light before 
the induced damaged has been shown to provide enhanced neuroprotective effects 
compared to treatment with red/NIR light post damage. Due to the added challenge of 
using retinal explants from much older mice and a mutation that increases susceptibility 
to dendrite loss, an in vivo treatment protocol was chosen to enhance the 
neuroprotective effects of 670 nm light against dendropathy in the current experiment.   
Thus we tested the protective effects of 670 nm light against the RGC dendritic pruning 
that occurs ex vivo, upon axotomy, in cultured retinal flat mounts from 12-15 month old 
Opa1 (+/-) (Het) mice. The effectiveness of 670 nm light was also tested on retinal flat-
mounts from 12-15 month old wild-type mice (WT) to control for the effect of increased 
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age on the response of the RGCs to 670 nm. Therefore, WT and Het mice were treated 
in vivo with 670 nm light daily for 5 consecutive days with the final treatment delivered 
30 minutes before culling and axotomy. A 30 minute delay between the final treatment 
and culling was chosen as it has been shown that the expression of genes which are 
induced by nitric oxide signalling peaks 30 minutes after nitric oxide exposure in cultured 
cells (Hemish et al. 2003).   
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5.3 Results  
 The effects of 670 nm light on ex vivo dendropathy in RGCs 
RGCs from WT and Het mice, pre-treated with 4.4 J/cm2 of 670 nm light or sham for five 
consecutive days, were diolistically labelled either immediately (0 hour), 8 or 16 hours 
after flat mounting, before confocal images were obtained (Figure 5.1). 
In order to quantitatively analyse the dendritic complexity of the RGCs, Sholl analysis was 
employed. The Sholl profiles, depicting the average dendritic complexity for the RGCs in 
each experimental group, showed a loss of dendritic complexity in RGCs from sham wild-
type mice, which increased from 8 to 16 hours ex vivo (Figure 5.2). There was a 
statistically significant reduction in the number of dendritic intersections at 50 and 60 
µm from the soma after 8 hours (p<0.05), and at 20-50 µm (p<0.01) and at 60-90 µm 
(p<0.05) from the soma after 16 hours ex vivo. There were no statistically significant 
reductions in any point on the Sholl curve in RGCs from light-treated wild-type mice. This 
shows the ability of 670 nm light to prevent the statistically significant reductions in the 
number of dendritic intersections from 20 to 90 µm from the soma in RGCs from wild-
type mice.  
In RGCs from sham treated het mice there were not statistically significant reductions in 
the number or dendritic intersections at any point on the Sholl curve, even after 16 hours 
ex vivo. Therefore the effects of 670 nm light on preventing the changes of the Sholl 
curve of RGCs from het mice could not be determined by this method of analysis. 
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Figure 5.1: Representative images of RGCs from sham and light treated WT and Het 
mice over time ex vivo. The main image shows the tracing of the Diolistically labelled 
RGC and inset is the original confocal image. Time points represent time post axotomy 
at which cells were labelled. Scale bars represent 100 µm. Arrows indicate the axon. 
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Figure 5.2: Red light treatment prevented the significant reductions seen after 8 and 
16 hours in various points of the Sholl profile of RGCs from wild-type mice, however, 
the effect of 670 nm light on the Sholl profiles of Het RGCs could not be determined. 
Sholl profile of RGCs from (A) sham treated WT at 0 and 8 hours, (B) light treated WT at 
0 and 8 hours, (C) sham treated WT at 0 and 16 hours, (D) light treated WT at 0 and 16 
hours, (E) sham treated Het at 0 and 8 hours, (F) light treated Het at 0 and 8 hours, (G) 
sham treated Het at 0 and 16 hours, (H) light treated Het at 0 and 16 hours over time ex 
vivo. Stars indicate statistically significant reduction in the number of dendritic 
intersections over time ex vivo. * p<0.05, ** p<0.01; Mann-Whitney U test. Error bars 
represent SEM. 
 
 
Figure 5.3: Cartoon diagram of a Sholl profile of RGC degeneration showing the 
primary, secondary and tertiary dendrites. (A) An example of a typical change in the 
Sholl profile of a degenerating RGC. The black curve represents the healthy RGC before 
dendrite loss. The grey curve represents the Sholl profile after dendropathy. The loss of 
dendrites occurs from the region of the Sholl curve that represents the tertiary dendrites. 
(B) An example of an atypical change in the Sholl profile of degenerating RGCs. The black 
curve shows the healthy RGC before dendrite loss. The grey curve represents the Sholl 
profile after dendropathy. The loss of dendrites appears to affect the primary and 
secondary dendrites while the tertiary dendrites are still present. This is due to high 
variability in the degeneration, with some cells appearing to have lost the majority of 
their dendrites and other cells appearing resistant to ex vivo degeneration. To overcome 
this problem a higher cell number is required. 
 
After 16 hours ex vivo the AUC decreased by 26% in sham treated wild-type RGCs 
(p<0.01) (Figure 5.3A). However, the AUC of RGCs from light treated wild-type mice after 
16 hours ex vivo was not significantly different from the value at 0 hours (p=0.205). 
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Further, there was a statistically significant difference in the AUC of RGCs from sham 
treated wild-type mice and light treated wild-type mice after 16 hours ex vivo (p<0.05). 
There was a significant reduction in the AUC by 17% in RGCs from het mice when 
compared to wild-type mice at baseline, however, a further statistically significant 
reduction in the AUC in RGCs from sham treated het mice was not observed after 16 
hours ex vivo (p=0.347) (Figure 5.4A). 
The average maximum peak of the Sholl curve at baseline was 21 intersections in RGCs 
from sham treated wild-type mice and 21 intersections in RGCs from light treated wild-
type mice (Figure 5.4B). A decrease to 15 intersections was observed after 16 hours ex 
vivo with sham treatment (p<0.001), however, with light treatment the AUC decreased 
to 19 intersections, which was less that the decrease in wild-type and was not statistically 
significant (p=0.125). There was a significant reduction in the average maximum of the 
Sholl peak from 21 intersections in sham treated wild-type RGCs to 18 intersections in 
sham treated het RGCs at baseline (p<0.01). However, there was no further statistically 
significant reduction in the average maximum Sholl peak in RGCs from sham treated  
mice after 16 hours ex vivo (p=0.124).  
To further support the findings of Sholl analysis on the dendritic complexity of the RGCs 
the average total dendritic length was computed, as an additional measures of dendritic 
complexity. Total dendritic length (Figure 5.4C), presented a similar pattern to the Sholl 
analysis data, with sham-treated wild-type RGCs showing a decrease from 2348 µm at 0 
hours to 1748 µm after 16 hours ex vivo (p<0.01). Conversely, light treated wild-type 
RGCs did not experience a significant reduction in dendritic length after 16 hours, 
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showing an insignificant  decrease from 2466 µm at 0 hours to 2373 µm at 16 hours ex 
vivo (p=0.247). Further, a significant difference was seen between light and sham treated 
wild-type RGCs after 16 hours (p<0.05). Although a significant decrease was observed 
from 2348 µm in RGCs from sham treated wild-type mice to 1926 µm in RGCs from sham 
treated het mice (p<0.01), the dendritic length did not decrease further after 16 hours in 
RCGs from sham treated het mice.  
670 nm light provided partial protection against the dendropathy that occurs in RGCs 
from sham treated wild-type mice after 16 hours ex vivo. Since there was no further 
statistically significant reduction in the AUC, maximum peak of the Sholl curve or 
dendritic length after 16 hours ex vivo in RGCs from het mice, the effects of 670 nm light 
on these parameters in RGCs from the het could not be determined by this analysis. 
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Figure 5.4: Pre-treatment with 670 nm light prevented the statistically significant 
reductions in the Area under the curve, and dendritic length and partially prevented 
the reduction in the Sholl peak, seen in wild-type RGCs after 16 hours. The effects of 
670 nm light on these parameters could not be determined in het RGCs. Area under the 
Sholl curve (A), Average maximum peak of Sholl curve (B) and Average dendritic length 
(C) of light and sham treated WT and Het RGCs over time ex vivo. Wt sham 0 hours (n=35), 
Wt sham 8 hours (n=29), Wt sham 16 hours (n=32), Wt light 0 hours (n=35), Wt light 8 
hours (n=27), Wt light 16 hours (n=43), Het sham 0 hours (n=51), Het sham 8 hours 
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(n=31), Het sham 16 hours (n=38), Het light 0 hours (n=35), Het light 8 hours (n=28) and 
Het light 16 hours (n=38).  Error bars represent SEM.* p<0.05, ** p<0.01, *** p<0.001. 
 The effects of 670 nm light on dendropathy in ON-centre RGCs 
Analysis of the entire population of RGCs from het mice did not allow the evaluation of 
the potential protective effect of 670 nm light on ex vivo dendropathy due to the lack of 
significant ex vivo dendropathy from 0 hours to 16 hours in sham-treated RGCs from 
these mice. It has been shown previously that ON-centre RGCs from het mice degenerate 
faster than OFF-centre RGCs (Williams, Morgan and Votruba, 2010). Consequently, the 
ON-centre RGCs from the sample population were selected for sub-analysis. 
 There was a statistically significant reduction in the number of dendritic intersections at 
50 µm (p<0.01), 60 µm (p<0.05) and 80 µm (p<0.05) from the soma after 8 hours (Figure 
5.5A), and at 30-40 µm (p<0.01) and at 50-80 µm (p<0.05) from the soma after 16 hours 
(Figure 5.5C) ex vivo in RGCs from sham treated WT mice. In RGCs from light treated wild-
type mice there were no statistically significant reductions in any point on the Sholl 
curve, with the exception of 90 µm from the soma in RGCs from light treated wild-type 
mice (Figure 5.5 B and D). This shows the ability of 670 nm light to partially prevent the 
statistically significant reductions in the number of dendritic intersections from 20 to 90 
µm from the soma that occur over time ex vivo in the ON-centre RGCs in wild-type mice. 
In RGCs from sham treated het mice, there were no statistically significant reductions in 
the number or dendritic intersections, even after 16 hours ex vivo (Figure 5.5 E-H).  
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Figure 5.5: Pre-treatment with 670 nm light prevented the significant reductions seen 
after 8 and 16 hours in various points of the Sholl profile of ON-centre RGCs from wild-
type mice, however, the effect of 670 nm light on the Sholl profiles of ON-centre Het 
RGCs could not be determined. Sholl profile of ON-centre RGCs from (A) sham treated 
WT at 0 and 8 hours, (B) light treated WT at 0 and 8 hours, (C) sham treated WT at 0 and 
16 hours, (D) light treated WT at 0 and 16 hours, (E) sham treated Het at 0 and 8 hours, 
(F) light treated Het at 0 and 8 hours, (G) sham treated Het at 0 and 16 hours, (H) light 
treated Het at 0 and 16 hours over time ex vivo. Stars indicate statistically significant 
reduction in the number of dendritic intersections over time ex vivo. * p<0.05, ** p<0.01; 
Mann-Whitney U test. Error bars represent SEM. 
The area under the Sholl curve (AUC) was 1650 a.u. in RGCs from sham treated wild-type 
mice and 1684 a.u. in RGCs from light treated wild-type mice (p=0.224) at 0 hours ex vivo. 
After 16 hours ex vivo the AUC decreased to 1183 a.u. in sham treated wild-type RGCs 
(p<0.01) (Figure 5.6A). The AUC of RGCs from light treated wild-type mice after 16 hours 
ex vivo was 1452 a.u., which was not significantly different from the value at 0 hours 
(p=0.129). There was a reduction in the AUC from 1650 a.u. in sham treated wild-type 
RGCs to 1303 a.u. in sham treated RGCs from het mice at baseline, however, this 
reduction did not reach statistical significance (p=0.558). There was a further reduction 
in the AUC in RGCs from sham treated het mice to 922 a.u. after 16 hours ex vivo (p<0.05). 
The decrease in the AUC of RCGs from light treated het mice from 1150 a.u. at 0 hours 
to 1064 a.u. after 16 hours was smaller than that observed with sham treatment and was 
not statistically significant (p=0.331). 
The average maximum of the Sholl peak was 20.5 intersections and 21 intersections at 0 
hours ex vivo for RGCs from sham and light treated wild-type mice, respectively (Figure 
5.6B). The value decreased after 16 hours to 15 intersections in sham treated RGCs 
(p<0.01). The decrease in light treated RGCs to 18 intersections after 16 hours was less 
than in sham treated RGCs and was not statistically significant (p=0.122). The average 
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maximum of the Sholl peak was reduced to 17.7 intersections in RGCs from sham treated 
het mice at 0 hours when compared with 20.5 intersections in the wild-type controls 
(p<0.05). There was also a statistically significant reduction in the maximum of the Sholl 
peak in RGCs from sham treated Opa1 (+/-) mice after 16 hours ex vivo, to 11.9 
intersections (p<0.05). Light treated RGCs from het mice had an average maximum of the 
Sholl peak of 16.4 intersections at 0 hours. After 16 hours a reduction in this value to 
13.7 intersections was observed, which was less than that which was observed over the 
same ex vivo period in RCGs that were sham treated and did not reach statistical 
significance (p=0.0986).  
The average total dendritic length was 2320 µm at 0 hours in RGCs from sham treated 
wild-type mice and 2433 µm in RGCs from light treated wild-type mice (p=0.315). The 
dendritic length decreased to 1650 µm with sham treatment (p<0.05) and to 2066 µm 
with light treatment (p=0.147) after 16 hours ex vivo (Figure 5.6C). In RGCs from het mice, 
the average total dendritic length was reduced to 1794 µm at 0 hours when compared 
to the wild-type value (p<0.05). A further statistically significant reduction in dendritic 
length was observed after 16 hours (p<0.05) in RGCS from sham treated Opa1 (+/-) mice. 
In RGCs from light treated het mice, the reduction in dendritic length from 1617 µm to 
1502 µm after 16 hours ex vivo was much less than that observed with sham treatment 
and was not statistically significant (p=0.344). 
Treatment with 670 nm light prevented the statistically significant reductions in all 
measures of dendritic complexity explored in ON-centre RGCs from wild-type mice. In 
ON-centre RGCs from Opa1 (+/-) mice 670 nm light provided protection against statistically 
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significant reductions in the AUC, maximum of the Sholl peak and dendritic length. This 
shows the ability of 670 nm light to provide partial protection against dendropathy in 
ON-centre RGCs from het mice. 
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Figure 5.6: Pre-treatment with 670 nm light partially prevented the statistically 
significant reductions in the Area under the curve, dendritic length and the Sholl peak, 
seen in wild-type and Het ON-centre RGCs after 16 hours ex vivo. AUC (A), Sholl peak 
(B) and Dendritic length (C) of ON-centre RGCs from sham and light treated WT and Het 
mice, over time ex vivo. Wt sham 0 hours (n=19), Wt sham 8 hours (n=21), Wt sham 16 
hours (n=23), Wt light 0 hours (n=21), Wt light 8 hours (n=21), Wt light 16 hours (n=22), 
Het sham 0 hours (n=27), Het sham 8 hours (n=19), Het sham 16 hours (n=17), Het light 
0 hours (n=20), Het light 8 hours (n=21) and Het light 16 hours (n=17). Error bars 
represent SEM. * p<0.05, ** p<0.01. 
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5.4 Discussion 
 The effects of 670 nm light on RGC dendritic pruning in the aged 
WT retinal explant 
In the retinal explants from aged wild-type mice, the RGC dendritic complexity, as 
quantified by Sholl analysis (AUC and Sholl peak) and total dendritic length, experiences 
a marked decrease 16 hours post axotomy. Reductions in these parameters were not 
seen in RGCs from aged wild-type mice pre-treated with 670 nm light. The results 
demonstrate the ability of 670 nm light to prevent dendropathy in the aged wild-type 
when delivered in vivo for 5 days, prior to axotomy. In Chapter 4, a single 10 minute 
exposure to 670 nm light provided partial protection against ex vivo dendropathy in RGCs 
from young wild-type mice. This was shown by the ability of 670 nm light to prevent 
statistically significant reductions in various measures of dendritic complexity, for up to 
16 hours ex vivo, in the absence of a statistically significant difference in those measures 
between sham and light treated young wild-type retinae after 16 hours. Delivery of 5 
exposures of red light to aged wild-type retinae in vivo, as a pre-treatment to axotomy, 
the trigger of ex vivo degeneration, had a more potent effect on protecting RGCs from 
ex vivo dendropathy than exposure to 670 nm light post axotomy. This was 
demonstrated by the statistically significant differences in the measures of dendropathy 
between light and sham treated aged wild-type retinae, for up to 16 hours ex vivo. The 
results suggest that 670 nm light is effective in preventing ex vivo dendropathy in retinae 
from 12-15 month old mice, which is an important finding in terms of expanding on the 
potential of this therapy as an effective treatment for the dendropathy that is associated 
with age related neurodegenerative diseases. 
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 Effects of 670 nm light on dendritic pruning in the aged Het retinal 
explant 
Although the results revealed a significant difference in the dendritic complexity in RGCs 
between sham-treated WT and sham-treated Het mice at time zero, there was no further 
significant reduction in the dendritic complexity of the entire subpopulation of Het RGCs 
from time zero to 16 hours ex vivo. Considering that there was a statistically significant 
reduction after 16 hours in the dendritic complexity in the entire subpopulation of RGCs 
from young wild-type mice and aged wild-type mice, and the Opa1 mutation has been 
shown to cause a reduction in the ability of RGCs to maintain their dendrites in mice of 
12-15 months, it was intriguing that ex vivo dendropathy was hindered rather than 
intensified in Het RGCs. As Het RGCs may struggle to meet the energy demands required 
for the maintenance of their dendrites it may be possible that Het RGCs had already 
upregulated survival pathways in vivo to compensate for their compromised ability to 
function optimally. The Het RGCs may have a greater resistance to further degeneration 
at the time of axotomy compared to wild-type RGCs, resulting in a delay in the axotomy-
induced dendropathy in aged Het RGCs.  
 As ON-centre RGCs were the most vulnerable to the effects of the Opa1 mutation, ON-
centre RCGs were analysed separately. There was significant dendropathy after 16 hours 
ex vivo in Het ON-centre RGCs, similar to the results obtained from the entire RGC 
population in young and aged wild-type RGCs. Pre-treatment with 670 nm light brought 
about partial protection from ex vivo dendropathy in ON-centre Het RGCs. Comparing 
the effects of 670 nm light on ON-centre cells from Het to those from aged matched WT 
controls, there was a reduction in the protection achieved in the in ON-centre RGCs from 
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Het. The reduced effectiveness could be due to the increased challenge of preventing ex 
vivo dendropathy in cells with an increased vulnerability to dendrite loss. 
The extent of the ex vivo RGC degeneration observed after 16 hours, triggered by 
mechanical insult, is comparable to that which occurs in vivo in the het mouse, beginning 
at 12 months, triggered by a loss in the RGCs ability to function normally with reduced 
Opa1. As 670 nm light has been shown here to partially protect against RGC dendritic 
pruning ex vivo in ON-centre Het RGCs, at an aged when Opa1 induced-dendropathy is 
ongoing, a similar protection against the dendropathy that takes place after 12 months 
in the het mouse could be achieved with 670 nm light. The increased effectiveness of 
pre-treatment in the prevention of ex vivo dendropathy provides further support to the 
theory that survival pathways are upregulated at the time of axotomy, enhancing the 
neuroprotective effects. Therefore, it may be may be most beneficial, when testing this 
therapy on in vivo dendropathy in the het mouse, to commence treatment in younger 
mice before the initiation of dendropathy.  
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6.1 Introduction 
 The underlying molecular and cellular effects of 670 nm light in 
retinas of 12-15 month old wildtype and het mice 
As discussed in Chapter 5, morphological changes are seen in RGCs after 16 hours post 
axotomy, ex vivo. Yet, the change in dendritic architecture that we see after 16 hours, 
occurs downstream of a series of molecular changes (Wang et al., 2012). Firstly, axotomy 
of the RGCs results in depriving the cells of neurotrophic factors that support cell survival 
(Lieven and Levin, 2007).  In addition, explanting the retina transfers the RGCs from a low 
oxygen environment to one rich in oxygen, fuelling the surge in the generation of reactive 
oxygen species (ROS), which may play a role in the initial stages of degeneration (Lieven 
and Levin, 2007). Modifying the molecular environment of the RGCs in such a way as to 
reduce their vulnerability to the molecular changes that precede dendropathy may offer 
some resistance against dendropathy. 
As discussed in detail in Chapter 1, the underlying molecular mechanisms responsible for 
the neuroprotective effects of 670 nm light are not fully understood. There are, however, 
four main theories available which attempt to explain the mechanism underlying the 
observed therapeutic effects, mechanisms that may also be responsible for countering 
the degeneration-inducing molecular events initiated by axotomy. Each potential 
mechanisms of action of red light, discussed in Chapter 1, could all theoretically play a 
role in delaying the many molecular events that contribute to RGC dendritic pruning that 
occurs post axotomy. The results of Chapter 5 suggested that genes are upregulated to 
support survival in the presence of the Opa1 mutation, and that a similar survival 
response may be triggered by 670 nm light exposure. We hypothesise that 670 nm light 
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is hijacking the same cell survival response employed by cells to aid their survival during 
challenging conditions, by inducing a transient increase in oxidative and nitrostrative 
stress. To explore this hypothesis we investigated the effects of 670 nm light and the 
Opa1 mutation on the expression levels of a section of particular genes known to be 
influenced by oxidative and nitrostrative stress. 
The presence of 3-nitrotyrosine is used as a marker of oxidative damage mediated by 
peroxynitrite, and therefore is considered as a biomarker for endogenous peroxynitrite 
activity (Ahsan, 2013). Low levels of peroxynitrite can trigger signalling pathways that 
promote neuroprotection, with minimal damage to the cell, whereas high levels are 
detremental to the cell. We hypothesised in Chapter 1 that upregulation of reactive 
nitrogen species such as peroxynitrite may be playing a role in the upregulation of genes 
involved in neuroprotection in response to 670 nm light. Of the genes upregulated in 
response to peroxynitrite signaling are those with roles in reducing oxidative and 
nitrostrative stress. This may explain the seemingly contradictory results on the effects 
of red/NIR light on 3-nitrotyrosine in the literature. For example, an increase in 3-
nitrotyrosine was found in spinal cord slice cultures from neonatal rats following a partial 
transection, an effect that was reduced with 660 nm light (Ashworth et al., 2016).  
 We sought to investigate the effect of 670 nm light on a marker of peroxynitrite activity 
in RGCs. Also, the transcription factor, nuclear factor kappa B (NFκB), which is well known 
for its role in the regulation of immune and inflammatory responses, is activated in 
response an increase in oxidative/nitrostrative stress. More recently its pivotal role in 
the regulation of energy metabolism has been uncovered (Tornatore et al., 2012). 
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Previous studies have shown that NfκB was activated in response to NIR light exposure 
in murine embryonic fibroblasts (Chen et al., 2011). 
The activation of Nrf2 by oxidative and nitrostrative stress leads to the transcription of 
genes involved in antioxidant defence and cell survival, as discussed in 1.4.6.3. Due to its 
role in promoting the resistance of the cell to oxidative stress and promoting its survival 
under challenging conditions, Nrf2 was also hypothesized to be playing a role in the 
neuroprotective effects of 670 nm light observed in axotomised RGCs (Ma, 2013).  
DJ1 is another potential molecular effector of 670 nm light as it is upregulated and 
activated in response to an increase in oxidative stress, which triggers a downstream 
anti-oxidant defence mechanism, as described in 1.4.6.3. Further, there are reports of 
increased expression of DJ1 in the brain under conditions of oxidative stress and in post 
mortem brains of AD patients (Baulac et al., 2009). Other studies have found that DJ1 
can regulate the expression of anti-oxidants and attenuate oxidative stress in 
cardiomyocytes (Yan et al., 2015). 
Akt activation is known to promote neuronal survival which is supported by the findings 
in a mouse model of dementia where a decrease in phosphorylated Akt was found in the 
hippocampus (Snigdha et al., 2012). The PI3K-Akt-mTOR pathway plays an essential role 
in dendrite formation (Kumar et al., 2005). It has been shown that the phosphorylation 
of Akt is required for BDNF induced dendrite formation in cortical neurons (Dijkhuizen 
and Ghosh, 2005). However, it must be mentioned that in the hippocampus there is 
constant formation of new synapses, a process that is not required in the retina. 
Therefore, a downregulation of Akt in the retina may have different effects than in the 
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hippocampus. However, phosphorylated Akt supports neuronal survival, therefore we 
hypothesise that increasing the levels of Akt in the RGCs pre axotomy will promote their 
ability to resist degeneration. 
The results of Chapter 5 suggested that genes are upregulated to support survival in the 
presence of the Opa1 mutation. In support of this, nuclear Nrf2 fluorescence, as reported 
to represent Nrf2 activation, was upregulated in primary cortical neurons transfected 
with siRNA directed against Opa1 (Millet et al., 2016). However, as mentioned in 1.2, 
cells deficient in Opa1 are thought to lack the ROS dependent upregulation of genes 
involved in promoting cell survival, an effect that is hypothesised to contribute to their 
increased susceptibility to cell death in ADOA. This hypothesis was based on results from 
cells in vitro, however, in the drosophila model of ADOA, discussed in 1.3.1, an increase 
in ROS was found. In our aged model, therefore, it is likely that ROS is produced as the 
result of aberrant mitochondrial functioning. We hypothesise that the ROS present in the 
RGCs of the het mice upregulates signalling pathways that support cell survival, 
increasing the resistance of those RGCs to axotomy induced degeneration.  
 The effect of 670 nm light treatment on microglial activation in the 
retinae of 21-26 month old het mice 
As mentioned above and in Chapter 1, both pro- and anti-inflammatory effects can occur 
downstream of NFκB activation, depending on the particular state of the cell at the time 
of activation. Therefore, if 670 nm light is mediating its protective effects via NFκB, the 
effect of 670 nm light on inflammation would also depend on the cellular environment 
upon 670 nm light exposure. Neuroinflammation is a characteristic feature of retinal 
neurodegenerative diseases including glaucoma, AMD and diabetic retinopathy, with 
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evidence for the involvement of activated microglia in the initiation and progression of 
the degenerative process (Madeira et al., 2015). There is also much evidence available 
to associate the activation of microglia with the degeneration of RGCs in diseases 
associated with optic atrophy such as glaucoma (Wang et al., 2016). Although our group 
have previously shown that RGC dysfunction in 12-15 month old het mice was found to 
occur in the absence of soma loss and microglial activation, the activation of microglia in 
het mice over 20 months, when severe dendropathy is present, has not been 
investigated (Williams et al., 2011). As  
The dendropathy in the het mouse is accompanied by synaptic atrophy (Williams et al., 
2012). It is known that microglial activation plays a role in the removal of dysfunctional 
synapses (Kettenmann et al., 2013). Further, there is evidence from animal studies to 
show that there are changes in microglial morphology and an increase in lectin reactivity 
for microglia in the retina as a result of nonpathological aging (Conde et al., 2006). It was 
therefore hypothesised that ativated microglial would be present in wild-type mice 
above 20 months and het mice over 20 months. Additionally, as microglial activation is 
associated with other optic atrophies, it was hypothesised that there would be increased 
microglial activation in the very aged het mouse compared to the very aged wild-type 
mouse.  As discussed in Chapter 1 red/NIR light has been shown to modulate the immune 
response; however, the particular effect produced by 670 nm light appears to be 
dependent upon extent of the inflammatory response in the cell or tissue at the time of 
exposure. Therefore, we sought to explore the effects of 670 nm light on microglial 
activation in very aged wild-type and het mice. 
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6.2 Experimental design 
 The underlying molecular and cellular effects of 670 nm light in 
retinas of 12-15 month old wildtype and het mice 
We investigated changes in expression or activation of the potential molecular effectors 
of 670 nm light, discussed in the introduction. As we were particularly interested in the 
effects of delivering 670nnm light to RGCs prior to axotomy as discussed in chapter 5, we 
sought to explore molecular changes in sham- and light-treated RGCs from wild-type and 
het mice that were present upon axotomy. Therefore, 12-15 month old wild-type and 
het mice were sham- or light-treated for 5 consecutive days before axotomy. Of the mice 
assigned to the 0 hour time point in the dendropathy study from which one eye was 
taken for Diolistic labelling of RGCs, the fellow eye was placed in 4% PFA immediately 
after axotomy for immunohistochemical analysis. The activation of transcription factors 
NFκB and Nrf2 is dependent on their translocation from the cytoplasm to the nucleus. 
Therefore, we calculated the nuclear-cytoplasmic ratio of the integrated density values 
to obtain a measure for the activation of each transcription factor in response to 670 nm 
light treatment. The protective effect that occur downstream of DJ1 are triggered by 
both an upregulation of endogenous DJ1 and its translocation to the mitochondria. 
Therefore, we measured the mean fluorescence of DJ1 in RGCs from 12-15 month old 
wild-type and het mice in response to 670 nm light treatment. We also measured the 
amount of DJ1 co-localised with a mitochondrial marker to measure the extent of 
translocation of DJ1 to the mitochondria. The phosphorylation of Akt on its Ser473 is 
required for its full activation upregulation, before it can produce its cytoprotective 
effects. Thus the mean fluorescence of p-Akt was measured in the RGCs in response to 
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670 nm light. To back up the findings of the immunohistochemistry data for Akt, wild-
type mice were 670 nm light treated (n=3) and sham-treated (n=3) to find the ratio 
between p-Akt and total Akt in the entire retina, to explore the effect of 670 nm light on 
p-Akt activation in the entire retina. As 3-nitrotyrosine is a marker of peroynitrite activity, 
the mean fluorescence of 3-nitrotyrosine in RGCs was measured in response to 670 nm 
light treatment in wild-type and het mice.  
 The effect of 670 nm light treatment on microglial activation in the 
retinae of 21-26 month old het mice 
Wild-type and het mice were selected in numbers sufficient to have a minimum of five 
mice in each of the following experimental groups: wild-type sham treated, het sham 
treated and het 670 nm light treated. The mice were aged until all mice were a minimum 
of 21 months old to test whether or not 670 nm light could provide therapeutic effects 
in the very advanced stages of disease in the het mouse. As such we sought to explore 
the involvement of microglial activation in end stage dendropathy, which may be 
associated with the synaptic and dendritic atrophy found in this model and investigate 
the effect of 670 nm light on microglial activation. 
Accordingly, we treated 21-26 month old het mice (n=6) with 670 nm light twice daily for 
7 consecutive days as described in Chapter 2. As therapeutic effects were found with 
seven 90s exposures of 670 nm light with an irradiance of 40 mW/cm2, and our single 
device gave an irradiance of approximately 20 mW/cm2 (Gkotsi et al., 2014), we delivered 
670 nm light to our mice over 14, 90 s exposures. A group of 21-26 month old wild-type 
(n=5) and het mice (n=4) were sham treated to compare the levels of microglial 
activation between very aged wild-type and het mice and as a control for the effects of 
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normal aging on microglial activation. After the final treatment the mice were killed by 
cervical dislocation and one eye from each mouse was fixed in 4% PFA before 
cryopreservation. The second eye was prepared for exploration of mitochondrial 
bioenergetics as mentioned in Chapter 3. Microglia were labelled with an Iba1 antibody 
using immunohistochemistry to enable the identification of both resting and activated 
microglia in the retina. 
Amoeboid microglia are associated with maximum pro-inflammatory activation and are 
characterised by a rounded morphology with few or no processes (Crews and Vetreno, 
2016). Ramified or “resting” microglia can be identified by long ramified processes; 
mildly activated hyper ramified microglia can be identified by increased branching of 
dendrites; and microglia with intermediate activation can be identified as being 
branched but having swollen truncated processes. For analysis, the microglial states 
were divided into fully activated and all other stages of microglial activation, which were 
identified by amoeboid microglia and ramified microglia, respectively. 
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6.3 Results 
 The underlying molecular and cellular effects of 670 nm light in 
retinas of 12-15 month old wildtype and het mice 
 Reactive oxygen and nitrogen species can trigger the translocation of NfkB to the 
nucleus where it can induce the trancription of genes involved in the regulation of the 
inflammatory response and cytoprotection. NfkB staining was present in retinae from all 
experimental groups (Figure 6.1). The staining was particularly noticable in the GCL and 
was detectable in the nuclear region and cytoplasmic region of the RGCs. The overall 
expression of NfkB in the GCL was unaffected by the Opa1 mutation or 670 nm light 
treatment (Figure 6.2A). The mean fluorescence values of NFkB in the nuclear and 
cytoplasmic region of wild-type RGCs were both significantly reduced with light 
treatment (Figure 6.2B-C). Similarly, the mean fluorescence of NFkB in the cytoplasmic 
region was reduced significantly with the Opa1 mutation (Figure 6.2C). The nuclear-
cytoplasmic ratio of NFκB, representing the extent of NfκB translocation from the 
cytoplasm to the nucleus, (Figure 6.2D) was significantly reduced in RGCs from sham 
treated het mice compared to sham treated wild-type mice (Figure 6.2D). The nuclear to 
cytoplasmic ratio of NFκB increased with 670 nm light treatment in RGCs from het, 
restoring the ratio up to wild-type levels. However, despite the reports of NFκB activation 
in response to 670 nm light treatment in the literature, we found no effect of 670 nm 
light treatment on the nuclear to cytoplasmic ratio of NFκB in RGCs from wildtype mice. 
Therefore, 670 nm light significantly increased the activation of NfkB in RGCs from het 
mice but had no effect on wild-type RGCs.  
 
Chapter 6. The underlying cellular and molecular effects of 670 nm light 
176 
 
Figure 6.1: Representative images of NFκB expression in the wild-type sham treated 
(n=3), wild-type light treated (n=6), het sham treated (n=4) and het light treated (n=3) 
retinae. Images are presented at 60X magnification to show the staining in the nuclear 
region of the RGCs. The top row shows NFκB staining with an example image of a retina 
from each group, the middle row shows the nuclear stain and the bottom row shows an 
overlay of the two stains. Scale bar represents 20 µm. 
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Figure 6.2: The activation of NFκB is reduced by the Opa1 mutation and is restored with 
670 nm light treatment, in the absence of a change in the overall expression levels of 
this protein. (A) The mean fluorescence of NFκB in the GCL. (B) The mean fluorescence 
of NFκB in RGC nuclei. (C) The mean fluorescence of NFκB in RGC cytoplasm. (D) The 
average nuclear-cytoplasmic ratio of the integrated density of NFκB fluorescence in the 
GCL of retinae from each experimental group. Error bars represent SEM. * p<0.05, ** 
p<0.01. 
 
  The effect of 670 nm light treatment on microglial activation in the 
retinae of 20-26 month old het mice 
NFκB activation can bring about both pro- and anti-inflammatory responses depending 
on the cellular state at the time of activation, therefore as 670 nm light induced NFκB 
activation in het mice, we sought to explore the effects of 670 nm light exposure on 
microglial activation in very aged het mice. Iba1 staining, which labels microglia of all 
activation states, was present in the GCL, the IPL and the OPL (Figure 6.3). 
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Figure 6.3: Representative images of Iba-1 expression in the wild-type sham treated 
(n=5), het sham treated (n=4) and het light treated (n=6) retinae. The top row shows 
Iba-1 staining with an example image of a retina from each group, the middle row shows 
the nuclear stain and the bottom row shows an overlay of the two stains. The secondary 
only control image shows the non-specific staining that occurs in the absence of the 
primary antibody. Scale bar represents 20 µm. 
 
For analysis the microglial states were divided into fully activated (amoeboid microglia) 
and all other stages of microglial activation (ramified microglia) (Figure 6.4).  
There was no significant difference in the percentage of ameboid microglia in the GCL or 
IPL of retinae from sham treated wild-type and sham treated het mice (Figure 6.5A-B). 
Similarly, there was no significant difference in in the percentage of ameboid microglia 
in the GCL or IPL of retinae from sham and light treated het mice.  
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Figure 6.4: Examples of amoeboid and ramified microglia on the GCL and IPL of the 
retina. Amoeboid microglia in the GCL are indicated by the white arrows and ramified 
microglia in the IPL are indicated by the orange arrows. Scale bar represents 20 µm. 
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Figure 6.5: In very aged mice 670 nm light had no significant effect on the activation of 
microglia in het RGCs. The the percentage of ameboid microglia in the GCL or (A) and IPL 
(B) of retinae from each experimental group. Error bars represent SEM. 
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 Further exploration of the underlying molecular and cellular 
effects of 670 nm light in retinas of 12-15 month old wildtype and 
het mice 
The unexpected lack of NfkB activation in WT mice and the lack of an effect on microglial 
activation in het mice prompted us to test other transcription factors activated by 
oxidative stress which lead to upregulation of antioxidant and pro-survival pathways, 
namely Nrf2 and DJ1. We sought to explore the translocation of Nrf2 from the cytoplasm 
to the nucleus of RGCs by measuring the nuclear to cytoplasmic ratio of Nrf2. We also 
measured the expression of Nrf2 in the nuclear region, the cytoplasmic region and the 
entire GCL. Nrf2 staining was present in the retina, most noticeably in the GCL, IPL and 
INL in each experimental group (Figure 6.6A). Much of the Nrf2 staining in the RGCs was 
present in the nuclear region, with most of the Nrf2 fluorescence co-localised with the 
nuclear stain (Figure 6.6B). There was no significant difference in any of these 
measurements between sham treated wild-type and het mice or in either genotype in 
response to 670 nm light exposure (Figure 6.7). Of note, we observed an increase in 
nuclear Nrf2 fluorescence represent Nrf2 activation, in RGCs from het mice when 
compared to wild-type, however this increase was not statistically significant (Figure 
6.4B).  
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Figure 6.6: Representative images of Nrf-2 expression in the wild-type sham treated 
(n=6), wild-type light treated (n=6), het sham treated (n=5) and het light treated (n=3) 
retinae. A: images taken at 20X magnification, B: images taken at 60X magnification. The 
top row shows Nrf-2 staining with an example image of a retina from each group, the 
middle row shows the nuclear stain and the bottom row shows an overlay of the two 
stains. The secondary only control image shows the non-specific staining that occurs in 
the absence of the primary antibody. Scale bar represents 20 µm. 
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Figure 6.7: There was no significant difference in Nrf2 expression or activation in aged 
RGCs as a result of the het mutation or from treatment with 670 nm. (A) The average 
nuclear-cytoplasmic ratio of the integrated density of Nrf-2 fluorescence in RGCs from 
each experimental group. (B) The mean fluorescence of Nrf2 in RGC nuclei. (C) The mean 
fluorescence of Nrf2 in the RGC cytoplasm. (D) The mean fluorescence of Nrf2 in the GCL. 
Error bars represent SEM.  
 
The upregulation of Dj1 by oxidative and nitrostrative stress triggers a cellular defence 
mechanism to support cell survival during unfavourable conditions. DJ1 staining was 
found in the retinae from each experimental group, which was most intense in the GCL, 
the INL and the ONL (Figure 6.8). Much of the staining was colocalised with the nuclear 
stain.  DJ1 was found to be upregulated in the GCL of retinae from het mice compared to 
wild-type (Figure 6.9A). There was also an increase in DJ1 expression in the GCL in 
response to 670 nm light treatment in retinae from wild-type mice. There was, however, 
no observed effect of 670 nm light treatment on total DJ1 expression in RGCs from het 
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mice. Upon exploration of the expression of DJ1 in the IPL, there was no significant 
difference between wild-type and het mice, but a significant increase was seen with 670 
nm light treatment in retinae from both wild-type and het mice (Figure 6.9B).  
 
Figure 6.8: Representative images of DJ-1 expression in the wild-type sham treated 
(n=4), wild-type light treated (n=6), het sham treated (n=6) and het light treated (n=3) 
retinae. The top row shows DJ-1 staining with an example image of a retina from each 
group, the middle row shows the nuclear stain and the bottom row shows an overlay of 
the two stains. The secondary only control image shows the non-specific staining that 
occurs in the absence of the primary antibody. Scale bar represents 20 µm. 
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Figure 6.9: DJ1 was upregulated in the GCL of retinae from sham treated het mice and 
670 nm light treated wild-type mice, and in the IPL of retinae from wild-type and het 
mice in response to 670 nm light treatment. Average mean values of DJ-1 fluorescence 
presented as a percentage of the maximum fluorescence reading from each group in the 
GCL (A) and the IPL (B). Error bars represent SEM. * p<0.05, ** p<0.01, *** p<0.001. 
 
The data presented above show total DJ1 expression in the GCL and IPL layer. We next 
sought to further explore the subcellular distribution of DJ1 as this contributes to the 
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triggering of the associated downstream protective effects.  We looked at the 
localisation of DJ1 to the mitochondria in response to 670 nm light in RGCs (Figure 6.10).   
The results show that the percentage of RGCs with DJ1 staining colocalised with the 
mitochondrial marker was not significantly changed with either the Opa1 mutation or 
670 nm light treatment (Figure 6.11A). The percentage of RGCs with DJ1 staining that 
was not colocalised with the mitochondrial marker was significantly reduced in het mice 
that received 670 nm light treatment compared to sham treatment (Figure 6.11B). The 
results suggests that although 670 nm light can increase the expression of DJ1 in RGCs of 
wild-type mice it does not influence its localisation to the mitochondria, an event 
associated with enhanced neuroprotection. In het RGCs where DJ1 expression is 
upregulated, 670 nm light does little to influence the localisation of Dj1 to the 
mitochondria to enhance neuroprotection.  
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Figure 6.10: An example of DJ1 and COX IV expression in RGCs to enable identification 
of cells where DJ1 is localised to the mitochondria. (A) A cell with weak DJ1 staining. (B) 
A cell where DJ1 is co-localised with cytochrome c oxidase which is used as a 
mitochondrial marker. (C) A cell where DJ1 is non-colocalised with the mitochondrial 
marker. Scale bar represents 20 µm. 
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Figure 6.11: Analysis of DJ1 co-localisation with the mitochondrial marker, COX IV, in 
the GCL of retina from wild-type sham (n=3), wild-type light (n=3), het sham (n=3) and 
het light (n=2). (A) The percentage of cells labelled strongly with DJ1 and co-localised 
with COX IV staining. (B) The percentage of cells strongly labelled with DJ1 but not co-
localised with COX IV. (C) The percentage of cells with weak DJ1 staining. 
 
As described in Chapter 1.4.6.3, activation of DJ-1 can upregulate antioxidant defences, 
and therefore we investigated whether an increased expression of DJ-1 can protect from 
nitration of tyrosine residues. There was no effect of 670 nm light on 3-nityrosine levels 
in RGCs from aged wild-type or het mice (Figure 6.12-13).  We did, however, find that the 
amount of 3-nitrotyrosine was upregulated in RGCs of retinas of aged het mice.  
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Figure 6.12: Representative images of 3-nitrotyrosine expression in the wild-type sham 
treated (n=3), wild-type light treated (n=4), het sham treated (n=4) and het light 
treated (n=2) and young wild-type untreated (n=1) retinae. The top row shows 3-
nitrotyrosine staining with an example image of a retina from each group, the middle 
row shows the nuclear stain and the bottom row shows an overlay of the two stains. The 
young wild-type retina was used as a negative control for 3-nitrotyrosine staining in the 
retina. Scale bar represents 20 µm. 
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Figure 6.13: The expression of 3-nitrotyrosine was increased in RGCs from het mice. 
Average mean values of 3-nitrotyrosine fluorescence in the GCL from each experimental 
group. Error bars represent SEM. * p<0.05, ** p<0.01, *** p<0.001. 
 
The activation of Akt can be quantified by the phosphorylation of Ser473, an effect that 
is associated with increased protection against oxidative stress and increased cell 
survival. Phosphorylated Akt staining was present in the retinae of both sham and light 
treated wild-type mice, with an increase in staining intensity noticeable in the GCL of 
wild-type retinae (Figure 6.14). Most unexpectedly, p-Akt was found to be significantly 
down-regulated in the GCL and IPL of retinae from wild-type aged mice treated with 670 
nm light (Figure 6.15A-B). The increased activation of p-Akt was exclusive to the GCL and 
IPL as there was no significant difference in p-Akt expression in the INL or ONL (Figure 
6.15C-D). Similarly, after comparing the protein expression levels of Akt and p-Akt from 
the entire retinae, there was no significant difference in the p-AKt/Akt ratio between 
light treated and sham treated retinae (Figure 6.16A-B). 
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Figure 6.14: Representative images of p-Akt expression in aged wild-type sham treated 
(n=3) and aged wild-type light treated (n=3) retinae. The top row shows p-Akt staining 
with an example image of a retina from each group, the middle row shows the nuclear 
stain and the bottom row shows an overlay of the two stains. The positive control shows 
p-Akt staining in a retinal flat mount from a young adult mount treated with 10 nM 
insulin for 5 minutes to upregulate p-Akt. There is higher background staining in the Wt 
sham and Wt light sections than in the control sections. This may be due to differences 
in fixation as the control sections were obtained from a fixed froxen explants while the 
experimental samples were obtained from fixed frozen whole eyes. The secondary only 
control image shows the non-specific staining that occurs in the absence of the primary 
antibody. Scale bar represents 20 µm. 
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Figure 6.15: The expression of p-Akt was significantly reduced in the GCL and IPL of 
aged wild-type mice treated with 670 nm light but was unchanged in the other retinal 
layers.  Average mean values of p-Akt fluorescence in the GCL from each experimental 
group. Error bars represent SEM. ** p<0.01. 
 
Figure 6.16: Akt activation was unchanged in the wild-type retina with 670 nm light 
treatment. The protein expression levels of p-Akt and Akt were analysed by western blot 
(A) and the ratio of the protein levels of p-Akt and Akt was calculated (B). Results are 
based on 3 biological samples per experimental group and the western blots were ran 
twice. Control represents the protein expression of of p-Akt and Akt from a retina treated 
with insulin as a positive control for Akt activation. Error bars represent SEM.
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6.4 Discussion 
 The underlying molecular and cellular effects of 670 nm light in 
retinas of 12-15 month old wild-type and het mice 
In wild-type RGCs 670 nm light had no effect on the activation of NFκB. The results 
differ to that published previously by Chen et al who found that 810 nm light 
increased NFκB activation in mouse embryonic fibroblasts via the generation of ROS 
(Chen et al., 2011). As the experiment was done on fibroblasts, the authors suggest 
that different cell types may show a different pattern of NFκB activation in response 
to LLLT. We found this predicted varying effect in our work as although 670 nm light 
treatment had no effect on the activation of NFκB in wild-type, it increased NFκB 
activation in RGCs from het mice up to wild-type levels. As NFκB activity is known to 
be increased with aging and is associated with neurodegenerative diseases it was 
intriguing that NFκB was downregulated in aged het mice (Tilstra et al., 2011). There 
are many molecules that are known activators of NFκB within neurons, some of 
which act as repressors of NFκB activity at higher concentrations, revealing an 
essential role for NFκB in preconditioning (Kaltschmidt et al., 2005). Aged het RGCs 
may have had suboptimal levels of NFκB activation which may have contributed to 
their in vivo neurodegeneration. Treatment with 670 nm light increased NFκB activity 
in het RGCs to a level which may be optimal for neuroprotection so that upon 
axotomy the RGCs were more resistant to ex vivo degeneration. The result for the 
het RGCs is in accord with the result found by Chen et al, showing an increase in NFκB 
activation following red/NIR light treatment. In wild-type RGCs, since NFκB activity is 
not altered with 670 nm light treatment, NFκB activity may already be at the optimal 
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level required for neuroprotection in wild-type RGCs, therefore altering NFκB 
activation is not a mechanism by which 670 nm light is providing neuroprotection 
against ex vivo degeneration in wild-type RGCs. 
 The effect of 670 nm light treatment on microglial activation in 
the retinae of 21-26 month old het mice 
In 21-26 month old mice there was no significant difference in the number of 
activated microglia surrounding the RGC cell soma or dendrites in very aged wild-
type and het mice, as assessed by the numbers of amoeboid microglia in the GCL and 
IPL. In another mouse model of ADOA, microglial activation has been found to be 
involved in phagocytosing dying RGCs from 18 month old mice (Heiduschka et al., 
2010). In our mouse model of ADOA, however, the extent of microglial activation in 
GCL and IPL, even at this late stage of the disease was no different from that 
associated with normal aging. However, NFκB activation was downregulated in aged 
het mice. Since microglia are one of the downstream effectors of NFκB activation it 
was interesting that the downregulation of NFκB activation had no effect on 
microglial activation.  
Due to the less severe phenotype of our mouse model of ADOA, showing dendrite 
degeneration without RGC death, microglial activation may be playing a less 
prominent role in the progression of the disease phenotype. Also, microglial 
activation increases as a result of normal aging (Sloane et al., 1999). Therefore, 
microglial activation may be playing a role in RGC degeneration in het mice, but the 
increase in microglial activation with normal aging in addition to the limited 
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availability of such aged mice may have resulted in any real increase in microglial 
activation to evade detection by our analysis.  
Albeit not increased in het RGCs compared to wild-type, it was of interest to explore 
the effects of 670 nm light therapy on the microglial activation associated with 
normal aging in RGCs from wild-type and het mice. Red light therapy has been shown 
to inhibit microglial activation in a model of TBI (Khuman et al., 2012). Additionally, 
NFκB activation appears to be playing a role in providing protection to het mice and 
microglia are one of the downstream effectors of NFκB activation. However, in the 
current experiment, there was no significant effect of 670 nm light treatment on 
microglial activation in the GCL or IPL of het mice.  
The lack of effect of 670 nm light on microglial activation in very aged (21-26 months) 
het mice may be due to the advanced age of the mice. It would have been of great 
interest to explore the effect of 670 nm light on complex IV activity as was planned 
for the fellow eye in Chapter 3. As an increase in complex IV activity is a well-
documented effect of 670 nm light, this experiment would have shown whether or 
not 670 nm light can produce therapeutic effects in aged mice with mitochondrial 
dysfunction. This would have determined whether 670 nm light is simply having no 
effect on microglial activation in het mice or whether the mice are too old to receive 
therapeutic benefits from 670 nm light.  
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 Further exploration of the underlying molecular and cellular 
effects of 670 nm light in retinas of 12-15 month old wildtype 
and het 
There was no significant effect of 670 nm light treatment on Nrf2 activation in either 
wild-type or het RGCs. Despite an increase in Nrf2 activation in cortical neurons with 
reduced Opa1 (Millet et al., 2016), the haploinsufficiency of Opa1 in our aged mice 
had no effect Nrf2 on activation. This may be explained by one experiment using 
neurons in vitro and the other experiment using neurons from aged mice. It is known 
that Nrf2 activation is impaired with ageing, therefore the cell of an aged organism 
cannot effectively respond to oxidative insults via Nrf2 signalling (Zhang et al., 2015). 
Due to the age of the RGCs from het mice, Nrf2 activation may be impaired, which 
may explain why we don’t see an increase in the activation of Nrf2 in this study. The 
fact that Nrf2 activation may be impaired with ageing may also explain why we don’t 
see an increase in its activation in response to 670 nm light treatment in either wild-
type or het mice. Our theory that 670 nm light is triggering upregulation of cell 
survival genes in response to transient oxidative stress may therefore involve an 
alternative signalling pathway in aged tissue. 
Red light brought about an upregulation of DJ1 expression in the GCL and IPL of 
retinae from wild-type mice and in the IPL of retina from het mice. DJ1 expression is 
triggered by oxidative stress inducing events to protect the cell against such stress. 
Mutations in Opa1 in some models of ADOA can increase ROS production, therefore 
the RGCs from het mice may have increased DJ1 expression in an attempt to mitigate 
the resulting oxidative stress. Pre-treatment of the wild-type RGCs with 670 nm light 
appears to have increased the DJ1 expression to that of the het RGCs, an effect which 
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may have helped them to cope with the increased ROS that accompanies axotomy 
and therefore delay the associated dendropathy. Investigating the total cellular DJ1 
levels in RGCs provides information on the ability of 670 nm light to induce the 
upregulation of DJ1, an event that may equip the cell to better cope with subsequent 
oxidative stress inducing events.  
Upregulating endogenous DJ1 is one mechanism by which the RGCs may have 
increased their defence against oxidative stress. Another mechanism by which cells 
can increase their antioxidant defence is increasing the translocation of DJ1 to the 
nucleus or the mitochondria. It has been found that localisation of DJ1 to the 
mitochondria can bring about greater neuroprotection than its localisation to the 
nucleus or cytoplasm in the battle against oxidative stress (Junn et al., 2009). 
However, we did not find any significant difference in the number of RGCs where DJ1 
was colocalised with mitochondria, in response to 670 nm light treatment in wild-
type or het RGCs. This suggests that 670 nm induced neuroprotective effects by 
upregulating DJ1, but further enhancement of such effects was not achieved by 
increased mitochondrial localisation of DJ1.  
There was no effect of 670 nm light on 3-nitrotyrosine expression in the GCL of wild-
type retinae. Although 3-nitrotyrosine expression was upregulated in the GCL of 
retina from het mice, 670 nm light had no effect on the expression levels of 3-
nitrotyrosine as they were up-regulated in the GCL from both sham treated and light 
treated het mice. Therefore, there was no involvement of 3-nitrotyrosine in the 
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underlying molecular mechanism 0f 670 nm light responsible for neuroprotective 
effects seen on aged wild-type and het mice.  
Despite not revealing any effects of 670 nm light our experiment on 3-nitrotyprosine 
expression did reveal an interesting finding. We show for the first time that 3-
nitrotyrosine is upregulated in the presence of the Opa1 mutation, as we found an 
increase in 3-nitrotyrosine in the GCL of aged het mice. It has been shown that 3-
nitrotyrosine can elicit neurodegenerative effects in vivo (Mihm et al., 2001). Free 3-
nitrotyrosine inhibited complex I, decreased ATP production and increased 
superoxide production in neurons in vitro (Ma et al., 2007). Therefore 3-nitrotyrosine 
may contribute to the mitochondrial deficits in ADOA and the associated RGC 
degeneration. 
Although Akt is known to promote cell survival and has been shown to protect against 
neurodegeneration, we found that 670 nm light treatment caused a downregulation 
in the expression of p-Akt in the GCL of wild-type retinae. The findings were 
unexpected or rather counterintuitive since 670 nm light protected the RGCs from 
neurodegeneration, yet neuroprotection is commonly associated with an up-
regulation of p-Akt. However, another study showed that preconditioning of PC12 
cells with 6hr of oxygen and glucose deprivation (OGD) on day one significantly 
reduced basal p-Akt expression during a second exposure to OGD 24 hours later 
(Hillion et al., 2006). The initial exposure to OGD induced a strong increase in p-Akt 
after 2hr but went back to basal levels after 6 hr. Although the second exposure to 
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OGD increased p-Akt expression after 2 hours the increase was significantly lower 
than in preconditioned cells compared to non-preconditioned cells.  
This may also be happening with 670 nm light treated retinae; there may have been 
an initial increase in p-Akt in response to 670 nm light treatment, however, after each 
of the five treatments, the p-Akt level in light treated retinae may have been reduced 
to below basal levels. This seems like a plausible explanation for why light is reducing 
instead of increasing levels of p-Akt, but it does not explain how reducing p-Akt can 
increase the RGC resistance against degeneration. Nevertheless, in the OGD model, 
the preconditioning that was associated with reduced levels of p-Akt was associated 
with a significant decreased in cell death induced by 15 hours of OGD (Hillion et al., 
2006). The cell death induced by OGD was reported to be induced predominantly by 
apoptosis, with the involvement of caspase-3. 
The authors state their awareness of the evidence that has been gathered over the 
past decade that consistently show the role of Akt in counteracting apoptotic stimuli 
and that their results seem counterintuitive, but claim that their results suggest that 
too much activation of Akt is damaging (Hillion et al., 2006). Decreased activation of 
the downstream targets of Akt can trigger apoptosis, an effect which is well known, 
however, this effect can also regulate cell proliferation and trigger growth arrest. In 
situations of stress or low energy, driving cells into a state of quiescence may provide 
neuroprotective effects.  
A similar unexpected effect was seen with the pro-apoptotic protein caspase-3; in 
mice where caspase-3 was inhibited or knocked out there was increased cell death 
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in response to chemical and environmental stressors (Khalil et al., 2012). This reveals 
that caspase-3 plays an important role as a cell stress sensor, triggering responses 
that either result in apoptosis, as has been well documented, or triggering a cellular 
programme that promotes increased cell survival in response to cellular stressors.  
The studies are counterintuitive regarding the effects of anti-apoptotic p-Akt and 
pro-apoptotic caspase-3 downregulation. The studies highlight the need for further 
exploration into the precise functions of these proteins as the terms anti and pro-
apoptotic are over simplistic. The evidence suggests that the functions of these 
proteins are vast and are highly dependent on the state of the cell and its 
environment at the time of analysis. In terms of the effects of 670 nm light on p-Akt 
proteins, our results also seem counter-intuitive based on our original hypothesis. 
However, in support of our findings, 670 nm light has previously been shown to 
prevent the upregulation of p-Akt in RGC5 cells in response to 30 mM glucose, an 
effect that was associated with inhibition of RGC degeneration (Tang et al., 2013b).  
The results reveal the enormity of the challenge presented when trying to uncover 
the mechanism of action of 670 nm light that is responsible for its neuroprotective 
effects. If the role of its molecular effectors are complex and vary depending on the 
state of the neuron at the time of exposure, this makes it increasingly difficult to 
predict the effect that 670 nm light would have on any given neuronal tissue.  
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7.1 Conclusions 
Light at 670 nm was found to produce neuroprotective effects in models of RGC 
degeneration. As the therapy was found to provide resistance against RGC 
dendropathy in retinal explants from a mouse model of ADOA, it has great potential 
to be effective in preventing the RGC dendropathy that is associated with a loss in 
visual acuity in the ADOA mouse. However, the underlying cellular and molecular 
mechanism responsible for the neuroprotective effects remain unclear. In particular: 
1. The effects of 670 nm light on mitochondrial function in retinal explants from 
12-15 month old wild-type and het mice could not be determine due to the 
practical limitations of the experiment.  
2. A single exposure of 670 nm with a radiant exposure of 31.7 J/cm², delivered 
post axotomy to young wild-type retinal explants provided partial protection 
from dendropathy in the entire population of RGCs for up to 16 hours ex vivo. 
3. Five daily exposures to 670 nm light with a total radiant exposure of 22 J/cm² 
to the eyes of 12-15 month old wild-type and het mice prior to axotomy 
provide protection against ex vivo dendropathy in the entire population of 
wild-type RGCs and a partial protection from ex vivo dendropathy in ON-
centre RGCs from wild-type and het mice. 
4. Exposure of the eyes of 12-15 month old wild-type mice to a total of 22 J/cm² 
of 670 nm light for 5 consecutive days had no effect on NFκB activation. The 
same treatment in 12-15 month old het mice caused an increase in NFκB 
activation. No downstream effects of NFκB activation were seen on microglial 
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activation in 21-26 month old het mice approximately 23 J/cm² of 670 nm 
light treatment. 
5. A total in vivo radiant exposure of 22 J/cm² of 670 nm light for 5 consecutive 
days caused an upregulation of DJ1 expression in RGCs from 12-15 month old 
wild-type and het mice. This treatment had no effect on Nrf2 activation or the 
levels of 3-nitrotyrosine in RGCs from 12-15 month old wild-type or het mice. 
There was a reduction in Akt activation in response to this treatment in 12-15 
month old wild-type mice. 
The findings of this thesis show for the first time a protective effect of 670 nm 
light in ON-centre RGCs from a mouse model of ADOA at an age when these RGCs 
show an increased susceptibility to degeneration. However, to ensure maximum 
protective effects are achieved from this therapy in vivo, a greater understanding 
of the mechanism of action is necessary.
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7.2 Future work 
 The effect of 670 nm light on caspase 3 activation in wild-type 
and het mouse 
In Chapter 6 we found an upregulation of DJ1 in response to 670 nm light. DJ1 has 
been shown to inhibit the extrinsic apoptotic pathway by blocking Fas-associated 
protein death domain-mediated caspase-8 activation (Fu et al., 2012). It also inhibits 
p53, decreases the expression of Bax and inhibits caspase-3 activation. Experimental 
evidence from hippocampal cultures demonstrates that caspase 3 can be activated 
locally within distal dendrites and dendritic spines in the absence of neuronal cell 
death for the regulation of spine density and dendritic morphology in a process 
essential for development and synaptic plasticity (Ertürk et al., 2014). Since 
pharmacological inhibition of caspase-3 activity rescued the dendritic spine 
degeneration that is associated with a deficiency in hippocampal-dependent memory 
in a mouse model of AD, this suggests an essential role for caspase 3 activation in the 
degeneration of dendritic spines that is associated with the early stages of 
neurodegeneration (D'amelio et al., 2011).  Similarly, in post mortem brains of AD 
patients there was increased activated caspase 3 in the post synaptic density 
fractions of synapses, providing more evidence to suggest an important role for 
caspase3 in synapse degeneration during disease progression (Louneva et al., 2008).  
Although there is experimental evidence to show that caspase 3 plays a primary role 
in the execution of dendritic degeneration both in neurons in vitro and in vivo, and 
from post mortem neural tissue, there is insufficient evidence for the role of caspase 
3 in RGC dendropathy that occurs post axotomy. Exploration of caspase 3 activation 
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by Binley et al. found that there was no significant increase in the expression of 
caspase 3 in the GCL or IPL of explanted retinae from zero to 14 days ex vivo (Binley 
et al., 2016). However, the expression level was not explored at any time point 
between zero and three days, a critical period during which significant dendropathy 
occurs. Therefore, although it is most likely, it is impossible to say whether or not 
caspase 3 is also required for the initiation of the ex vivo dendropathy that occurs 
post axotomy.  
If the activation of caspase 3 is required for the initiation of dendritic pruning then 
inhibiting this activation may play a role in protecting the cells against axotomy 
induced dendropathy. As DJ1 can inhibit caspase 3 activation and prevent apoptosis, 
then the upregulation of DJ1 in the IPL in response to 670 nm light treatment may be 
preventing ex vivo dendropathy by inhibiting the activation of caspase 3 in the 
dendrites of wild-type and het  mice.  
 It would be very interesting to look at the expression levels of caspase-3 at a time 
before significant dendropathy is established to confirm that caspase 3 is involved in 
triggering ex vivo dendritic pruning. We therefore want to look at the expression of 
activated caspase 3 in the GCL and IPL at a number of time points between 0 and 16 
hours to establish whether or not caspase 3 activation in dendrites is involved in 
dendropathy. If we find that caspase 3 activation is involved, we will then select the 
time point with the highest expression of activated caspase 3 and chose this ex vivo 
time point to explore the effects of 670 nm light treatment on caspase 3 activation.    
Chapter 7. General discussion 
206 
 
As we plan to do this work using immunohistochemistry, we have commenced with 
the optimisation of the antibody to detect activated caspase 3 on fixed frozen 
sections. We used mouse spleen sections to optimise the antibody (Figure 7.1). 
However, we need to optimise the antibody on retinal sections and establish a 
suitable positive control. Therefore, we treated retinal explants with 5 µM 
staurosporine and fixed after 4 hours ex vivo, cryopreserved and stored at -80 °C. We 
will use these retinae to establish a positive control as our starting point for this work. 
To back up the findings of the immunohistochemistry we will use western blot 
analysis. Staurosporine treated retinal explants have also been flash frozen as a 
positive control for the western blot of activated caspase.  
 
Figure 7.1: Optimisation of activated caspase 3 antibody on fixed frozen mouse 
spleen sections. The left column shows the mouse spleen sections that were 
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probed for anti-activated caspase 3. The right column shows mouse spleen sections 
where the primary antibody was omitted from the staining protocol. 
 
7.2.1.1 Retinal shaves for Western blot analysis 
Any results seen with immunohistochemistry should be confirmed with Western blot 
analysis. This was done for Akt activation, however, the results shown are based on 
the entire retina, yet the RGCs make up a relatively small percentage of retinal cells. 
Therefore, the results from the Western blot analysis is most likely coming from 
photoreceptors which are the most abundant cell in the retina. Since we are only 
interested in the RGCs it would be most useful to perform retinal shaves to localise 
the GCL and IPL. Western blot analysis on the RGC portion of the retina would allow 
for a more reliable confirmation of immunohistochemistry results. 
 
 Testing the effects of 670 nm light treatment on in vivo 
dendropathy in the het mouse 
As success was found on ex vivo dendropathy in ON-centre RGCs from aged het mice 
in the therapy has high potential for success on in vivo dendropathy in this model. In 
vivo treatment prior to axotomy, the trigger of ex vivo dendropathy, enhanced the 
neuroprotective effects of the therapy. This result is very valuable when applying this 
therapy to the in vivo situation, in terms of the age at which we should begin 
treatment to yield the greatest neuroprotective effects. Treatment should therefore 
commence before significant dendropathy is present in this model. It has been 
reported that although dendropathy is significant after 12 months in the het mouse, 
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it has been shown to present as early as 10 months. Therefore, treatment should 
commence no later than 9 months in this model. 
 Establishing the optimal dose for maximum efficacy in vivo in 
the retina 
The results of the thesis show that 670 nm light can alter the activity of various 
effector proteins to produce downstream neuroprotective effects. However, as we 
only looked at the activity of these markers at one specific time point after exposure, 
we do not know how long the increased activation of the effector proteins was 
sustained for. Additionally, the effector proteins that were not found to be activated 
in the RGCs after five exposures may have been activated after fewer exposures, but 
returned to baseline levels before fixation. Although we found beneficial effects of 
670 nm light with a daily radiant exposure of 4.4 J/cm² this may not be the optimal 
dose for the prevention of RGC degeneration in aged het mice.  
A more thorough understanding of the mechanism of action of 670 nm light is 
required to enable the design of an efficacious therapy for ADOA. To achieve this, the 
effect of different parameter combinations, such as irradiance and radiant exposure, 
on the molecular effectors that are responsible for the neuroprotective effects, need 
to be tested. A comparison could then be made to find the combination that results 
in the activation of the molecular effectors for the longest period of time before 
downregulation occurs. This would provide valuable information on the dose 
required per treatment and the treatment frequency.  
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 Assessing the possible thermal effects of 670 nm 
Red/NIR light may be producing neuroprotective effects by inducing mild heat stress 
in the irradiated tissue. Heat stress can upregulate the expression of heat shock 
proteins (HSPs) that that function as molecular chaperones, assisting the cell in the 
presence of stress (Jolly and Morimoto 2000). During cellular stress misfolded 
proteins can accumulate in the cell leading to apoptosis. Upregulation of heat shock 
proteins can help to repair the damaged proteins or facilitate degeneration, thereby 
restoring cellular homeostasis and preventing apoptosis. The mild heat produced 
during 670 nm light exposure may be sufficient to produce heat shock in the cells 
which induces the expression of heat shock proteins, with negligible damage to the 
irradiated tissue.  
There are many different HSPs that are named according to their molecular weight. 
High molecular weight HSPs such as HSP60 HSP70 and HSP90 are dependent on ATP 
for chaperone activity whereas low molecular weight HSPs such as HSP27 are ATP 
independent (Lanneau et al., 2008). HSP70 and HSP90 appear to be upregulated in 
response to heat acclimation, which is an adaptive response that occurs in response 
to heat stress (Jee, 2016). It would be of great interest to monitor the expression 
levels of HSP70 and HSP90 in response to 670 nm light to explore a possible thermal 
effect of 670 nm light. However, HSPs are upregulated by a various other cellular 
stressors including oxidative stress which is also hypothesised to be responsible for 
triggering a stress response following red/NIR light exposure. Therefore, exploring 
the effects of 670 nm light on HSPs alone will not be sufficient to determine whether 
or not the therapeutic effects are as a result of a thermal effect of light exposure.  
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Appendix I Published studies using low energy 630 nm light for therapeutic 
purposes 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Model Device Energy 
density 
Treatment 
period 
Duration of 
irradiation 
Frequency of 
irradiation 
Power 
density 
Results Reference 
Tympanic membrane 
perforation 
Guinea Pig 
630  
Diode 
laser 
1.8 
J/cm2 
10 days 1 minute Daily 30 
mW/cm2 
Reduction in tympanic membrane 
thickness 
Reduction in the number of inflammatory 
cells infiltrating the tympanic membrane 
[1] 
 
Mandibular 
advancement 
Rabbit 
(Albino) 
630 low 
level laser 
1.8 
J/cm2 
3 weeks 3 minutes Daily 10 
mW/cm2 
Increase in bone formation in the 
condylar region of the mandible 
 
[2] 
Cultured pancreatic 
islet cells 
630 Ga-As 
low level 
laser  
1, 3 or 5 
J/cm2 
Single 
treatment 
8, 25 or 42 
seconds 
Single 
treatment 
40 
mW/cm2 
A significant increase in insulin secretion, 
but only with 1 J/cm2 
[3] 
Genetically diabetic 
mice 
Argon dye 
laser 
5 J/cm2 4 days 
 
250 
seconds 
Daily 
Starting 6 hours 
after wounding 
20 
mW/cm2 
A significant increase in percentage 
wound closure at both 10 and 20 days 
after wounding 
[4] 
Injured cartilage  
5 mm Ear punch hole 
Rabbit 
630 laser 1.8 
J/cm2 
20 days 1 minute Daily 3-5 days 
after punch hole 
Every other day 
thereafter until 
day 20 
30 
mW/cm2 
A decrease in punch hole diameter at 7 
14 and 21 days, however not significant. 
Increased pericondrial cell growth, 
increased longitudinal cartilage  
[5] 
Wound healing  
Rat 
630 nm 
LED 
 5 days  10 minutes Daily 50 
mW/cm2 
No significant effect of 630 nm light on 
wound area but a significant effect of 
blue light of on wound size 
[6] 
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Appendix II Published in vitro studies using low energy 670 nm light on 
neuronal cells for therapeutic purposes 
  
Cell Type Radiant 
exposure 
Treatment 
period 
Duration of 
irradiation 
Frequency of 
irradiation 
Irradiance Results Reference 
Retinal cells 5 J/cm2 4 days 200 seconds Twice Daily 25 mW/cm2 Prevents increased superoxide production, 
expression of inflammatory biomarkers and cell 
death induced associated with exposure to 30 mM 
Glucose  
 
[1] 
PC 12 cells 0.45 mJ/cm2 4 days 20 seconds  Daily 3 mW/cm2 Extention of NGF stimulated neurite out growth 
Prevents H202 induced decrease in MMP 
Has a positive effet on cell viability 
[2] 
PC 12 cells 0.45 mJ/cm2 4 days 15 minutes  Daily 3 mW/cm2 Prevents H202 induced decrease in MMP 
No effect on cell viability 
[2] 
Primary Visual 
cortical neurons 
 
 
 
 
 
4 J/cm2 5 days 
 
80 seconds Twice Daily  50 mW/cm2 Reversal of the detrimental effects of low levels of 
KCN on COX activity 
and partially reversed the effects or NaN3 
[3] 
Pretreated   4 J/cm2 3 days prior to 
toxin exposure 
In addition to 
above 
treatment 
80 seconds Daily 50 mW/cm2 A greater increase in COX activity  
  
[3] 
Primary Visual cortical 
neurons 
 
30 J/cm2 Single 
pretreatment 
10 mins Single 
exposure 
50 mW/cm2 Significant reduction in the number of apoptotic cells 
and the KCN induced increase in ROS 
[4] 
Primary occipital 
cortical and striatal 
neurons 
4 J/cm2 3 or 5 days 80 seconds Twice daily 50 mW/cm2 Rescued cells from the toxic effects of MPP+ 
Rotenone and KCN. Increase in COX activity, ATP 
production, a reduction in apoptosis, ROS and RNS 
[5] 
 
Primary rat cortical 
neurons 
4 J/cm2 5 days 80 seconds Daily 50 mW/cm2 Reversion of the down-regulation of COX activity by 
TTX to control levels 
[6] 
Primary rat striatal 
and cortical neurons 
4 J/cm2 2 days 80 seconds Twice daily 50 mW/cm2 LED treatment prior and during  MPP+ and Rotenone 
exposure had more profound protective effects 
against neurotoxicity compared to LED treatment 
alone during toxin exposure 
[7] 
Rat neonatal myocytes 
and cardiac muscle 
cell line 
Hypoxia and 
reoxygenation 
induced 
cardiomyocyte injury 
1.5, 7.5 
and 15 
J/cm2 
Single 
treatment 
5 minutes Single 
treatment 
5, 25 and 50  mW/cm2 7.5 J/cm2 was optimal dose in reducing cell 
membrane injury, decreasing caspase 3 activity and 
preventing cytochrome c release from the 
mitochondria, reversing the NO induced inhibition of 
oxygen consumption, increases ATP production  
[8] 
 
References 
1. Tang, J., et al., Low-Intensity Far-Red Light Inhibits Early Lesions That Contribute to 
Diabetic Retinopathy: In Vivo and In VitroFar-Red Light Inhibits DR. Investigative 
Ophthalmology & Visual Science, 2013. 54(5): p. 3681-3690. 
2. Giuliani, A., et al., Low infrared laser light irradiation on cultured neural cells: effects 
on mitochondria and cell viability after oxidative stress. BMC Complementary and Alternative 
Medicine, 2009. 9(1): p. 8. 
3. Wong-Riley, M.T., et al., Photobiomodulation directly benefits primary neurons 
functionally inactivated by toxins role of cytochrome c oxidase. Journal of Biological 
Chemistry, 2005. 280(6): p. 4761-4771. 
4. Liang, H.L., et al., Photobiomodulation partially rescues visual cortical neurons from 
cyanide-induced apoptosis. Neuroscience, 2006. 139(2): p. 639-649. 
5. Liang, H.L., et al., Near-infrared light via light-emitting diode treatment is therapeutic 
against rotenone-and 1-methyl-4-phenylpyridinium ion-induced neurotoxicity. Neuroscience, 
2008. 153(4): p. 963-974. 
6. Wong-Riley, M.T., et al., Light-emitting diode treatment reverses the effect of TTX on 
cytochrome oxidase in neurons. Neuroreport, 2001. 12(14): p. 3033-3037. 
7. Ying, R., et al., Pretreatment with near-infrared light via light-emitting diode provides 
added benefit against rotenone-and MPP+-induced neurotoxicity. Brain Research, 2008. 1243: 
p. 167-173. 
8. Zhang, R., et al., Near infrared light protects cardiomyocytes from hypoxia and 
reoxygenation injury by a nitric oxide dependent mechanism. Journal of Molecular and 
Cellular Cardiology, 2009. 46(1): p. 4-14. 
 
Appendix III Published in vivo studies using low energy 670 nm light in 
models of neurodegeneration 
 
 
 
 
 
 
 
 
 
 
Animal 
models 
Tissue 
treated 
Fluence 
per 
treatment 
Duration 
of total 
treatment 
period 
Frequency 
of 
irradiation 
Power 
intensity 
Distance 
of light 
source 
from 
animal 
General effect 
with light treatment 
Molecular effects 
With light treatment 
Ref. Additional 
information 
EAE 
Mice 
 
C57BL/6 
  
Spinal 
cord 
5 J/cm2 7 days on 
7 days off 
7 days on 
Daily 28 
mW/cm2 
2 cm Protection against 
apoptosis in the CNS 
Reduced clinical EAE in 
wt but not in iNOS 
knockout mice 
Reduced apoptosis at all 
stages of EAE 
 
Down requlation of NO and iNOS 
Upregulation of antiapoptotic 
protein Bcl-2 
No difference in pro apoptotic 
protein Bax 
[1]   
Diabetic 
retinopathy 
induced  
rats 
 
Lewis 
Retina 
 
6 J/cm2 10 weeks Daily  25 
mW/cm2 
1 inch 
Above 
head 
Inhibition of RGC death 
50% improvem-ent in 
reduced ERG amplitude 
Inhibition of diabetes induced 
superoxide production  
Correction of the diabetes induced 
decrease in MnSOD 
Prevention of diabetes induced 
increase in leukostasis and 
expression of ICAM-1  
[2] Animals not 
forced or 
encouraged to 
look at light 
Induced 
wound  
Mice 
 
SKH1-hr 
(Albino) 
Skin 3.6 J/cm2 
was total 
fluence for 
high 
medium 
and low 
flux 
delivery of 
light 
 
5 days Daily 40 
mW/cm2 
 
8 
mW/cm2 
 
1.6 
mW/cm2 
 
2-3 cm 
from 
wound 
Percentage of wounds 
healed greater than 
control at 1 week after 
injury but not significant 
after 2 weeks and effect 
was greater than at 
lower fluxes 
No difference in inflammation from 
control  
No difference in cell proliferation 
between the light treated groups 
and control 3 days after injury 
[3] Cage equipped 
with LEDs 
with LEDs 
Mice were 2 
weeks younger in 
the lower flux 
group 
 
 
 
 
 
 
 
 
 
 
Diabetic mice 
 
Skin 4 J/cm2 14 days Daily 28 
mW/cm2 
N/A Reduction in wound area 
Upregulation of tissue 
regenerating genes 
 [4]  
MTPT induced 
Parkinsons 
mice 
 
BALB/c 
(Albino) 
Brain  2 J/cm2 30 hours 4 
treatments  
Evenly 
spaced 
over 30 
hours 
40 
mW/cm2 
5.3 
mW/cm2 
reaching 
brain 
(10%) 
1 cm 
above 
head 
Reduction MTPT induced 
cell loss in SNc but no 
effect on cells in ZI-Hyp 
 [5] Animals 
euthanized 6 days 
after last 
treatment 
Light induced 
retinal 
degeneration 
rat 
 
Sprague–
Dawley 
(Albino) 
Retina  9 J/cm2 5 days 
prior to 
light 
induced 
damage 
Daily 60 
mW/cm2 
2.5 cm 
from eyes 
1 week post induction of 
light damage: reduced 
photoreceptor death 
and preserved structural 
integrity of muller cells 
 
Upregulation of genes involved in 
neuroprotection 
Maintains muller cell ability to 
recycle neurotoxic glutamate 
Reduction in the upregulation nof 
TNFα 
[6]  
Light induced 
model of 
atrophic AMD 
 Rat 
Sprague–
Dawley 
(albino) 
Retina  9 J/cm2 pre-
treatment 
5 days 
Daily 60 
mW/cm2 
2.5 cm 
from eyes 
Prevention of the 
reduction in ONL 
thickness associated 
with light damage 
Reduced expression of 
complement genes 
Reduced immunoreactivity for 
oxidative damage marker 
Reduuction in the recruitment of 
C3 expressing 
microglia/macrophages in the 
retina 
[7]  
 
 
 
 
 
 
 
 
 
Photoreceptor 
degeneration 
rat 
(albino) 
Retina 
 
9 J/cm2 Pre con: 5 
days 
(Prior light 
damage)  
 
Mid con: 
During 
light 
damage 
Post con: 5 
days (post 
light 
damage) 
 
 
3 minutes 
daily 
 
60 
mW/cm2 
2.5 cm 
form eyes 
Positive results in pre-
treated but not post 
treated animals 
Prevents photoreceptor 
cell loss and structural 
changes to the outer 
retina 
Loss in retinal function 
was reduced 
The number of TUNEL+ cells was 
lowest in the Pre con group 
Reduction in the expression of 
outer segment cone protein was 
prevented in pre and mid con 
groups only 
[8]  
Macular 
degeneration 
mice 
Retina 
 
 35 hours 5 
exposures 
over 35 
hours 
40 
mW/cm2 
1 cm 
above the 
head 
Increased membrane 
potential 
Reduction in 
macrophage number, 
TNFα and inflammatory 
biomarkers  
 [9]  
Macular 
degeneration 
mice 
Retina 
 
 14 days Twice daily 
For 6 
minutes 
Between 
6 and 19 
mW/cm2  
Between 
0.4-13 cm 
from 
mouse 
(LED on 
both sides 
of cage)  
 
Increased COX 
expression by 50?% 
Reduction in 
inflammatory and retinal 
stress markers 
Number of Iba+ cells was reduced 
with 670 nm treatment however 
not significantly 
Cell bodies of macrophages were 
reduced in size while there 
processes extended  
The inflammatory marker was 
reduced on Bruchs membrane and 
photoreceptor outer segments 
[10] The animals cage 
was equipped 
with 670 nm LEDs 
which emitted 20 
mW/cm2 
The lights were 
set to come on at 
6 am and 6pm for 
6 minutes 
 
 
 
 
 
 
 
 
 
Optic nerve 
secondary 
degeneration 
Rats 
 
PVG 
ON  7 days Daily 
30 minutes 
60 
mW/cm2 
at source 
3 cm 
above 
head 
(WARP 10) 
Prevention of changes in 
mitochondrial structure 
associated with 
secondary degeneration 
Reduced number of mitochondrial 
autophagic profiles  
Aconitase which is inhibited by ROS 
is increased  
Citrate synthase (marker of 
mitochondrial content) was 
increased in dorsal ON while 
decreased in the ventral ON 
[11]  
Photoreceptor 
degeneration- 
light damage 
model 
Rat (albino) 
Sprague–
Dawley 
Retina 5 J/cm2 Various (2, 
5, 7 and 10 
days) 
Daily 
3 minutes 
28 
mW/cm2 
1-2 cm 
above 
head 
(WARP 75) 
Reduced photoreceptor 
death 
Protection of 
photoreceptors 
increases with longer 
treatment periods 
 
GFAP expression on Müller cells 
(upregulates with various stresses) 
is reduced 
[12] Device placed 
over animals 
head while in 
cage, mild 
restraint used 
TBI model 
Sprague–
Dawley 
Rat 
 
Brain 15 J/cm2 72 hours 
(biochemic
al) effects) 
 
10 days 
behavioura
l effects) 
Twice daily 50 
mW/cm2 
0.5 cm An improvement in nose 
poke behaviour 
Significant decrease in the 
proapoptotic protein Bax and an 
increase antiapoptotic protein Bcl-
2 
Reduced glutathione levels 
[13]  
Type 1 
diabeties 
model 
rat 
 9 J/cm2 18 
days(acute
) or 14 
weeks 
(chronic) 
(treatment 
not given 
on 
weekend 
days) 
Daily 30 
mW/cm2 
 Increase in antioxidant 
enzyme activity as 
measured after 18 day 
treatment but not after 
14 week treatment 
 [14]  
 
 
 
 
 
 
 
 
 
Light induced 
photoreceptor 
damage 
Rat 
Retina 90 J/cm2 48 hours 3 hours 
before and 
0, 24 and 
48 hours 
after light 
damage 
50 
mW/cm2 
1 inch 
above 
head 
Decrease in retinal 
degeneration 
Protected against 
damage induced 
reduction in retinal 
function 
 [15]  
Optic nerve 
secondary 
degeneration 
Rats 
ON 5 J/cm2 
Per 88 
second 
dose 
3 months 
(6 days/ 
week) 
Daily 60 
mW/cm2 
3 cm 
above 
head 
Prevents the RGC loss 
resulting from retinal 
injury and the associated 
loss in visual function 
 [16]  
Optic nerve 
secondary 
degeneration 
Rats 
ON 5 J/cm2 
Per 88 
second 
dose 
Single 
treatment 
Single 
treatment 
60 
mW/cm2 
3 cm 
above 
head 
Increase in cytochrome c 
oxidase activity 
Reduction in ROS and 
RNS 
 [16]  
Oxygen 
induced 
retinopathy  
 
C57BL/6J mice 
or Sprague-
Dawley albino 
rats 
Retina Retina 9 J/cm2 Daily  
18 days 
50 
mW/cm2 
 Decrease in severity of 
vascular pathology 
Reduced cell death in all 
retinal layers 
 [17]  
Light induced 
retinal 
degeneration 
Rat 
ON 3.4 J/cm2 5 days pre-
treatment 
Daily 
3 mins 
18.8 
mW/cm2 
2.5 cm 
from eye 
Reduction in the number 
of TUNEL+ cells 
 [18]  
TBI Rat SC 28.4 J/cm2 7 days Daily  
30 mins 
15 
mW/cm2 
3 cm 
above 
animal 
No significant 
improvements in motor 
or sensory function 
 [18]  
Partial optic 
nerve injury 
Rats 
ON 28.4 J/cm2 7 days Daily 28.4 
J/cm2 
2.5 cm 
from eye 
Increase in the number 
of visual responses 
Reduced ROS 
 [19]  
 
 
 
 
 
 
 
 
 
MPTP mice Brain 4 J/cm2 4 days Daily 50 
mW/cm2 
Protocol 1. 
Directly to 
head 
Protocol 2. 
Directly to 
body-head 
foil 
covered 
Significant rescue of 
tyrosine hydroxylase-
positive cells in the 
substantia nigra pars 
compacta 
Protocol 2 less effective 
that protocol 1 
 [20]  
Rodent model 
of retinal 
toxicity 
Retina 4 J/cm2 50 hours 3X 2 mins 
24 sec 
exposures 
5, 25 and 
50 hrs 
after 
induced 
toxucity 
28 
mW/cm2 
1 inch Significant recovery of 
rod- and M-cone-
mediated retinal 
function and a significant 
recovery of UV-cone-
mediated function 
Protection from 
methanol-induced 
histopathology 
 [21]  
Hyperoxia-
induced 
retinopathy 
mouse 
Retina 9 J/cm2 Pre-
treatment 
5 days 
daily 60 
mW/cm2 
2.5 cm 
from eyes 
Slowed, but did not 
prevent photoreceptor 
loss  
Reduced expression of markers of 
oxidative stress, acrolein and 
Hmox-1 stress, and reduced 
expression of complement 
component 3 
[22]  
12 month old 
C57/BL mice  
Retina 
and 
brain 
 84 hours 7X 90 s 
exposures 
spaced 
evenly 
over 84 hrs  
40 
mW/cm2 
15 cm 
from 
source 
Increase in ATP 
Upregulation of COX un 
outer retina 
Acrolein expression reduced in 
outer retina 
[23]  
MPTP model 
of PD 
Brain  6 days Exposure 
was 
continuous 
for 6 days 
0.16 
mW/cm2 
Delivered 
intracrania
lly 
No significant protection 
against cell death in SNc 
with pulsed or 
continuous protocol but 
fewer TH+ cells in MPTP 
 [24] An optical fiber 
linked to an LED 
or laser device 
was surgically 
implanted into 
 
 
 
 
 
 
 
 
 
 or 90 sec 
per day for 
4 days 
group compared to 
MPTP-NIR groups 
the lateral 
ventricle of the 
rats 
MPTP model 
of PD C57/BL6 
or albino 
Balb/c mice 
Brain 0.5 J/cm2 
per 
treatment 
 
6 days 4X 90 s 
treatments 
over 6 
days 
 1-2 cm 
above 
head 
TH+ cells significantly 
higher in MPTP-NIR 
group compared to 
MPTP group- 30% higher 
in Balb/c compared to 
20% in C57BL/6  
Locomotor activity 
values significantly 
higher with 670 nm light 
in Balb/c mice but did 
not reach significance in 
C57/BL6 
 [25] Treatment with 
670 nm light had 
different effects 
on different 
strains of mice 
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Appendix IV Published studies using low energy 810 nm light in animal 
models of neurodegeneration 
 
 
 
 
 
 
 
 
Model Device Radiant 
exposure 
Treatment 
period 
Duration of 
irradiation 
Frequency of 
irradiation 
Irradiance Result 
 
Reference 
TBI mice Ga-Al-As 
diode laser 
10 Hz 
pulsed 
wave or 
CW 
36 J/cm2 Single 
treatment 
4 hours 
post TBI 
12 minutes Single 
treatment 
50 mW/cm2 
3-7.5 mW/cm2 
reaching brain 
28 days post TBI: Reduced lesion volume 
Improvement in NSS 
Antidepressant effect  
Increased effectiveness at 10-Hz pulse frequency 
than at CW and 100-Hz 
4 hours post TBI: No significant increase in ATP 
content 
[1] 
Familial 
amyotrophi
c lateral 
sclerosis 
mice 
 12 J/cm2 5 months 
(51 days 
old until 
death) 
120 seconds Daily 140 mW/cm2 No significant  difference in motor neuron survival 
No significant improvement in motor function 
[2] 
Murine 
bone 
marrow 
derived 
dendritic 
cells 
Laser 
(HOYA 
Conbio, 
Fremont, 
CA) 
30, 3, 0.3 
J/cm2 
Single 
treatment 
5 minutes Single 
treatment 
100, 10, 0.1 
mW/cm2 
Increased cell viability 
Reduced IL-12 secretion stimulated by LPS 
Reduced NF-kB activation in cells stimulated with 
CpG 
No observed dose response 
[3] 
Glutamate 
toxicity 
model 
Murine 
primary 
cortical 
neurons 
Diode laser 
(Photother
a, Inc., 
Carlsbad, 
CA), 
3 J/cm2 single 2 minutes single 25 mW/cm2 A significant yet modest decrease in cell death 
Highly significant increase on ATP production and 
MMP. 
Highly significant reduction in intracellular Ca2+, 
oxidative stress and NO. 
 [4] 
Oxidative 
stress model 
Murine 
primary 
cortical 
neurons 
Diode laser 
(Photother
a, Inc., 
Carlsbad, 
CA), 
3  J/cm2 single 150 seconds single 20 mW/cm2 Increased MMP, reduced ROS in stressed cells and 
increased ROS in control cells 
Reduction in cell death in stressed cells 
[5] 
 
 
 
 
 
 
 
 
Dermal 
abrasion 
model  
      4 J/cm2           7 days 6.6 minutes Daily        10 mW/cm2 Reduction in wound area 
Increased collagen accumulation 
[6] 
Diabetic 
mice 
Diode laser 2 J/cm2 7 days 40 seconds Daily 50 mW/cm2 Blood plasma fructosamine levels were lower in 
mice irradiated on left inguinal region compared to 
non-irradiated 
 
[7] 
Oxygen-
glucose 
deprived 
primary 
cortical 
neurons 
Diode laser 3 J/cm2 single 2 minutes Single 25 mW/cm2 Reduction in cell death 
Increased mitochondrial reductive capacity 
Restoration of MMP and ATP production  
[8] 
Primary 
Cortical 
neurons 
Diode laser  30, 10, 3, 
0.3, 0.03 
J/cm2 
single various single 25 m W/cm2 Biphasic dose response was observed 
ATP and MMP and Ca22 increased at low radiant 
exposure and decreased at higher. 
ROS and NO increased at low radiant exposure, 
decreased at mid-range radiant exposure and had 
the largest increase at higher radiant exposures 
[9] 
Spinal cord 
injury 
Rat 
continuous 
wave 810 
nm diode 
laser with 
a delivery 
optical 
fibre  
1,589 
J/cm2 
14 days 2,997 
seconds 
Daily 150 mW Greater axon regrowth length and higher total 
axon number in following hemisection and 
contusion injuries with 810 nm light 
[10] 
Rat model 
of chronic 
mild stress 
laser 120 J/cm2 3 weeks 2 minute 3 times per 
week 
350 mW peak 
power 
Less stress-induced immobility with 810 nm light [11] 
Spinal cord 
injury  
Rat 
808-nm 
diode laser 
CW and 
pulsed 
1,500 
J/cm2 
3 weeks 50 minutes daily 0.5 W/cm2 Significantly higher total axon number in with both 
pulsed and CW  
No significant difference between pulsed and CW 
[12] 
 
 
 
 
 
 
 
 
Significantly greater length of axonal regeneration 
with pulsed and CW but significantly greater in 
pulsed that CW 
 
 10-Hz 
pulsed 
wave laser 
810 nm 
and       
630 nm 
1.2 J/cm­2 
per 
treatment 
 
14.4 J/cm 2 
total 
3 weeks  4 times per 
week 
562 mw/cm2 Mice had significantly reduced immobility and 
increased swim time with 810 nm laser but not 630 
nm laser 
Cortisol levels were reduced with 630 nm but not 
810 nm laser and blood glucose levels were 
reduced with both wavelengths 
[13] 
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